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Abstract 
The emergence of the cancer stem cell (CSC) hypothesis has helped to 
explain previously poorly understood clinical concepts such as metastases, 
late tumour recurrence and resistance to chemotherapy. Triple Negative 
Breast Cancer (TNBC) has the worst prognosis of all types of breast cancer 
with a more frequent relapse rate and reduced length of survival in metastatic 
disease. It has been shown to contain a higher proportion of CSCs than other 
types of breast cancer. Paclitaxel, a taxane in widespread use in breast 
cancer, induces apoptosis in a ligand-independent manner through the 
extrinsic apoptosis pathway. cFLIP is both an antagonist of this apoptosis 
pathway and can interfere with the ubiquitynation and subsequent 
degradation of both HIF1α and β-catenin, two molecules involved in CSC-
signalling. Using a novel compound targeted against cFLIP, we wanted to 
assess whether its combination with paclitaxel effectively targeted CSCs.  
Using a combination of in vitro models of cancer stem/progenitor-like activity 
and the surrogate marker of CSCs, ALDH, we demonstrated that a number of 
chemotherapeutic agents, including paclitaxel, docetaxel and FEC increased 
CSC-like behaviour. A mathematical model demonstrated that paclitaxel 
increased the absolute number of CSCs after treatment suggesting that CSC-
like activity was being induced. OH14, a novel inhibitor of c-FLIP developed in 
our laboratory, abrogated the paclitaxel-mediated induction of CSC-like 
activity in TNBC cell lines.  While apoptosis may play a role in CSC viability in 
vitro, it did not appear to play a major role in OH14-mediated suppression of 
CSC acquisition following paclitaxel treatment.  Instead, OH14 appeared to 
suppress CSCs through disruption of HIF1- α, as HIF1α-mediated signalling 
was increased by paclitaxel and abrogated by the addition of OH14. These 
beneficial effects of combinatorial OH14 were confirmed in vivo, where OH14 
suppressed tumour initiation of TNBC xenografts and prevented relapse of 
paclitaxel treated tumours in a xenograft model of systemic treatment.  cFLIP 
thus has a dual effect in both increasing apoptosis and targeting signalling in 
TNBC CSCs. In a breast cancer subtype in desperate need of novel 
therapeutic strategies, targeting cFLIP warrants further investigation and 
progression towards clinical trials. 
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 1 Introduction 
 
  
     1 
1.1 Cancer 
Despite a declaration of a ‘war on cancer’ by President Nixon in 1971, cancer 
remains today as one of the world’s largest killers as well as being a huge 
economic drain on society.  Cancer caused 8.2 million deaths worldwide in 
2012 (CRUK 2014) and is estimated to cost the countries within the European 
Union €50 billion per annum in diagnosis, treatment and lost productivity 
(Luengo-Fernandez et al. 2013).  
 
1.2 Breast cancer 
1.2.1 Incidence and mortality 
Breast cancer remains a significant burden in terms of morbidity and mortality.  
In 2008, 1,380,000 breast cancer diagnoses worldwide led to 458,000 deaths, 
ensuring that breast cancer remains one of the commonest cancer diagnoses 
and cause of cancer death (Ferlay et al. 2010).  In the UK, age-standardised 
incidence of breast cancer increased by 6% over the last decade to 2010 with 
50,285 new diagnoses in 2011 (CRUK 2014).  It is currently estimated that 
there are over 500,000 people living with or after a diagnosis of breast cancer 
in the UK (Maddams et al. 2009) - with this population projected to triple by 
2040 due to improvements in detection and treatment (Maddams, Utley and 
Møller 2012).   
 
Owing to advances both in detection and in therapy, mortality rates from 
breast cancer have been decreasing steadily in most Western countries for 
the past two decades (Jemal et al. 2009). Depending on prognostic factors, 
up to 30% of node-negative and up to 70% of node-positive breast cancers 
will relapse (Cardoso et al. 2012).  Approximately 5% to 10% of breast 
cancers are metastatic at diagnosis with an associated 20% 5-year survival.  
As over 90% of cancer deaths are associated with metastatic disease, new 
strategies are needed in order to reduce relapse rates and improve survival 
(G. P. Gupta and Massagué 2006).  In the UK this has led to a concerted 
effort to identify research gaps and priorities to improve both the prevention 
and treatment of breast cancer (Eccles et al. 2013). 
 
     2 
1.2.2 Breast cancer treatment 
The mainstay of localised breast cancer treatment is surgery and 
radiotherapy.  In addition to this, a wide range of hormonal, cytotoxic and 
targeted therapies exist for both the metastatic and adjuvant treatment of 
breast cancer.  The focus of this work is chemotherapy, trying to increase its 
effectiveness by targeting cells that are both resistant to present drugs and 
have the potential to cause spread and recurrence. 
 
1.3 Chemotherapy for breast cancer 
1.3.1 Background 
In treating breast cancer chemotherapy is given in three distinct settings. 
Firstly, neoadjuvantly, that is prior to surgery, to decrease tumour size and 
improve the success of surgery on a primary breast tumour both in terms of 
clinical and cosmetic outcome.  Secondly, adjuvantly (within twelve weeks of 
surgery) to decrease the risk of tumour recurrence in the future.  Lastly, in the 
metastatic setting, where disease is known to be incurable, chemotherapy 
plays a role in both improving the quality and quantity of life that a patient may 
experience (Rampurwala, Rocque, and Burkard 2014).  
 
1.3.2 Development 
In the early 1970s, breast cancer oncologists were some of the first to adopt 
chemotherapy in the treatment of their patients. The combination of 
cyclophosphamide, methotrexate and 5-fluoruracil (CMF) yielded impressive 
results with a response rate of 50% and a complete remission rate of 20% in 
metastatic disease (Canellos et al. 1974).   
 
Adjuvant trials by the mid-1970s had shown a relapse rate of 24% in controls 
and 7% of those treated with adjuvant CMF (Bonadonna et al. 1976).  By 
2007, the mortality from all cancer types in the United States had fallen 
significantly since 1990, with half of this effect being due to the inclusion of 
chemotherapy in treatment regimens (DeVita and Chu 2008).  
     3 
1.3.3 Adjuvant and neoadjuvant use 
The allocation of chemotherapy to patients in the neoadjuvant and adjuvant 
settings depends on a number of factors including their tumour stage (that is 
itself dependent on tumour size, grade and lymph node involvement) as well 
as age, hormone and Her-2 receptor status of the patient (Cardoso et al. 
2012).  For patients, hormone or Her-2 receptor positivity not only confers a 
benefit in terms of survival, but also allows the use of hormone reducing 
drugs, such as tamoxifen or the aromatase inhibitors, or trastuzumab in the 
case of Her-2 receptor positive disease.  The latter has transformed the care 
of Her-2 positive patients and, due to the multitude of targeted anti-Her-2 
therapies now available, the prognosis of Her-2 positive disease has been 
transformed over the last decade (Denduluri et al. 2016). 
 
If the disease is considered advanced enough, or the patient’s tumour lacks 
expression of all three receptors, then the use of cytotoxic chemotherapy is 
likely to be recommended.  Even then, chemotherapy sometimes only confers 
a small long-term survival benefit and its use needs careful consideration and 
discussion between oncologists and patients.  This complexity has led to the 
development of many different algorithms to try and quantify benefit based on 
genetic as well as clinical factors, and include Adjuvant online and the 
Oncotype DX recurrence scores (Gage et al. 2015). 
 
Much of the data used to populate these algorithms comes from the Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG). The EBCTCG 
performs a meta-analysis every five years to review the data on adjuvant 
treatment of breast cancer based on individual patient level data.  
 
In a meta-analysis of trials involving over 9000 patients, the EBCTCG showed 
the regimes containing high-dose anthrayclines (equivalent to over 240mg/m2 
of doxorubicin) were only marginally superior to the older CMF regimes, 
reducing the absolute risks of recurrence by 2.6%, breast cancer mortality by 
4.1% and overall mortality by 3.9% (Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) 2012). This is fairly striking in highlighting the 
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small progress that has been made since the original discovery of CMF in the 
1970s, some forty years ago.     
 
The small benefit of adding the taxane class of chemotherapy agents to an 
anthraycline-containing regime was also demonstrated.  In trials where the 
treatment and control regime was the same in both arms, (excluding the use 
of the taxane) the addition of a taxane agent led to an improvement in 
absolute recurrence-free survival of 4.6%, of breast-cancer specific overall 
survival of 2.8%, and an overall survival benefit of 3.2%.  The benefits of 
taxane incorporation that were seen were independent of age, nodal status, 
tumour size, tumour grade, and oestrogen receptor status (Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) 2012).   
 
1.3.4 Standard regimes in use in the neo/adjuvant setting 
It is important to note that there is not a single-standard regime for breast 
cancer.  Use of regime depends on clinician, patient and institution.  However, 
most clinicians would agree that regimes containing both an anthraycline and 
cyclophosphamide (AC) as well as a taxane (T) appear to offer the best 
chance of reducing disease recurrence and improving overall mortality.   
 
These regimes can take many forms: one could be a regime consisting of 
dose-dense doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2 for 
four cycles) followed by paclitaxel (175 mg/m2 for four cycles) (AC-T) 
(Sparano et al. 2008).  In the United Kingdom, the slightly alternative regimes 
of FEC (Fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and 
cyclophosphamide (500 mg/m2) for six cycles administered every three 
weeks (Brufman et al. 1997) or FEC-T – (FEC every three weeks for three 
cycles followed by docetaxel (100 mg/m2) for three cycles; FEC for four 
cycles followed by weekly paclitaxel (100 mg/m2) for eight weeks) are often 
used (Roché et al. 2006; Martín et al. 2008).  In addition the TAC regime 
(docetaxel 75mg/m2, doxorubicin 50mg/m2 and cyclophosphamide 
500mg/m2) given every three weeks is also used.  For patients who are 
unable to tolerate an anthracycline (for example due to pre-existing cardiac 
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disease), another option includes the TC regime – Docetaxel (75 mg/m2) plus 
cyclophosphamide (600 mg/m2) for four to six cycles, administered every 
three weeks (Jones et al. 2006). 
 
The benefits of adding trastuzumab to adjuvant chemotherapy in patients with 
Her-2 positive disease were confirmed in a 2012 meta-analysis of eight trials 
of chemotherapy plus trastuzumab versus chemotherapy alone, involving 
nearly 12,000 patients (Moja et al. 2012).  These analyses showed a 
improvement in disease-free survival of 40% and a reduction in mortality of 
36% when combined with chemotherapy.  Traditionally, in the United 
Kingdom, FEC would be given alone for three cycles, followed by a 
combination of a taxane and trastuzumab (Herceptin®) for three cycles before 
completing a total of one year of treatment with Herceptin. A table of the 
common regimes in use the adjuvant and neo-adjuvant setting can be seen in 
Table 1.1 (Cardoso et al. 2012; Elżbieta Senkus, Cardoso, and Pagani 2014). 
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Regime 
Name 
Drugs Frequency Number of 
cycles 
AC-T Dox (60 mg/m2) Cyc (600 
mg/m2) followed by Pac 
(175 mg/m2) 
Three weekly, 
or dose 
dense (AC 2 
weekly and 
paclitaxel 
weekly) 
8 (4 of each) 
FEC 5-FU (500 mg/m2), Epi (75 
or 100 mg/m2), and Cyc 
(500 mg/m2)  
Three weekly 6 
FEC-T FEC followed by doc (100 
mg/m2)  
Three weekly 6 (3 of each) 
FEC-TH As above plus trastuzumab 
for Her-2 receptor positivity 
(8mg/kg loading dose 
followed by 6mg/kg 
maintenance three weekly) 
Three weekly 18, 3 of FEC, 
3 of TH, 12 of 
H alone 
TAC DOC (75mg/m2) DOX 
(50mg/m2) and CYCLO 
(500mg/m2) 
Three weekly 6 
Table 1.1- Adjuvant and neoadjuvant regimes in use in the clinic for 
breast cancer 
Key: Dox: Doxorubicin, Cyc: Cyclophosphamide, PAC: Paclitaxel, 5-FU: 
fluorouracil, Epi: Epirubicin, Doc: Docetaxel 
 
1.3.5 Metastatic disease 
The median survival for metastatic disease is between eighteen and twenty 
four months (Kiely et al. 2011) and for these patients the aim of treatment is to 
prolong survival and maintain a higher quality of life.  Cytotoxic chemotherapy 
adopts a central role in treatment as all patients will invariably become 
resistant to both hormone and/or Her-2 targeted treatment (if their tumour type 
allows for its use).  Nevertheless, tumours will either be resistant or acquire 
resistance to chemotherapy.  Typically, unless disease is rapidly progressing, 
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patients will receive single agent chemotherapy to reduce side effects from 
treatment.  Table 1.2 below lists the classes of chemotherapy commonly in  
use in the metastatic setting in breast cancer. 
 
 
 
Table 1.2 Chemotherapy drugs and classes in use in metastatic breast 
cancer 
 
  
 Mechanism Examples 
Alkylating agents Direct DNA damage  Cyclophosphamide 
Antimetabolites Interfere with DNA and 
RNA production 
5-fluorouracil, 
gemcitabine, 
methotrexate 
Anti-tumour 
antibiotics  
eg.Anthracyclines 
Interfere with enzymes 
involved in DNA 
replication 
Doxorubicin, Epirubicin 
Mitotic Inhibitors Stop mitosis in M phase 
of cell cycle and can 
prevent enzymes 
producing proteins 
needed for cell 
reproduction 
Taxanes: Paclitaxel & 
docetaxel  
Eribulin 
Platinum Agents Inhibition of DNA, RNA 
and protein synthesis by 
cross-linking 
Cisplatin, carboplatin 
Vinka Alkaloids Disrupts microtubule 
function 
Vinorelbine 
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1.3.6 Paclitaxel 
Paclitaxel is a chemotherapeutic agent from the bark of the Pacific yew tree 
first discovered by a drug-screening programme from the National Cancer 
Institute in the 1960s.  It has shown activity against many human tumours 
including head and neck, lung, pancreatic, ovarian and breast cancers (Day et 
al. 2006).  It works by targeting the microtubule network required for cell 
mitosis and proliferation, ensuring that cells are stuck in G1 and G2/M phases 
(Jordan et al. 1993).  Different concentration of paclitaxel can trigger distinct 
effects on both the microtubule network and intracellular biochemical 
pathways with low concentration (up to 30nM) leading to altered microtubule 
dynamics and G2/M cell cycle arrest with higher concentrations (up to 30μM) 
causing significant microtubule damage (Tzu-Hao Wang, Wang, and Soong 
2000).  The main apoptotic mechanisms at higher concentrations are 
signalling changes in the mitogen-activated protein kinase (MAPK), Raf-1, c-
jun NH(2)-terminal kinase (JNK), cyclin dependent kinase (CDK) and 
caspases (Stone and Chambers 2000).  At lower concentrations, paclitaxel 
works by inducing apoptosis primarily through the extrinsic apoptosis pathway 
but independently of the Fas, TNFα and TRAIL receptors, but is dependent 
upon FADD (S.J. Park et al. 2004).  Furthermore, the apoptotic process was 
primarily Caspase 10 dependent but also partially dependent upon Caspase 8 
-with inhibitors of the former completely abrogating apoptosis and the later 
partially (S.J. Park et al. 2004).  As discussed in a later section on the role of 
cFLIP and apoptosis (Chapter 5), these effects mean that the combination of 
paclitaxel and targeting cFLIP, a molecule involved in abrogating apoptosis 
through the Caspase 8/10 apoptotic pathway, holds great potential in 
overcoming resistance to apoptosis seen in breast cancer cells. 
 
1.4 Reasons for treatment failure 
Despite the wide array of treatment options available, current treatment 
strategies are clearly not eradicating all tumour cells and therefore tumours 
are relapsing.    There are many reasons for this: often many patients present 
with disease that has already metastasised to distant sites within the body 
and they cannot be removed surgically.  Even in patients with localised 
disease, micro–metastatic disease almost certainly exists, but often lies in a 
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dormant state for many years after the initial diagnosis and treatment of the 
cancer.  There are no current methods to detect these microscopic deposits.   
 
The major limitation of cancer chemotherapy is drug resistance, whether this 
is acquired by the tumour after an initial response, or innate.  An example of 
the former is the recurrence of breast cancer after a seemingly good initial 
response to neoadjuvant chemotherapy, whereas pancreatic cancer is often 
poorly responsive to any form of chemotherapy, with response rates varying 
between 10-30% and the most aggressive form of chemotherapy conferring a 
median survival of only 11.1 months (Seufferlein et al. 2012).    
 
Our understanding of the biology of breast cancer has grown exponentially 
over the past few decades.  It is now apparent that a large component of the 
therapeutic complexity in treating breast cancer arises not only from the 
differences that exist in the biology of tumours in different patients (inter-
tumour heterogeneity), but also from the biological differences within tumours 
in the same patient (intra-tumour heterogeneity).  The differences between 
cells within tumours has led to the so-called ‘Dandelion hypothesis’ - certain 
cells are more capable of forming tumours and represent the roots of a weed.  
Failure to eradicate these cells will lead to a cancer returning or a failure to 
effectively treat it from the beginning of therapy. 
 
1.5 Tumour heterogeneity 
1.5.1 Inter-tumour heterogeneity 
The treatment of breast cancer patients and prognostication has long been 
based on the presence or absence of several receptors based on the cell 
surface of breast cancer cells that are routinely tested for in clinical practice.  
These include the oestrogen (ER) receptor, progesterone (PR) receptors, and 
the human epidermal growth factor receptor 2 (Her2).  Despite improving 
survival since the 1970s, it was clear that not all the biological heterogeneity 
in terms of response to treatment and molecular alterations were accurately 
accounted for using clinical parameters (such as tumour grade and node 
status) or cell surface markers.  
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Insights based on gene expression analyses over the last decade have shone 
further light on the degree of inter-tumour heterogeneity with the subdivision 
of breast cancer into four main molecular subtypes - Luminal A, Luminal B, 
Her-2 enriched and Basal-like, as well as the Normal-Breast like and Claudin-
low groups that have also more recently been identified (Table 1.3) (Prat and 
Perou 2011).    
 
These groups have been shown to have differences in their incidence, 
survival, and response to treatment, and complements and expands on the 
information provided by the classical clinical and pathological markers (Sorlie 
et al. 2001; Parker et al. 2009; Carey et al. 2007; Carey LA et al. 2006; Prat et 
al. 2010). Patients with basal, Claudin-low or Her-2 enriched cancers tend to 
respond better to initially to chemotherapy.  However, significant differences in 
relapse free survival after initial diagnosis and treatment, as well as overall 
survival, were seen in patients from two patient cohorts of around 400 patients 
with known clinical data who have undergone molecular subtyping (Figure 
1.1).   The data clearly show that Luminal A patients have the best overall 
survival - with while those with a Basal-like, Claudin-low or Her-2 
overexpression having the worst overall survival (Prat et al. 2010). 
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Subtype ER PR Her-2 Other features 
Luminal A + + - Ki67 low 
Luminal B + + -/+ Ki67 can be high 
Her-2 
enriched 
-/+ -/+ +  
Basal-like - - -  
Claudin-low - - - Low expression of claudins, high 
mesenchymal gene expression such 
as vimentin 
Normal-Breast 
like 
- - - Rare. Strong expression of basal 
epithelial genes and low expression of 
luminal epithelial genes. 
Table 1.3- Molecular subtypes of breast cancer 
Table showing the multiple different molecular subtypes of breast cancer and 
their distinguishing features.   The Claudin-low and Normal-Breast like groups 
were identified later on as a subset of triple negative breast cancers (lacking 
expression of oestrogen, progesterone and Her2) (Sorlie et al. 2001; Prat and 
Perou 2011) 
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A      B 
 
Figure 1.1- Kaplan-Meier Relapse Free Survival and Overall Survival 
Curves by Molecular Subtype.   
Adapted from Prat et al. 2010. Graphs showing significant differences 
between (A) relapse free survival and (B) overall survival between different 
molecular subtypes.  
 
1.5.2 ER and Her-2 receptor positive cancer 
Luminal A breast cancer is characterised by overexpression of ER and PR 
receptors but not with Her-2 overexpression, whereas Luminal B tumours are 
defined by overexpression of ER and PR receptors, but Her-2 overexpression 
can be present or absent (when absent, it is defined by markers of high 
cellular proliferation (such as the Ki67)).  Her-2 tumours are usually negative 
for the ER and PR receptors but have overexpression of the Her-2 gene and 
are usually aggressive.   
 
1.5.3 Triple-negative breast cancer 
Triple negative breast cancer (TNBC) accounts for between 15-20% of new 
diagnoses of breast cancer and is more likely to affect younger patients of 
African and Hispanic descent (Amirikia et al. 2011; Carey LA et al. 2006).  
The paradox of TNBC is that, although it has an excellent initial response to 
chemotherapy, patients with TNBC have a higher risk of both local and distant 
recurrence (Carey et al. 2007).  Most relapses occur within the first three 
years after diagnosis before declining until 5 years, after which the recurrence 
     13 
pattern is similar to those with more indolent oestrogen receptor-positive 
disease (see Figure 1.2).  In addition, relapses are more likely to be visceral, 
that is affecting key body organs such as the brain, liver and lungs, compared 
to other forms of breast cancer.  This correlates with the outcomes amongst 
this type of breast cancer being worse than others, with a three times increase 
in risk of death in the 5 years of diagnosis compared to ER and Her-2 positive 
breast cancers, and a significantly higher recurrence rate (Dent et al. 2007). 
 
 
Figure 1.2- Rate of distant recurrence after surgery in triple negative and 
other breast cancers  
Figure showing the higher initial rate of relapse from triple negative breast 
cancers (TNBC) up until three years.  This then declines until reaching the 
same recurrence rates as oestrogen receptor positive from 5 years onwards. 
Adapted from (Dent et al. 2007). 
 
1.5.3.1 Subtypes of TNBC 
Our understanding of the biology of TNBC has increased over the past five 
years and we now know that in fact there is a large amount of heterogeneity 
within this group.  Initially described as basal, Claudin-low or normal-like, our 
understanding of TNBC was transformed in a seminal paper in 2011.  Here, 
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Lehmann et al. characterised gene expression profiles from 21 breast cancer 
data sets and identified 587 TNBC cases. Cluster analysis identified 6 TNBC 
subtypes: 2 basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal 
(M), mesenchymal stem–like (MSL), and a luminal androgen receptor (LAR) 
subtype (Table 1.4)  (Lehmann et al. 2011).    These subtypes differed in their 
prognosis and in their sensitivity to targeted treatments.  This understanding 
has now led to clinical trials stratifying on the basis of molecular subtype, for 
example with the androgen receptor drug enzalutamide, a therapy initially 
designed for prostate cancer, for the androgen receptor positive subtype 
(Moulder-Thompson 2016). 
 
Our increased understanding of the differences between tumours over the last 
decade has also revealed that there are large differences between cells within 
a tumour.  This intra-tumour heterogeneity has perhaps begun to explain why 
some molecular subtypes relapse more quickly than others.  Interestingly, in 
TNBC, the focus of this work, it has been shown that tumours contain a higher 
proportion of cancer stem cells (CSCs) as compared to other molecular 
subtypes of breast cancer - perhaps explaining its poor prognosis (Habib and 
O’Shaughnessy 2016). This will now be explored in more detail.
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Subtype Upregulated 
pathways 
Gene expression Clinical Behaviour Representative 
cell lines 
Basal-Like 1 Cell cycle and cell 
division, DNA damage 
response, cell cycle 
checkpoint loss 
Aurora kinases, Myc, NRAS, 
ATR/BRCA, Ki67 
High pathological complete 
(pCR) response rate to 
chemotherapy (60-70%) 
HCC1599, 
MDA-MB-468, 
HCC 1937 
Basal-Like 2 Cell cycle and cell 
division, DNA damage 
response, cell cycle 
checkpoint loss 
EGF, NGF, MET, Wnt/β-catenin, 
and IGF1R 
High pathological complete 
(pCR) response rate to 
chemotherapy (60-70%) 
SUM149, 
HCC70 
Immunomodulatory Immune cell signalling, 
cytokine signalling, ore 
immune signal 
transduction pathways 
TH1/TH2 pathway, Natural Killer 
cell pathway, B cell receptor 
signalling pathway, cytokine 
pathway, and T cell receptor 
signalling, IL12, IL7 and NFKB, 
TNF, and JAK/STAT 
Favourable prognosis 
(significant genetic overlap 
with the high-grade but 
prognostically favourable 
medullary breast cancer 
subtype) 
HCC1187, 
DU4475 
Mesenchymal Cell motility ECM 
receptor interaction, 
and cell differentiation 
ALK, TGF-β signalling pathway 
components, ZEB1, ZEB2, 
TWIST.  Decreased E-cadherin 
Pathological complete 
(pCR) response rate to 
chemotherapy around 30-
BT549, CAL-51 
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pathways and Wnt/β-catenin signaling 40%. Trend towards lower 
relapse rates 
Mesenchymal 
Stem-Like 
Low levels of 
proliferation genes, 
increased angiogenesis 
and immune signalling 
ABC1, ALDHA1, HOX genes, 
EGFR, PDGF, calcium 
signalling, G-protein coupled 
receptor, and ERK1/2 signaling. 
Low expression of claudins 3, 4, 
and 7 
Trend towards lower relapse 
rates 
SUM 159, MDA-
MD-436, MDA-
MD-231 
Luminal Androgen 
Receptor 
Enriched in hormonally 
regulated pathways 
including steroid 
synthesis, porphyrin 
metabolism, and 
androgen/estrogen 
metabolism 
Androgen receptor targets and 
co-activators (DHCR24, 
ALCAM, FASN, FKBP5, APOD, 
PIP, SPDEF, and CLDN8) 
Poor pathological complete 
(pCR) response rate to 
chemotherapy (10-20%). 
Higher relapse rates 
MDA-MB-453, 
SUM185 
Table 1.4- Subtypes of TNBC  
The different subtypes of TNBC, their signalling pathways and gene profiling, unique clinical behaviour and representative cell lines. 
Adapted from Lehmann et al 2011
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1.5.4 Intra-tumour heterogeneity 
A greater understanding of the heterogeneity of cells within tumours over the 
last decade has led to previously complex clinical concepts, such as therapy 
resistance, the ability to metastasise and cell dormancy leading to tumour 
recurrence, being better understood (Vermeulen et al. 2012; Hanahan and 
Weinberg 2011). 
1.5.4.1 Clonal expansion theory 
The changes leading to normal cells forming cancers were long believed to 
follow the clonal expansion model first proposed in the 1970s (Nowell 1976).  
In this model, individual cells undergo a mutation that confers an ability to 
divide more rapidly and outgrow their neighbours - forming a clone of cells.  
Through repeated acquisition of known critical genetic or epigenetic changes, 
perhaps half a dozen or more times, cancers form (Cho and Vogelstein 1992). 
1.5.4.2 Cancer Stem Cell (CSC) model 
The clonal view has been challenged by the emergence of the cancer stem 
cell model - a theory that a small population of cells either within or outside 
the tumour are responsible for both tumour growth as well as the spread of 
the cancer to distant sites (Visvader and Lindeman 2008).  This model 
proposes that there are different populations within a tumour. 
 
The CSC model is not novel. In the 1970s it was recognised that stem cells 
existed within numerous different cancer types and formed colonies in vitro 
(Hamburger and Salmon 1977).  This model proposed that only a certain 
population within tumours had the ability to self-renew, differentiate and 
regenerate to form similar tumours.  This theory was first proved in acute 
myeloid leukaemia in the 1990s where cells sorted according to the 
CD34+/CD38- surface markers (representing 1% of total cells) were the only 
cells capable of leukaemia formation (Lapidot et al. 1994).  Similar 
experiments undertaken in breast cancer, established that CD44high/CD24low 
cells (representing 2% of the total tumour cells) were able to form tumours in 
immunocompromised mice, whereas cells without these markers were not (Al-
Hajj et al. 2003).  Subsequently, similar experiments were undertaken in brain 
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(S. K. Singh et al. 2004), colon (O’Brien et al. 2007; Ricci-Vitiani et al. 2007) 
and pancreatic cancer (Hermann et al. 2007).   
 
The CSC theory has not been without controversy as debate has focused on 
how to integrate CSC theory with the clonal expansion tumour model.  The 
original concept assumed that the progression from CSC to a progenitor-like 
cell and finally a differentiated cell was rigid and hierarchical.  Once formed, 
the differentiated cells lost clonogenic ability to form new tumours and tumour 
growth and expansion was driven by the CSCs (Vermeulen et al. 2012).  
Cancers were formed by progressive mutations within the CSC pool leading 
to more aggressive cellular phenotypes. 
 
There are however two major issues with this theory.  Firstly, the rate of 
mutation of the pre-neoplastic stem cell population (that would form CSCs) is 
very low, perhaps as low as one mutation per million cell divisions (Drake et 
al. 1998).  Combined with the generally low numbers of stem cells within a 
tumour, this makes the chances of mutation improbably low.  Secondly, stem 
cells tend to divide only occasionally, with the clear majority of mitotic activity 
occurring in differentiated cells.  As most mutations occur during DNA 
replication, this again leads to a conclusion that cancers arising purely as a 
result of mutated stem cells are unlikely (Scheel and Weinberg 2011).  These 
issues led to a revision of the hierarchical CSC theory, with insights coming 
from a better understanding of the process that lead to metastases. Such 
processes include non-genetic determinants of CSC fates, including histone 
modifications and epithelial to mesenchymal transition – EMT (Kreso and Dick 
2014; Mani et al. 2008). 
1.5.5 Epithelial to Mesenchymal Transition (EMT) 
EMT is increasingly recognised in a vital step in the progression of 
malignancy, with epithelial cells losing their epithelial characteristics and, via 
changes in their cytoskeleton, cell structure, morphology and adhesion 
molecules, acquiring more mesenchymal traits (Britton et al. 2011).  Adhesion 
molecules such as E-cadherin and integrins are substituted for N-cadherin, 
vimentin and fibronectin that allow the cell to become detached from the 
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basement membrane and either begin invading into surrounding tissue or 
separate and spread to distant sites (J. Yang and Weinberg 2008).   EMT is 
characterised by a scattered mesenchymal phenotype, with an increased 
invasive and metastatic potential of cancerous cells (Ferrand et al. 2014). 
 
EMT has also been shown to bestow non-CSC differentiated epithelial cells 
with increased ‘stemness’ properties (Mani et al. 2008; Morel et al. 2008). It 
has also been shown to be an important programme in normal cell 
differentiation and tissue repair (Acloque et al. 2009).  A number of signalling 
pathways are known to induce EMT including Notch, hedgehog, Wingless 
(Wnt), transforming growth factor-B (TGFB) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NFkB) (Thiery et al. 2009; Yoo et al. 
2011; Takebe, Warren, and Ivy 2011; Shin et al. 2010; Jung and Yang 2015).  
It has also been show to confer resistance to chemotherapy (Fischer et al. 
2015).  
 
The connection between stem cells and EMT applies to both cancerous and 
non-cancerous cells.  Cancerous cells adopt the stem cell programme to 
organise the complex tissues structures and behaviour that is seen at various 
stages of the malignant process (Scheel and Weinberg 2011).  This EMT-
stem cell relationship is troublesome as it confers mesenchymal 
characteristics on epithelial cells leading to higher degrees of motility, 
invasiveness and resistance to apoptosis that results in metastatic 
dissemination (Singh and Settleman 2010).  It also confers the capacity of 
self-renewal that allows large colonies of cancer cells to form both as primary 
tumours and macroscopic metastases (Brabletz et al. 2005). 
 
EMT also potentially solves the issues listed in the previous section - namely 
that mutations affecting stem cell populations are likely to be too rare to 
explain their role in the malignant process. Instead, cells that have already 
undergone cancerous mutations receive signals and can harness them to 
dedifferentiate and create new CSCs.  It is far more likely that mutations strike 
a population of transient-amplifying cells that are far larger and mitotically 
active than the stem cell population.  Mutations first gained by this pool of 
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cells are able to be introduced into the stem cell population via EMT where 
they can divide and generate progeny that harbour the mutant genotype 
(Scheel and Weinberg 2011).  This is shown in Figure 2 below. 
 
   
1.5.6 EMT to Mesencyhmal Epithelial Transition (MET) 
To further complicate the theory that an EMT process confers CSC traits on 
cancerous cells, it was shown that cells that had undergone EMT were able to 
invade and enter blood vessels but not form lung metastases in a mouse 
tumour model (Tsuji et al. 2008).  EMT and non-EMT cells were both required 
for distant metastases to form.  This led to the authors concluding that EMT 
cells invaded to form blood vessels to allow distant spread but that non-EMT 
cells were required to form these metastases. 
 
Figure 1.3- Multi-step progression 
and the CSC model of cancer  
A) A hierarchical model. Normal 
stem cells acquire mutations 
(depicted as coloured quarters 
within the circles) and evolve into a 
mutant stem cell population.  
Incremental mutations lead 
eventually to a neoplastic stem cell 
population. B) Mutations do not 
strike the stem cells but transient-
amplifying cells that are able to de-
differentiate (via EMT) into stem 
cells.  This leads to a neoplastic 
stem cell population. (from Scheel 
and Weinberg 2011).   
 
     21 
This introduces the concept that EMT is potentially a reversible process and 
that cells can undergo a reverse mesenchymal to epithelial transition (MET) 
where cells re-express E-cadherin and regain their cellular polarity. Indeed, 
significant interplay between EMT and MET has been shown with cells that 
have undergone EMT revering to an epithelial phenotype after a couple of cell 
divisions (Beerling et al. 2016). 
 
EMT has been the favoured model for explaining distant metastases in 
epithelial cancers such as breast cancer.   The disruption of intercellular 
adhesion molecules (such as E-cadherin) and tight junctions leads to cells 
adopting a fibroblast-like mesenchymal morphology and having increased 
motility, invasion and resistance to apoptotic stimuli (Scheel and Weinberg 
2011).  Cells that have undergone EMT also acquire cancer stem cell, tumour 
initiation and therapy resistant properties (Mani et al. 2008; Hennessy et al. 
2009). 
 
However, most of this evidence has come from laboratory work based on cell 
culture models.  In patients, it is very difficult to prove EMT as samples are 
taken from primary and metastatic sites at different time points and may have 
undergone MET - thereby losing their mesenchymal features.  It is also very 
difficult to pathologically discriminate fibroblasts from mesenchymal-like cells 
(Fischer et al. 2015) 
1.5.7 Different breast cancer stem cell populations and their 
characteristics 
In addition to breast CSCs (bCSCs) identified by the markers 
CD44high/CD24low, it has been demonstrated that cells with high levels of 
aldehyde dehydrogenase (ALDH) enzyme also possessed tumour initiating 
characteristics (Ginestier et al. 2007).  Both CD44high/CD24low and ALDH 
markers identified overlapping but not identical populations that were both 
able to form tumours in immunocompromised mice from primary breast 
cancer samples.  The cells that expressed all markers were the most 
tumourogenic of all, with tumours being generated from as few as 20 cells.  
ALDH status was shown in a cohort of American breast cancer patients to 
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significantly correlate with overall survival (Ginestier et al. 2007).  ALDH has 
also been shown to be associated with an ER negative, inflammatory and 
basal forms of breast cancer (Tiezzi et al. 2013; Charafe-Jauffret, Ginestier, 
Iovino, et al. 2010).  
 
Subsequently, CD44, CD24, and ALDH were demonstrated in CSCs from a 
wide variety of cancers, including sarcomas, pancreas, colon, lung, ovary, 
prostate gland and some haematological malignancies (Suling Liu et al. 
2013).  The key question remained as to whether tumours contain multiple 
types of CSCs and whether CSC markers identify distinct CSC populations. 
 
Subsequently, the gene expression profiles of the CD44high/CD24low  cells 
showed that they were mesenchymal CSCs (or EMT-like) resembling those of 
basal stem cells within the normal breast, whereas the profiles of ALDH+ cells 
were those of the epithelial CSCs (or MET-like), resembling luminal stem cells 
(Suling Liu et al. 2013).  These two stem cell types were shown to be distinct 
and able to transition between the EMT-like and MET-like states with purified 
CD44high/CD24low or ALDH+ cells generating heterogeneous populations 
matching the proportion of CD44high/CD24low or ALDH+ BCSCs present in the 
original cell line.  This interconversion is known as plasticity. 
 
Anatomical differences were also shown to exist between the two stem cell 
populations, with epithelial ALDH+ positive cells being shown to exist in the 
central hypoxic region of the tumour whilst CD44high/CD24low mesenchymal 
CSCs were identified at the invasive edge of the tumour (Fig 1.4). Importantly, 
the gene-expression profiles of the different CSC populations expressed 
similarity across all molecular subtypes of breast cancer. Also demonstrated 
was the increased invasiveness of the EMT-like stem cells using the matrigel 
assay, but also their relative quiescence compared to the proliferative 
potential (as measured by the Ki67 proliferative marker) of the ALDH+ MET-
like cells. 
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Figure 1.4- Distribution of breast cancer stem cells 
Localization of CD24 (magenta), CD44 (green), ALDH1 (red), and DAPI (blue) 
in clinical samples of human invasive breast carcinoma as assessed by 
immunofluorescence staining.  From Liu et al 2013 (red bar = 100 μm) 
 
                  
Figure 1.5- The two different CSC populations and their characteristics. 
From Liu et al 2013  
 
1.6 The effect of chemotherapy on bCSCs 
CSCs express high-levels of drug transporter proteins ie ABC. (Gottesman, 
Fojo, and Bates 2002), DNA repair enzymes (Martin, Hamilton, and Schilder 
2008; M. Zhang, Atkinson, and Rosen 2010) and anti-apoptotic proteins 
(Piggott et al. 2011; Madjd et al. 2009; Zobalova et al. 2008; G. Liu et al. 
2006). 
 
It has been shown that cells that have been induced into EMT are resistant to 
both chemotherapy and radiotherapy (P. B. Gupta et al. 2009) and that these 
signals are both paracrine (from other cells within the tumours) as well as 
from stromal tissue surrounding the tumour (Farmer et al. 2009).  
Furthermore, It is known that cells that have undergone EMT have a slower 
cell cycle than non-CSC cells and as such they are likely to be damaged less 
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by the cytotoxic agents in use the clinic (Pattabiraman and Weinberg 2014).  
In addition to this, there are multiple drug-resistance mechanisms that mean 
that even dividing cells can resist cytotoxic chemotherapy (H. Liu, Lv, and 
Yang 2015). As such, there is accumulating evidence that although traditional 
chemotherapy may reduce the ‘bulk’ of a tumour through targeting the non-
CSC population, a residual CSC population remains, that is capable of 
reforming tumours (Pattabiraman and Weinberg 2014; Kreso and Dick 2014).    
 
Numerous in vitro, in vivo and clinical studies have demonstrated that 
chemotherapy can increase the proportion of stem cells remaining within a 
treated tumour. 
1.6.1 Chemotherapy and ALDHpos ‘epithelial’ like bCSCs 
Numerous pre-clinical studies have shown a relationship between ALDH and 
stem-cell like behaviour (Magni et al. 1996; Ginestier et al. 2007; Charafe-
Jauffret et al. 2009; Cao et al. 2013a; Samanta et al. 2014; H. Zhang et al. 
2015).  High expression of ALDH in resected surgical samples is strongly 
associated with metastases and worse survival (Ginestier et al. 2007; Ohi et 
al. 2011) .  ALDH has been shown to correlate with both response to 
chemotherapy and overall survival in breast cancer, though the relationship is 
not always clear cut, with some negative studies (Y. Gong et al. 2014).  There 
is also evidence to suggest that anthracycline-containing regimes (such as 
epirubicin) target the ALDH population more than taxane-containing regimens 
(such as paclitaxel or docetaxel), though both increased ALDH staining 
(Alamgeer et al. 2014).  There have been a number of clinical studies showing 
that ALDH positivity is associated with chemoresistance to both paclitaxel and 
epirubicin (Tanei et al. 2009), overall survival (C. Gong et al. 2010) and that 
the upregulation of ALDH after neoadjuvant chemotherapy is associated with 
worse overall survival (Alamgeer et al. 2014; H. E. Lee et al. 2011; Tiezzi et 
al. 2013). 
 
The relationship between HIF1α and ALDH positivity is significant and there is 
good evidence to suggest that a strategy of combining HIF inhibitors 
alongside cytotoxic chemotherapy may be a valid therapeutic strategy.  
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Several groups have investigated this approach in preclinical models, 
Samanta et al being one (described in section 1.5.8.1) and another being 
Xiang et al who used ganetespib, a second-generation inhibitor of Heat Shock 
Protein 90 (HSP90), a molecule essential for the stability and function of many 
molecules including HIF1α.  Treatment of both breast cancer cell lines and 
orthotopic mouse tumours led to reductions in growth, metastases, HIF1α 
protein levels and HIF1α-mediated gene expression (Xiang, Gilkes, 
Chaturvedi, et al. 2014).  Though as ever, caution should be adopted, with a 
Phase 3 trial in non-small cell lung cancer combining ganetespib and 
docetaxel being stopped early due to no difference being noted between the 
combination and patients receiving docetaxel alone (Ramalingam 2016). 
1.6.2 Chemotherapy and CD44high/CD24low ‘mesenchymal’ bCSCs 
The relationship between CD44high/CD24low and clinical parameters such as 
overall survival and response to chemotherapy are more complex than ALDH 
with no clear correlation established (Angeloni et al. 2014).  Treatment of 
breast cancer with taxanes has been reported to increase the 
CD44high/CD24low population (Bhola et al. 2013; C. C. Zhang et al. 2013; P. B. 
Gupta et al. 2011; X. Li et al. 2008; H. E. Lee et al. 2011) though others have 
demonstrated a decrease and no relationship with overall survival (Aulmann 
et al. 2010). 
 
1.7 CSC Signalling 
CSC rely on signalling networks to undertake behaviour associated with them 
such as invasion, metastases and proliferation.  In breast cancer, Snail, Slug, 
Twist and zinc-figure E-box-binding homeobox (ZEB1 and ZEB2) are 
classified as EMT inducers. They can induce EMT via different cell signalling 
pathways of which the TGF-β (Transforming Growth Factor β), Wnt (wingless-
type MMTV (mouse mammary tumor virus))/β-catenin, and Notch (a family of 
transmembrane proteins) pathways have been strongly implicated in inducing 
EMT in epithelial cells (Wu, Sarkissyan, and Vadgama 2016).  There has also 
been considerable interest in Hypoxia Inducible Factors (HIF), that has been 
shown to induce EMT via ZEB1 (W. Zhang et al. 2015). 
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1.7.1 HIF1α 
The negative impact of hypoxia of the efficacy of both chemotherapy and 
radiotherapy has been known for a number of decades (Gray et al. 1953; 
Roizin-Towle and Hall 1978). Intra-tumoural hypoxia is a hallmark of 
advanced breast cancer, with up to 40% of cancers known to have a hypoxic 
region, and is associated with an increased risk of developing metastases and 
treatment resistance (Vaupel, Höckel, and Mayer 2007; Chun, Adusumilli, and 
Fong 2005).  Our understanding of the molecular basis of this phenomenon 
has advanced in the last twenty years with the characterisation of the HIFs.  
This set of transcription factors activate the gene transcription of genes that 
are associated with many features of breast cancer progression such as 
angiogenesis, invasion and metastasis (G. L. Semenza 2013; Gregg L. 
Semenza 2013).   
 
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a central 
role in development and in adaptation to hypoxia. Hypoxia has been shown to 
lead to the expression of CSC markers such as CD44, CD49, CD47 nanog 
and ALDH (Xing et al. 2011; Mathieu et al. 2011; Louie et al. 2010; Velasco-
Velázquez et al. 2012; H. Zhang et al. 2015). Recently, the importance of 
hypoxia inducible factors in generating a CSC-phenotype has been 
recognized (Gregg L. Semenza 2015). 
 
The hypoxic conditions within tumours leads to a variety of biological 
responses with the activation of HIF-1 being the major effect (Harris 2002).    
Although there are multiple subtypes of HIF, HIF1α has been implicated as 
the most important in breast cancer models.  HIF1 is a heterodimer composed 
of two subunits, the hypoxic response factor HIF1α and the nuclear 
constitutively expressed HIF1β subunit.  In the presence of oxygen, HIF1α is 
hydroxylated, allowing it to interact with the von Hippel-Lindau protein (pVHL), 
that enables it to be targeted for degradation by the ubiquitin-proteasome 
pathway (Huang et al. 1998).  Under hypoxic conditions, HIF1α is no longer 
hydroxylated - resulting in its stabilization and translocation to the nucleus.  It 
then dimerizes with HIF1β and its co-activator p300, forming an active HIF1 
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transcription factor that binds to a specific Hypoxia Response Element (HRE) 
target sequence in the promoter region of its target genes  
 
 
 
Figure 1.6- Response of HIF1α to normal and hypoxic conditions 
From Ratcliffe, Pugh, and Maxwell 2000 
 
 
Microarray data from more than 500 human breast cancers has shown that 
genes associated with HIF define the basal molecular subtype, a form of 
TNBC (Cancer Genome Atlas Network 2012).  HIFs contribute to multiple 
steps in allowing metastatic spread in TNBC and immuno-histological over-
expression of HIF1α is associated with increased mortality and 
overexpression of HIF related genes is also associated with a poor prognosis 
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in TNBC (Gilkes and Semenza 2013; Gregg L. Semenza 2014; Buffa et al. 
2010).  The importance of the HIF-related genes is further emphasised by the 
observation that exposure of TNBC cells to hypoxia leads to an increase in 
bCSCs in a HIF-dependent manner (Conley et al. 2012; Schwab et al. 2012; 
Xiang, Gilkes, Hu, et al. 2014).  In a recent article, Samanta and colleagues 
showed that in both the MDA-MB-231 and MCF7 cell lines, exposure to 
hypoxia for 72 hours increased the mammosphere formation and ALDH 
positivity of both cell lines (Gregg L. Semenza 2016). 
 
HIF1α has also been shown to confer resistance to chemotherapy (Unruh et 
al. 2003; Rohwer and Cramer 2011) through multiple mechanisms (see Figure 
1.7 below).  
 
 
Figure 1.7- Mechanisms through which HIF1α leads to chemotherapy 
failure 
From (Rohwer and Cramer 2011)  
 
Of interest in this thesis is the interaction between HIF1α and apoptotic 
signalling.  Flamant et al showed that HIF1α (as induced by hypoxia) 
protected against paclitaxel induced apoptosis in the TNBC cell line MDA-MB-
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231 (Flamant et al. 2010).  Gene expression profiling showed that five pro-
apoptotic genes BAK, Caspases 3,8 and 10 and Tumor Necrosis Factor 
Receptor Superfamily Member 10a (TNFRSF10A, that encodes TRAIL-
Receptor 1) were down-regulated when HIF1α was knocked out using siRNA, 
thus protecting the cells against apoptosis (Flamant et al. 2010). 
 
Treatment of breast cancer cells with a wide-range of compounds that are in 
use in the clinic such as doxorubicin, paclitaxel and gemcitabine, has been 
shown to induce HIF1α and enrich for bCSCs (Cao et al. 2013b; Samanta et 
al. 2014).  This was measured by both ALDH activity as well as 
mammosphere formation and the effect was abrogated by the use of digoxin 
and acraflavine, two known HIF inhibitors.  ALDH has been strongly 
associated with HIF1α in previous studies both before and after treatment of 
patients with chemotherapy (Tiezzi et al. 2013).  The effect of paclitaxel and 
gemcitabine was to induce reactive oxygen species (ROS) leading to HIF1α 
and HIF2α mediated upregulation of Interleukin 6 (IL-6), Interleukin 8 (IL-8) 
and the known drug protein Multi-Drug Resistance Protein-1 (MDR-1) 
(Samanta et al. 2014).  Both IL-6 and IL-8 have been shown to regulate bCSC 
survival and self-renewal (Hartman et al. 2013; Sansone et al. 2007; Charafe-
Jauffret et al. 2009) and MDR-1 is a well characterised protein that has been 
shown to be implicated in chemotherapy resistance and is up-regulated in 
bCSCs (Abdullah and Chow 2013; Pastan and Gottesman 1991). 
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Figure 1.8- Pathway of HIF activation secondary to chemotherapy 
From Samanta et al 2014. This shows that the generation of reactive oxygen 
species (ROS) from chemotherapy leads to the activation of HIF1α and HIF2α 
and the transcription of IL-6, IL-8 and MDR-1- genes associated with bCSC 
behaviour. 
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1.7.2  catenin and WNT signaling 
The Wnt/β-catenin signalling pathway was first described in colon cancer but 
it its activation has also been described in breast cancer (Prosperi and Goss 
2010).  This is particularly the case in TNBC where either cytoplasmic or 
nuclear accumulation of β-catenin is associated with a poor prognosis 
(Khramtsov et al. 2010; López-Knowles et al. 2010).  In the recent 
identification of six TNBC subtypes, three (basal-like, mesenchymal-like and 
mesenchymal stem-like) have constitutive activation of the WNT pathway 
(Lehmann et al. 2011).  
 
The WNT-signalling pathway has been shown to be involved in many 
malignancies- influencing CSC-behaviour through many mechanisms (Klaus 
and Birchmeier 2008).  These include: increased expression of genes such as 
survivin, a WNT target gene, enhanced telomerase expression (allowing 
increased self-renewal capacity) and driving EMT through β-catenin signalling 
(Blum et al. 2009; Hoffmeyer et al. 2012; DiMeo et al. 2009).  Over-expression 
of the WNT-target genes Slug, Snail and Twist has been shown to be 
associated with nuclear accumulation of transcriptionally active β-catenin as 
well as increasing the expression of CSC markers (Mani et al. 2008). 
 
β-catenin is the major effector of the canonical WNT pathway and, upon 
stabilisation by WNT, translocates to the nucleus where it controls gene 
expression through its association with members of the T cell factor (TCF) 
family of transcription factors.  Many of these targets have been associated 
with cell cycle progression and tumour initiation and include Cyclin D1, c-Myc, 
bmi-1 and Axin 2.  Knockdown of β-catenin has been shown to correlate with 
reduced colony formation, migration in vivo tumour forming capability, as well 
as increased sensitivity to chemotherapy.  In addition, it also decreased 
expression of ALDH (Jinhua Xu et al. 2015). 
 
However, a small study of paired biopsies in a series of 29 patients receiving 
neoadjuvant chemotherapy showed no difference between β-catenin pre- and 
post-chemotherapy using immuno-histological analysis (Rosa et al. 2015). 
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1.8 Targeting breast cancer stem cells 
Since the CSC hypothesis was first-postulated just over a decade ago, there 
has been considerable interest in novel ways of targeting stem cells.  This 
approach has been varied (See Fig 1.9 below).  Strategies include targeting 
markers associated with CSC behaviour such as CD44 and ALDH (Alamgeer 
et al. 2014; DeLeo 2012), targeting components of CSC signalling pathways 
such as Notch, WNT and Hedgehog (Schott et al. 2013) and using de-
differentiation therapy to push cells from a non-differentiated to differentiated 
state with drugs such as vorinostat (Roy et al. 2010).  The latter approach is 
being used to great effect in acute pro-myelocytic leukaemia with the drug all-
trans retinoic acid (ATRA).   There have also been attempts to target drug 
efflux pumps, known to be upregulated in CSCs and responsible for cytotoxic 
drug efflux, as well as metabolic characteristics of CSCs such as HIF1α (Y. Li, 
Atkinson, and Zhang 2017; Gregg L. Semenza 2016).  Another pathway that 
has attracted much attention is apoptosis, an area to which we now focus our 
attention 
 
Figure 1.9- Methods of targeting Cancer Stem cells 
From (Y. Li, Atkinson, and Zhang 2017) 
1.9 Apoptosis and TRAIL as a therapy for breast cancer and CSCs 
Apoptosis is a form of programmed cell death utilised in embryogenesis and 
adult cell homeostasis and has a central role in tissue development and the 
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immune system.  It is of vital importance in a number of diseases including 
autoimmune disease and cancer, with its inactivation considered one of the 
hallmarks of cancerous cells (Hanahan and Weinberg 2011).  bCSCs have 
been shown to be resistant to apoptosis and express high-levels of anti-
apoptotic proteins (Pattabiraman and Weinberg 2014).  There is a clear 
rationale towards the therapeutic targeting of apoptosis: genetic aberrations 
should drive cancerous cells towards apoptosis but blocks within these cells 
prevent this.  Targeting these blocks may render cancerous cells susceptible 
to apoptosis (Avi Ashkenazi, Holland, and Eckhardt 2008). 
 
There are two key routes that lead to apoptosis; the extrinsic and intrinsic 
pathways.  Both pathways share common regulatory proteins called caspases 
(cysteine aspartic acid specific proteases) that are synthesized as inactive 
zymogens that are activated upon cleavage as part of signalling cascades.  
Common to both pathways are ‘executioner’ caspases that are responsible for 
cleaving intracellular proteins such as the cellular cytoskeleton and DNA 
repair proteins (Cryns and Yuan 1998). 
 
1.9.1  The Intrinsic Pathway 
The intrinsic apoptosis pathway is activated by intracellular stress such as 
DNA damage, hypoxia, cell cycle arrest and the loss of pro-survival factors 
within the cell (Khan, Blanco-Codesido, and Molife 2014; Galluzzi, Kepp, and 
Kroemer 2012).  
 
A key molecule in detecting cellular damage and instigating the intrinsic 
pathway is the tumours-suppressor protein p53, the ‘guardian of the genome’ 
(Hanahan and Weinberg 2011).  Most cytotoxic chemotherapy and 
radiotherapy activates the intrinsic apoptosis pathway through activation of 
p53 (Lowe et al. 1994).  Unfortunately, as functional inactivation of p53 is one 
of the most commonly mutated genes in cancer, many tumours are either 
inherently resistant or acquire resistance to treatment.   
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The pathway is under tight control of both pro- and anti-apoptotic proteins that 
are part of the bcl-2 (B Cell Lymphoma-2) family.   Central to the intrinsic 
pathway is the release of cytochrome C into the cytoplasm from the 
mitochondria that subsequently activates a caspase-activating complex called 
the apoptosome.  The key component of the apoptosome is Apaf-1 that binds 
and activates pro-caspase 9 leading to the cleavage of effector caspases.  
This is the point where the intrinsic and extrinsic pathways converge (Hassan 
et al. 2014).  
 
The anti-apoptotic members of bcl-2 family include Bcl-2 related gene A1 
(A1), Bcl-2, Bcl-2-related gene, long isoform (Bcl-XL), Bcl-w, and myeloid cell 
leukemia 1 (MCL-1) with the pro-apoptotic members being BAD (Bcl-2 
antagonist of the cell death), BID (BH3 interacting domain death agonist), BIM 
(Bcl-2 interacting mediator of the cell death), BMF (Bcl-2 modifying factor), 
PUMA (p53 up regulated modulator of apoptosis) and Noxa (Khan, Blanco-
Codesido, and Molife 2014).  In addition to this, there are also inhibitors of 
apoptosis proteins (IAPs) can also inhibit apoptosis by binding to effector 
caspases as well as caspase 9.  There are 8 members of the IAP family - 
NAIP, XIAP, cIAP1, cIAP2, ILP2, livin, survivin and BRUCE (Plati, Bucur, and 
Khosravi-Far 2011).  
 
1.9.2 The extrinsic pathway 
The extrinsic apoptosis pathway causes apoptosis through binding of various 
compounds to trans-membrane death receptors (DRs) on the cell surface. 
There are functional surface receptors that have an extracellular cysteine rich 
domain (CRD) and an intracellular death domain (DD) as well as decoy 
receptors (DcRs) that have the CRD but no intracellular component.  Ligands 
that bind to these receptors include TRAIL (DR4 and DR5), FasL 
(Fas/APO1/CD95) and TNF (TNF-R1). 
 
Binding of the ligand to the receptor leads to trimerization and clustering of 
multiple death receptors that is thought to amplify the apoptotic response 
(Khan, Blanco-Codesido, and Molife 2014).  The death effector domain (DED) 
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of the adaptor protein Fas-associated death domain protein (FADD) recruit 
the initiator caspases 8 and 10 to the cytoplasmic tail of the receptor to form 
the death-inducing signaling complex (DISC).  This provides the platform for 
the autocatalytic activation of these initiator caspases allowing them to initiate 
the proteolytic cascade and activate the effector caspases 3, 6 and 7 allowing 
apoptosis and cross-talk with the intrinsic apoptosis pathway (Ashkenazi and 
Dixit 1998). 
 
The extrinsic apoptosis pathway is mainly under negative control at the level 
of the DISC.  Here it has been traditionally thought that Cellular FLICE-Like 
Inhibitory Protein (cFLIP), antagonizes caspases 8 and 10 by binding FADD 
via its own DED domains and prevents them forming part of the DISC and 
becoming activated (Safa 2012).  An alternative method of inhibition is the use 
of the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4) that lack 
either an intracellular death domain (DcR1) or have a truncated form (DcR2) 
that is unable to initiate apoptosis.  This results in no apoptosis when these 
receptors are bound by TRAIL.  However, recent work has demonstrated that 
cFLIP has a complex role in the extrinsic apoptotic pathway.  Whilst traditional 
thinking has been that cFLIP competed with pro-caspase 8 binding to FADD, 
Hughes et al showed that different mechanisms exist (Hughes et al. 2016).  In 
this paper it was demonstrated that cFLIP binding to the DISC is a co-
operative pro-caspase 8 dependent process. Even low levels of cFLIP-S 
inhibited DED-mediated caspase-8 oligomerization (and apoptosis) preventing 
the functional alignment of catalytic dimers that lead to apoptosis.  The 
relationship with cFLIP-L was more complex with high levels of cFLIP-L being 
required to form pro-caspase-8:cFLIP-L heterodimers and prevent apoptosis. 
Therefore, rather than competing for binding with caspases, cFLIP forms 
heterodimers with their pro-caspase precursors that prevents their catalytic 
activity and activation of the apoptotic cascade.  
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Figure 1.10- Intrinsic and extrinsic apoptosis pathways 
Figure showing both the extrinsic and intrinsic apoptosis pathways and their 
interactions.  The inhibitory role of cFLIP as it competes with Caspases 8 and 
10 for binding with FADD is also shown (figure taken from Holland 2014). 
 
1.9.3 Targeting apoptosis in breast cancer with TRAIL 
Whilst chemotherapy and radiotherapy target proliferation, the targeting of 
apoptosis has the potential to eliminate cancerous cells entirely - potentially 
leading to cure (Lemke et al. 2014).  Whereas conventional chemotherapy 
and radiotherapy depends on p53 to induce apoptosis, targeting the extrinsic 
apoptosis pathway bypasses this often-redundant protein in malignant cells. 
 
Since its discovery in the late 1990s, tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) has shown promising activity against a 
range of malignancies including leukaemia, multiple myeloma, 
neuroblastoma, lung, colon, breast, prostate, pancreas, kidney and thyroid 
carcinoma in in vitro models (Kruyt 2008).  It also selectively targeted 
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malignant cells and showed minimal systemic toxicity in mouse models 
(Walczak et al. 1999).  TRAIL works by binding to the external DR4 and DR5 
receptors and induces apoptosis via both the extrinsic and intrinsic apoptosis 
pathways through molecular crosstalk. It also displays minimal cytotoxic 
activity against normal non-cancerous cells (Rahman et al. 2009). 
Unfortunately, there does appear to be resistance amongst some tumour 
types to TRAIL (LeBlanc and Ashkenazi 2003), particularly amongst breast 
cancer cell lines (Rahman, Pumphrey, and Lipkowitz 2009a) and Phase 1 and 
Phase 2 clinical trials have been largely disappointing in a wide variety of 
tumour types (Holland 2014).  The phenotypic markers such as triple-
negative/basal-like features and mesenchymal gene expression seemed to 
predict response to TRAIL therapy, whereas epithelial gene expression and 
oestrogen receptor-positivity (expressed in 70% of breast cancers) predicted 
resistance (Rahman, Pumphrey, and Lipkowitz 2009b).  Despite this, a Phase 
2 clinical trial in triple negative, ‘mesenchymal-like’ breast cancer failed to 
show any difference in progression-free or overall survival between nab-
paclitaxel (a cytotoxic chemotherapy agent) in combination with either 
tigatuzumab (an anti-DR5 antibody) or placebo (Forero-Torres et al. 2015). 
  
Despite this, there is some evidence that TRAIL targets the CSC component 
of many breast cancer cell lines (Piggott et al. 2011 and French, unpublished 
work).  There has also been considerable interest in whether breast cancer 
cells can be sensitised to TRAIL. 
1.9.4 Sensitising breast cancer to TRAIL 
1.9.4.1 Chemotherapy 
A wide variety of classes of cytotoxic agents have been used to sensitise 
tumours to TRAIL-induced apoptosis including platinums, anthracyclines, 
taxanes, topoisomerase inhibitors and vinka alkaloids across a broad range of 
tumour types (El-Zawahry, McKillop, and Voelkel-Johnson 2005; Shankar, 
Chen, and Srivastava 2005; Shankar, Singh, and Srivastava 2004; Shamimi-
Noori et al. 2008; Ray and Almasan 2003). 
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In breast cancer, it has been demonstrated that a synergistic relationship 
between chemotherapy and TRA-8 (an antibody to DR5) exists with TRA-8 
treatment and doxorubicin or paclitaxel, producing synergistic cytotoxicity 
against 12/14 or 10/14 basal-like cell lines respectively, as well as some 
luminal and Her-2 positive lines that were resistant to TRA-8 treatment alone 
(Oliver et al. 2012).  Though, as stated above, clinical trials were a 
disappointment. 
 
Two studies have examined the effect of combining chemotherapy with TRAIL 
treatment on CSCs in breast cancer.  One study showed promising effects on 
triple-negative cell lines in vitro (as measured by ALDH and mammosphere 
activity) with a reduction in CSCs from 36% to 24% with docetaxel, 21% with 
cisplatin, 30% with TRAIL and 1% with cisplatin and TRAIL (Yin et al. 2011).  
This was mediated via a decrease in Wnt-1 signaling and its downstream 
targets, β-catenin and cyclin D1 and led to increased apoptosis, reduced 
proliferation and mammosphere formation.  The effects on CSCs of 
chemotherapy regimes in common use in the clinic, such as the combination 
of FEC and the drug docetaxel, in combination with TRAIL have not been 
examined. 
 
Various mechanisms have been proposed to underlie chemotherapy-induced 
TRAIL sensitization, including increased DISC formation, upregulation of pro-
apoptotic (including caspases) and suppression of anti-apoptotic proteins (ie 
IAPs, cFLIP and bcl2) including of the pro- (ie DR5) and potentially anti-
apoptotic TRAIL-Rs (ie DcR1) (Zinonos et al. 2014; Yin, Rishi, and Reddy 
2015; X. Liu et al. 2013; Oh et al. 2012; Newsom-Davis, Prieske, and Walczak 
2009).   
 
1.9.4.2 Targeted treatments to sensitise to TRAIL 
The identification of mechanisms of TRAIL resistance has led to extensive 
efforts to try and increase the sensitivity of cancerous cells to TRAIL through 
using targeted blockers against TRAIL-antagonistic pathways.  These include 
inhibitors of XIAP, Src, the Jak-2-Stat3-Mcl1 pathway, Bcl2 and Wee1.  Some 
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have promising pre-clinical results but none have yet made it into clinical trials 
(S. Park et al. 2014; Garimella et al. 2014; De Luca et al. 2014; Jing Xu et al. 
2013; Abdulghani et al. 2013; Kisim et al. 2012; Garimella, Rocca, and 
Lipkowitz 2012).  One key regulatory component of the extrinsic apoptosis 
pathway down-stream of the death receptors activated by TRAIL is cFLIP.  
 
1.9.5 cFLIP 
cFLIP is an anti-apoptotic protein that antagonises the activation of caspases 
8 and 10 in the death-receptor signalling pathways.  It consists of three forms: 
cFLIP long (cFLIP-L), cFLIP short (cFLIP-S) and cFLIP-R.  All of these can 
bind to FADD (Fas-associated death domain), caspase-8 or -10 and TRAIL 
receptor 5 (DR5) in a ligand-dependent and -independent fashion to form an 
apoptosis inhibitory complex (AIC).  All three forms contain two DED domains, 
DED1 and DED 2, and in addition cFLIP-L contains a large (p20) and small 
(p12) caspase-like domain with no catalytic activity.  cFLIP-S and cFLIP-R 
lack these domains and instead have a small c-terminus and all forms of 
cFLIP can be cleaved by Caspase 8 at D376 to form two cleaved products 
(p43-FLIP and p22-FLIP).  All of these variants can act as anti-apoptotic 
proteins (Safa 2012) ( Fig 1.11).   
 
 
Figure 1.11- Alternative variants of cFLIP 
From (Safa 2012) 
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Interference with cFLIP expression sensitises tumour cells to both TRAIL and 
chemotherapy (Day, Huang, and Safa 2008a, 2008a; Piggott et al. 2011).  
cFLIP has been shown to be upregulated in many malignancies and has been 
correlated with overall survival, though neither of these has been shown in 
breast cancer (Safa 2012).  cFLIP has been shown to be important in 
chemotherapy mediated apoptosis in colorectal cancer (Longley et al. 2005). 
 
In addition to its anti-apoptotic role, cFLIP has been shown to up regulate both 
proliferative and survival pathways such as NFkB, ERK, AKT and WNT – the 
latter being a key component in inducing EMT (Safa 2012, French 
unpublished work).  It has also been shown to have a role in the 
ubiquitynation of  both  catenin and HIF1 (Ishioka et al. 2007) 
 
cFLIP is an exciting target for therapeutic intervention. However, its high 
homology with pro-caspase 8 makes the design of a cFLIP specific inhibitor,  
(i.e. one which does not also inhibit the pro-apoptotic caspase-8), highly 
challenging (Day, Huang, and Safa 2008).   Previous studies have focused on 
chemotherapeutics that down-regulate cFLIP transcription and sensitise to 
death-receptor triggered apoptosis and include cisplatin and doxorubicin 
(Longley et al. 2005; Abedini et al. 2008; Song et al. 2003; El-Zawahry, 
McKillop, and Voelkel-Johnson 2005; Chatterjee et al. 2001).  Other agents 
that have also been found to have an effect on cFLIP on both the 
transcriptional and translational level are the histone deacetylase inhibitors 
(HDACi), of which vorinostat is the most promising (Frew et al. 2008; Piggott 
et al. 2011).   
 
In breast cancer specifically, low dose paclitaxel has been shown to induce 
apoptosis in a FADD- and cFLIP-dependent manner in the MCF7 cell line. 
Less than 10nM of paclitaxel, down-regulated cFLIP and led to apoptosis 
mediated through Caspases 8 and 10 (Day et al. 2006).  In the same cell line, 
siRNA knockdown of cFLIP led to DR5- and FADD-mediated apoptosis (Day, 
Huang, and Safa 2008a).  There is also evidence that overexpression of 
cFLIP in MCF7 cell lines protects against paclitaxel mediated-apoptosis (Z. 
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Wang et al. 2005), although this effect was not seen for docetaxel.  cFLIP has 
also been shown to mediate resistance to  paclitaxel and carboplatin in 
ovarian cancer cell lines and hepatocellular carcinoma (Vidot et al. 2010; 
Chen et al. 2010).  A further study from our laboratory, combining TRAIL with 
a siRNA knockdown of cFLIP, demonstrated that four breast cell lines 
(MCF7s, MDA-MB-231s, SK-BR3 and BT474) were sensitised to TRAIL-
induced apoptosis.  Strikingly, this combination seemed to preferentially target 
the CSCs within these populations (leading to a 80% reduction in primary 
tumours and a 98% reduction in metastases following transplantation in a 
mouse xenograft model) (Piggott et al. 2011). 
 
1.10 Linking cFLIP to the degradation of HIF1α and Wnt/β-catenin- the 
ubiquitin-proteosome system (UPS) 
 
The ubiquitin-proteasome system (UPS) controls the stability of many cellular 
proteins including HIF1α and Wnt/β-catenin (J. C. Lee and Peter 2003).  
Under normal conditions, the expression of HIF1α and β-catenin is maintained 
at a low level in the cytoplasm through degradation by the UPS (Kitagawa et 
al. 1999; Tanimoto et al. 2000).  When either system is stimulated, by hypoxia 
or WNT signalling respectively, the ubiquitynation is inhibited leading to 
translocation of these proteins to the nucleus and altered gene transcription 
(Forsythe et al. 1996; Polakis 2000).  It has been reported that protein 
aggregates within cells can alter the UPS, leading to accumulation of proteins 
that would normally be degraded. cFLIP-L has been shown to interfere with 
the degradation of both HIF1α and β-catenin (Naito et al. 2004; Ishioka et al. 
2007) by aggregating both with itself and with FADD, a component of the 
extrinsic apoptosis system. Homotypic interaction between the DEDs of cFLIP 
leads to filamentous structures called death effector filaments that interfere 
with the UPS (Tibbetts, Zheng, and Lenardo 2003).  It has been demonstrated 
that mutation of the DEDs on cFLIP-L lead to reversal of the impairment of the 
UPS and, in a lung cancer cell line, knockdown of cFLIP using shRNA led to a 
reduction in both HIF1α and β-catenin (Ishioka et al. 2007). The reduction in 
β-catenin was confirmed in two breast cancer cell lines (MCF7 and MDA-MD-
231) using siRNA-mediated knockdown of cFLIP (French et al. 2015).  The 
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effect has also been shown to be medicated through the UPS as well as 
through cFLIP co-localising with transcription factors within the nucleus to 
enchance β-catenin dependent gene expression (Naito et al. 2004; French et 
al. 2015) 
 
1.11 Development of a small molecule inhibitor of cFLIP 
Recently our laboratory has identified, through in silico protein modelling, a 
small-molecule that is able to specifically interfere with the binding pocket on 
DED1 of cFLIP.   As has been shown recently, DED1 is considered the most 
important of the two DED domains contained on cFLIP and has a role in both 
in the inhibition of apoptosis as well as the formation of the filamentous 
structures that inhibit the UPS (Hughes et al. 2016; Ishioka et al. 2007).  
Importantly, this small molecule, named OH14, does not interfere with pro-
caspases 8 or 10, as such apoptosis can still be induced via formation of the 
DISC.   Our c-FLIP inhibitor, OH14, has shown synergistic activity in 
combination with TRAIL on both bulk and stem cells in the TRAIL 
resistant MCF-7 and BT474 cell lines (Hayward, unpublished work).  One of 
the aims of this work will be to assess its role in combination with 
chemotherapy. 
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1.12 Projects aims and objectives 
It has been demonstrated that standard chemotherapy regimes currently in 
use in breast cancer may differ in their effectiveness in targeting breast CSCs 
and potentially increase the proportion of CSCs remaining after treatment. 
One reason for failure may be the resistance to apoptosis displayed by CSCs 
as well as increased CSC signalling.  
 
Previously we have demonstrated that siRNA-mediated knockdown of cFLIP, 
in combination with TRAIL, targets CSCs.  This subsequently led to the 
development of a novel compound targeted against the DED1 binding site of 
cFLIP that prevents activity.  In this project, we want to target residual CSCs 
remaining after chemotherapy using TRAIL, in combination with the c-FLIP 
inhibitor OH14. This may increase its effectiveness in targeting both the bulk 
and CSC components of these tumours.  This effect could be mediated by 
increased apoptosis in those cells but also through potentially affecting CSC 
pathways such as WNT/ β-catenin and HIF1α signalling.  
 
Therefore, the aims of this project are to: 
• Employ in vitro models through which the effect of regimens in 
common use in breast cancer clinic on CSCs can be evaluated 
• Establish that a combination of the c-FLIP inhibitor OH14 and TRAIL 
targets CSCs in breast cancer after chemotherapy 
• Assess the effect mechanism of any CSC-targeted effect.  Potential 
mechanisms include apoptosis and HIF1α/ β-catenin signalling.
  
  
2 Materials and Methods  
  44 
2.1 Cell lines and cell culture 
2.1.1 Experimental Cell Lines 
The human breast cancer cell lines MCF-7, HCC1954, MDA-MB-231 and 
MDA-MB-436 were gifts from other members of the Clarkson laboratory and 
the cell line SUM 149 was purchased from Asterand Bioscience (Detroit, 
USA).  These cell lines were chosen as they have been well characterised in 
regards to stem cell assays in regards to ALDH (Bhola et al. 2013; Conley et 
al. 2012; Charafe-Jauffret et al. 2009) and represent a wide-spectrum of the 
molecular subtypes of breast cancer.  Breast cancer cell lines have been used 
extensively to investigate the biology of breast cancer as well as to screen 
and investigate novel therapeutics (Kao et al. 2009).  They have yielded a 
wealth of information concerning the genes and signalling pathways that 
regulate the malignant process. Cell lines are advantageous in that they are 
easily propagated, relatively easy to genetically modify, and can yield 
reproducible results (Vargo-Gogola and Rosen 2007).  However, there has 
been some debate as to how representative of human breast cancers cell 
lines are.  Comparison of the gene-expression profiles of 51 human breast 
cancer cell lines and primary breast cancers has shown that there is some 
loss of the variation of genome copy number variations (CNVs) between 
luminal and basal subtypes of breast cancer when propagated as cell lines- 
suggesting that the process of establishment and propagation in culture has 
selected for a certain degree of genomic alteration (Neve et al. 2006).  In 
addition this study also showed that not all the molecular subtypes of breast 
cancer were represented with no clear distinction between luminal subtypes.  
These differences can probably be explained by the fact that most of the cell 
lines were obtained from advanced-stage tumours as well as pleural effusions 
and therefore may represent the most malignant variants that could be 
adapted to culture. 
2.1.1.1 MCF-7 
The MCF-7 cell line is an oestrogen-dependent luminal human breast 
adenocarcinoma that was isolated from a pleural effusion.  It is generally 
recognised to have poor metastatic properties and expresses receptors to 
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both oestrogen and progesterone but does not overexpress the Her-2 
receptor (Neve et al. 2006). 
2.1.1.2 HCC1954 
HCC 1954 is a moderately invasive basal invasive ductal adenocarcinoma 
obtained from a grade three primary breast carcinoma.  It lacks receptors to 
oestrogen, progesterone but overexpresses the Her-2 receptor (Neve et al. 
2006). 
2.1.1.3 MDA-MB-231 
The MDA-MB-231 cell line is a invasive basal B adenocarcinoma obtained 
from a pleural effusion.  It lacks receptors to oestrogen, progesterone and 
Her-2 receptor and has one mutant p53 allelle  (Neve et al. 2006). 
2.1.1.4 MDA-MB-436 
MDA-MB-436 is a moderately invasive basal invasive ductal carcinoma 
obtained from a pleural effusion.  It lacks receptors to oestrogen, 
progesterone and Her-2 receptor (Neve et al. 2006). 
2.1.1.5 SUM 149 
SUM 149 is a highly-aggressive inflammatory ductal carcinoma that is basal in 
origin and is negative for the oestrogen and progresterone receptors and does 
not overexpress the Her-2 receptor (Neve et al. 2006). 
2.1.2 Maintenance of cell lines  
The MCF-7, HCC 1954, MDA-MB-231 and MDA-MB-436 cell lines were 
cultured in RPMI medium (Invitrogen, Paisley, UK) with 10% fetal bovine 
serum (FBS; Sigma, Dorset, UK) and 2mM L-glutamine (Invitrogen).  Cells 
were treated with 1% penicillin/streptomycin (Sigma, Dorset, UK).  The SUM 
149 cell line was cultured in Hams F12 media (Invitrogen, Paisley, UK) 
supplemented with 5% fetal bovine serum (FBS; Sigma, Dorset, UK), 2mM L-
glutamine (Invitrogen), 10mM HEPES (Invitrogen), 1μg/ml Hydrocortisone 
(Invitrogen) and 5μg/ml insulin (Invitrogen). 
 
Cells were maintained in a sterile, humidified 37oC incubator and CO2 levels 
were kept at 5%. All cell lines were routinely cultured in either T25 or T75 
  46 
tissue culture flasks (Nunc, Leics, UK). When cells reached a confluency of 
80-90%, they were passaged on at a split ratio of 1:6- 1:10 at appropriate 
times (See Table 2.1). Cell passaging was carried out by removing used 
medium followed by the addition of 0.05% Trypsin/EDTA (Invitrogen, Paisley, 
UK) to each flask and left to incubate at 37oC for 5-10 minutes. Following this 
incubation period, cells were checked under the microscope to ensure that all 
cells had detached and were then diluted with culture medium according to 
appropriate splitting ratios. All cell lines were not maintained for any more 
than 30 recorded passages. 
 
Cell line Molecular subtype Passaging ratio 
MCF7 ER positive 1:8-1:10 
HCC 1954 Her2 positive 1:5 
SUM149 TNBC, inflammatory 1:6 
MDA-MB-231 TNBC 1:8-1:10 
MDA-MB-436 TNBC 1:6 
Table 2.1 List of cell lines and passaging ratios 
2.1.3 Long term storage of cell lines 
In order to maintain a low passage number, cells were frozen and cryo-stored 
in liquid nitrogen.  Confluent flasks were detached using 0.05% Trypsin/EDTA 
(Invitrogen, Paisley, UK), transferred to a 15ml falcon tube (BD Biosciences) 
and resuspended in at least the equivalent volume of media to 0.05% 
Trypsin/EDTA.  Cell were then spun at 1200rpm for 5 minutes before the 
pellet was resuspended in freezing medium (10% v/v dimethyl sulfoxide 
(DMSO, Sigma, Dorset, UK) and 1ml aliquots were placed in 1.5ml cryo-tubes 
(Nunc, Leics, UK).  These tubes were then placed in a container containing 
isopropanol to facilitate gradual freezing at -800C overnight.  After this, cells 
were transferred in dry ice to the liquid nitrogen container.  For retrieval of 
cells, cells were quickly defrosted in a 370C waterbath, resuspended in 10ml 
of complete media, centrifuged for 5 mins at 1200rpm, the supernatant 
removed and the pellet resuspended in 7mls of culture medium in a T25 flask. 
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2.1.4 Cell Seeding 
After cell detachment using trypsin, cells were collected in a 15 mL falcon 
tube.To ensure correct cell seeding densities, cells were counted using Fast 
Read Slides (Immune Systems,  UK),). Single cells were counted 
automatically by adding 9 μL of cell suspension to the each well of the 
counting slides. Cells were then diluted accordingly with culture medium and 
seeded into appropriate culture plates depending on the assay being 
performed (Table 2.2). 
 
Plate Relative Surface Area Volume (μL) 
 
96-well (Costar) 0.2 100 
24-well (Costar) 1 500 
12-well (Costar) 2.5 1000 
6-well (Costar) 5 2000 
60mm dish (Costar) 20 5000 
Table 2.2- List of plate formats and normal media volumes 
2.2 Viability 
2.2.1 Chemotherapy protocol 
Cells were plated at different concentrations based on the rate of growth of 
the cells in culture. On Day 1 50000 cells/ml of the MCF-7, HCC 1954 and 
MDA-MB-436 cell lines and 25000 cells/ml cells of the SUM 149 and MDA-
MB-231 cell lines were plated in 96-well plates and allowed to grow for 24 
hours in 90uL of media.  At this point an eight-log range of doses of 
chemotherapy was added (10uL of chemotherapy, leading to a total volume of 
100uL) and cells were treated for 72hrs.  Viability was assessed using the 
CellTiter Blue assay. 
 
The chemotherapy agents 5-FU, Epirubicin, Paclitaxel and Docetaxel were 
produced by Cayman Chemicals and purchased from Cambridge 
Biosciences, Cambridge, UK.  Cyclosphosphamide was purchased in the form 
of 4-Hydroperoxycyclophosphamide as this is the active metabolite that is 
formed from the degradation of cyclophosphamide in vivo from Niomech, 
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Bielefield, Germany.  Cells were diluted in DMSO for long-term storage with 
aliquots being thawed and diluted in cell-appropriate media prior to use.  
DMSO concentration did not exceed 0.1% and controls contained the same 
amount of DMSO as the maximum concentration that was used in any 
experiment. 
 
For dose finding experiments, chemotherapy was made near to a maximal 
concentration that 0.1% DMSO would allow and then diluted in an 8 log-fold 
fashion by diluting the media containing chemotherapy by 10.  This was used 
to generate an IC50 value that was used for further experiments that was 
controlled by the addition of the relevant DMSO concentration to control wells. 
 
For combination chemotherapy, the IC50 value of each individual compound 
was taken and tripled to represent a value of 300% of its individual IC50 value 
and combined with other compounds again at the same 300% concentration  
This was then diluted and added to cells to calculate a percentage value of 
the 100% IC50 concentration.  This method ensures that each individual 
compound remains in a fixed dilution in any given mixture and is a recognized 
method of testing combinations of drugs (T. C. Chou and Talalay 1984; T.-C. 
Chou 2006). 
2.2.2 OH14 and TRAIL protocol 
Cells were plated at the confluencies listed above but different amounts of 
media was used depending on the plates used and the experiments being 
undertaken (Table 2.2 and Section 2.2.1) 
 
The cytoxicity of OH14 (produced by Cardiff University) and TRAIL 
(SuperKillerTRAIL, Enzo Life Sciences) was assessed using a log-range of 
both with viability being assessed using the CellTiter Blue assay (Section 
2.2.3).  For experiments combining chemotherapy and TRAIL or OH14, TRAIL 
was added 72hrs after the addition of chemotherapy with OH14 being added 
one hour before.  OH14 was diluted from DMSO stock solutions at 100mM in 
cell appropriate media, leading to a concentration of DMSO never exceeding 
0.1% with controls containing the same amount of DMSO.  TRAIL was diluted 
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in TRAIL buffer and stored at -800C before being diluted in media and applied 
to cells.  For some cell lines the IC50 value of TRAIL was calculated, whilst for 
the MDA-MB-231 cell line 20ng/ml was used as this level has previously been 
shown by others in our laboratory to lead to the maximal amount of caspase 
activity (Piggott et al. 2011). 
 
2.2.3 Cell Titer Blue 
The CellTiter Blue assay (Promega, Southampton, UK) provides a 
fluorometric method for the number of viable cells present. This assay 
measures the metabolic capacity of cells using resazurin as an indicator dye. 
Viable cells have the ability to convert resazurin into resofurin, a highly 
fluorescent derivative. Any non-viable cells will lack the metabolic capability to 
make this conversion and thus fail to produce a fluorescent signal. 
 
Before use, CellTiter Blue reagent was thawed to room temperature. 20μl of 
CellTiter Blue reagent was added per 100μl of culture media and incubated at 
370C with 5% CO2 for a minimum of 90 minutes. The resulting fluorescence 
was then measured by setting excitation/emission wavelengths to 560/590nm 
on a Fluostar Optima plate reader (BMG Labtech, Bucks, UK). 
 
2.3 Tumoursphere formation assay 
The tumoursphere assay is a functional assay designed to isolate the cancer 
stem cells from cell lines or primary cultures by exploiting their capacity to 
resist anoikis. Cells are cultured in suspension which induce anoikis in the 
bulk population but allow the stem cells to remain. These cells continue to self 
renew and divide and as a result produce small colonies termed 
tumourspheres. These can be subjected to serial passaging to assay for self-
renewal. Quantification of tumourspheres is therefore indicative of stem cell 
number (Dontu et al. 2003; Shaw et al. 2012). Whilst the formation of primary 
mammospheres is a measure of both stem cell and early progenitor activity, 
their harvesting and dissociation into single cells before passaging them again 
allows for quantification of their self-renewal- a property of CSCs (Shaw et al. 
2012).  Tumoursphere assays were carried out in non-adherent conditions in 
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a serum-free epithelial growth medium (MEBM, Lonza), supplemented with 
B27 (Invitrogen), 20 ng/ml EGF (Sigma), Insulin (Sigma), and hydrocortisone 
(Sigma) for initial experiments. Further optimisation of the tumoursphere 
assays used MammoCult Media (Stem Cell Technologies) with the addition of 
heparin (Stem cell Technologies), hydrocortisone (Sigma) and 1% 
Penicillin/Streptomycin (Life Technologies).  For all tumoursphere 
experiments after a four day adherent treatment, MammoCult media was 
used. Cells were plated in ultra-low attachment plates (Costar, Corning) at a 
density of 5000 cells/ml. After 7 days tumourspheres were counted, then 
collected by gentle centrifugation (300rcf), dissociated in 0.05% trypsin, 
0.25% EDTA (Invitrogen) and re-seeded at 5000 cells/ml for subsequent 
passages.  
 
2.4 Mathematical model for absolute CSC number 
To determine the absolute number of CSCs that were present at the end of 
treatment in adherent conditions a simple mathematical model was 
constructed.  In this model we determined that a well of untreated cells in a 96 
well plate contained approximately 10000 cells and that this equated to a 
viability of 100% as measured by Cell Titer Blue.  For each chemotherapeutic 
agent we then entered the mean viability of the IC50 value calculated 
previously assuming a linear relationship between CTB and absolute cell 
number, a 50% reduction in CTB equates to a 50% reduction in cell number. 
This viability was then multiplied by the percentage mammosphere formation 
in Passage 2 for the corresponding treatment condition to give an absolute 
number of CSCs remaining at the end of the treatment for that condition.  This 
can be calculated by the following equation: 
 
Absolute CSC number= (10000 x viability) x Percentage mammosphere          
formation in Passage 2 
 
2.5 Colony formation assay 
To assess the ability of individual cells to survive, proliferate, and expand into 
small colonies, the colony formation assay was performed. (Locke et al. 2005)  
Cells were seeded at low density of 125 cells per/mL in 6-well plate format, in 
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normal growth medium, and left for 6 days. To quantify colonies, media was 
removed and cells gently washed with PBS before being stained with crystal 
violet/ethanol solution for 15 min at room temperature. The crystal violet 
solution was then removed before cells were washed twice with PBS and if 
necessary under running water to remove any excess solution. Colonies were 
then either counted manually or automatically using a GelCount plate reader, 
and software set to count colonies of sizes between 100-1000 μm.  
 
2.6 siRNA transfection 
Short interfering RNA (siRNA) targeting an irrelevant scrambled control, cFLIP 
and HIF1α were transfected into selected cells (ON-Target plus SMART pool, 
GE Dharmacon, Bucks, UK.  Each siRNA pool was resupended according to 
the manufacturers protocol in 250 μL of RNA-free water to obtain a 20 μM 
concentration. Transfection was performed on cell using Lipofectamine 
RNAiMAX (Invitrogen) and serum-free Opti-MEDM (Invitrogen) according to 
the manufacturers protocols to give a final concentration of 10nM.  Volumes 
and concentrations of each of the reagents used are listed in Table 2.3.  The 
appropriate volume of siRNA was diluted in Opti-MEM before the appoproate 
volume of Lipofectamine RNAiMAX was added.  This mixture was then 
vortexed for 15secs and left to incubate for 5 mins at room temperature. 
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Tissue 
Culture 
Vessel 
Surface 
Area 
(cm2) 
Volume of 
plating 
media 
Volume of 
OptiMEM 
medium 
Final 
SiRNA 
conc. 
(nM) 
Volume of 
Lipo-
fectamine 
RNAiMAX 
96 well 0.2 100μL 10 μL 20 nM 0.1 μL  
 
6 well 10 2mls 250 μL 20 nM 5 μL 
60mm 
dish 
20 4mls 552.5 μL 20 nM 10 μL 
 
Table 2.3- Volumes and concentrations for SiRNA transfections 
   
siRNA Target Sequence (5’-3’) Catalogue Number 
Human control ON-
Target plus SMART 
pool 
 
UGGUUUACAUGUCGACUAA Dharmacon D-
001810-10 
 
UGGUUUACAUGUUGUGUGA  
UGGUUUACAUGUUUUCUGA  
UGGUUUACAUGUUUUCCUA  
Human cFLAR ON-
Target plus SMART 
pool 
 
GUGCCGGGAUGUUGCUAUA Dharmacon 
L-003772-00-0005 CAAGCAGUCUGUUCAAGGA 
CAUGGUAUAUCCCAGAUUC 
CCUAGGAAUCUGCCUGAUA 
Human HIF1A ON-
Target plus SMART 
pool 
GAACAAAUACAUGGGAUUA Dharmacon 
L-004018-00-0005 AGAAUGAAGUGUACCCUAA 
GAUGGAAGCACUAGACAAA 
CAAGUAGCCUCUUUGACAA 
   
 
Table 2.4- SiRNA sequences used in this project 
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2.7 Flow cytometry 
2.7.1 Aldefluor assay 
The Aldefluor assay (Stemcell Technologies, Grenoble, France) is a method 
to identify stem cells on the basis of their high aldehyde dehydrogenase 
(ALDH) activity. A fluorescent aldefluor reagent diffuses into cells and is a 
substrate for ALDH. The amount of fluorescent ALDH reaction product is 
directly proportional to the ALDH activity in cells. Cells with high expression of 
ALDH are recognised by comparing the fluorescence of test cells with that of 
a control sample containing the specific ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB).  
 
Aldefluor reagents were prepared according to manufacturer’s instructions. 
Transfected cells were removed from tissue culture plates using 1mM EDTA 
and centrifuged at 1100rpm for 5 minutes. The cells were washed twice in 
FACS buffer by resuspension and centrifugation. Cells were suspended in 
1ml of aldefluor assay buffer and counted. The samples were adjusted to a 
concentration of 2x105 cells/ml with aldefluor assay buffer. A ‘control’ and a 
‘test’ tube were prepared for each sample to be tested and 1ml of the cell 
suspension was placed into each ‘test‘ tube. 5μl of DEAB reagent was added 
to the control tube and recapped immediately before 5μl of activated aldefluor 
substrate was added per ml of test suspension in the ‘test’ tube. The 
suspension was mixed and 0.5ml was immediately transferred to the ‘control’ 
tube containing the DEAB substrate. The ‘test’ and ‘control’ tubes were 
incubated for 45 minutes at 37oC. The tubes were then centrifuged at 
1100rpm for 5 minutes, the pellets resuspended in aldefluor buffer and placed 
on ice. The fluorescence of cells was measured in the green fluorescence 
channel of a FACS Accuri flow cytometer (BD Biosciences). Analysis was 
performed using FlowJo software.  
 
2.8 DAPI/Annexin V assay 
2.8.1 DAPI Cell Cycle 
For analysis of cell cycle progression the nuclear marker DAPI to determine 
the DNA content of individual cells which was used to determine the cell cycle 
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stage of cells. On the day of analysis cells were harvested, counted and 
diluted in PBS to equal cell numbers up to 1 x 106 cells/mL. Cells were then 
pelleted again be centrifugation for 5 min at 1200 rpm before being 
resuspended in DAPI solution containing 5 μg/mL DAPI (ThermoFisher 
scientific) in 0.01% IGEPAL CA-630 (Sigma) in PBS and incubated for 5 min 
at room temperature. Cells were then placed on ice and covered from light 
until analysed. 
  
To analyse DAPI stained cells, each sample was filtered through a 40 μm cell 
strainer (BD Biosciences) into a flow cytometry collection tube (BD 
Biosciences) to form a single cell suspension. Flow cytometry was performed 
on a BD LSRFortessa flow cytometer (BD Biosciences) and analysed using 
FlowJo analysis software. Cells were gated by FSC-area/SSC-area and by 
FSC-area/FSC-height to obtain a single cell population and to remove 
artefacts and doublets. Single cells were then analysed by histogram plots 
using DAPI-area to determine the DNA content of cells.  
 
2.8.2 Annexin V apotosis assay 
To analyse the levels of early and late apoptotic cells in differentially treated 
cells the annexin V apoptosis assay (ThermoFisher scientific) was used to 
detect levels of external phosphatidylserine on apoptotic cells. On the day of 
analysis cells were harvested, pelleted and washed in cold PBS before being 
recentrifuged. Washed cells were resuspended in 100 μL of 1X annexin-
binding buffer and counted. Cells were then diluted in 1X annexin-binding 
buffer to 1 x 106 cells/mL, with 100 μL of diluted cell suspension used per 
assay. To 100 μL of cells, 5 μL of FITC annexin V was added and left to 
incubate for 15 min at room temperature. After the incubation period a further 
400 μl of 1X annexin-binding buffer was added along with 5 μL of 5 μg/mL 
DAPI in PBS, with cells mixed and kept on ice for a minimum of 5 min before 
analysis. Cells were then analysed by flow cytometry using a BD 
LSRFortessa flow cytometer (BD Biosciences) and analysed using FlowJo 
analysis software. Cells were gated by FSC-area/SSC-area and by FSC-
area/FSC-height to obtain a single cell population and to remove artefacts and 
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doublets. Single cells were then gated based on the expression of green-FITC 
conjugated to annexin V and DAPI expression to determine cells that were 
either alive, dead, early apoptotic or late apoptotic  
 
2.9 Protein analysis by Western Blotting 
2.9.1 Protein extraction from cells 
Cell culture plates or dishes were removed from the incubator and placed on 
ice.  Media was completely aspirated from cell culture plates before an 
appropriate amount of ice-cold PBS was added.  Cells were then removed 
using a cell scraper before being placed into 15ml falcon tubes.  Cells were 
then centrifuged at 1200rpm at 40C for 5 minutes and the supernatant 
removed.  Cells were then either stored at -800C or immediately lysed by the 
addition of 100μL of RIPA buffer (150mM sodium chloride (Fisher Scientific), 
1% v/v Nonidet-P40 (Roche), 0.5% w/v sodium deoxycholate (Sigma), 0.1% 
w/v sodium dodecyl sulphate (SDS; Sigma), 50mM Tris (Sigma), pH8) 
containing 1:100 protease and phosphatase inhibitor cocktail (Cell Signalling 
Technologies, MA, USA).  Lysates were centrifuged at 10,000rpm for 15 
minutes at 40C to pellet cell debris and the supernatant was aliquoted into 
fresh tubes for protein quantification. 
2.9.2 Determination of protein quantification 
Protein concentrations were analysed using the Pierece BCA protein assay kit 
(ThermoFisher Scientific) according to the manufacturers intstructions.  
Briefly, protein standards were prepared by diluting 2mg/ml BSA in PBS to 
produce a range of 7 known protein concentrations (2mg/ml, 1mg/ml, 
0.5mg/ml, 0.25mg/ml, 0.125mg/ml, 0.0625mg/ml, and 0mg/ml) and 10μL of 
these standards or of sample were added to 100μL of solution containing 
BCA protein assay reagent A and BCA protein assay reagent B in a ratio of 
50:1 in a 96 well plate.  Samples were mixed and then incubated at 370C for 
30 minutes before being analysed on a Fluostar Optima plate reader (BMG 
Labtech, Bucks, UK) at 562nm.  The standards were used to generate a 
standard curve from which the concentration of protein in each sample could 
be extrapolated. 
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2.9.3 Western Analysis 
2.9.3.1 Preparation of protein samples 
After protein concentrations were determined, 25μg of protein were diluted in 
RIPA buffer to produce a final volume of 8μl.  To this, 2 μl of 5X laemmli buffer 
(0.125M Tris-HCL pH6.8, 4% w/v SDS, 40% v/v glycerol, 0.1% w/v 
bromophenol blue [Sigma], 6% v/v beta- mercaptoethanol [Sigma] in ddH20) 
was added to each sample. Just before loading, the samples were heated to 
95oC for 5 minutes to denature the proteins.  
 
2.9.3.2 Gels and gel electrophoresis 
After denaturing samples were stored on ice before loading into gels.  Precast 
gels were purchased from BioRAD (4–20% Mini-PROTEAN® TGX™ Precast 
Protein Gels) and placed in the Mini-Protean III (Bio-Rad) electrophoresis tank 
and immersed in 1 x Tris-Glycine-SDS running buffer (Biorad). Protein 
molecular weight marker (PageRuler, ThermoFisher) was loaded into the first 
and last lane of each gel and prepared protein samples were loaded into the 
appropriate remaining wells. The samples were resolved down gels for 
approximately 45-60 minutes at 150V until the dye front reached the bottom of 
the gel.  
 
2.9.3.3 Western transfer to membrane 
After electrophoresis, gels were removed carefully from their plastic cassettes 
using the specific tool (BioRad).  They were kept moist by dripping running 
buffer onto them and excess gel was trimmed.  They were then placed into a 
membrane system purchased from BioRAD in the correct orientation (Trans-
Blot® Turbo™PVDF, BioRAD) before being rolled to remove any air bubbles 
in Trans-Blot® Turbo™ Transfer System (BioRAD) Cassettes.  Cassettes 
were then placed in to the Trans-Blot® Turbo™System and run on a MIXED 
MW protocol for 7 minutes. 
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2.9.3.4 Blocking and antibody incubation 
 Following Western transfer, sandwiches were disassembled and membranes 
washed 3 x 5 min in PBST (1 x PBS solution (Fisher): 5 tablets 500 ml dH2O 
with 0.5 ml Tween (Sigma)) before being incubated in blocking buffer (5% w/v 
non-fat milk powder (Marvel): 0.75 g in 15 ml PBST per transfer membrane) 
with shaking for 1 h. The membranes were then transferred to 30ml universal 
tubes (Fisher) containing 2 ml of the desired primary antibody diluted in 5% 
w/v non-fat milke powder (Marvel) in PBST. Membranes were incubated in the 
primary antibody solution overnight at 4 ̊C on a roller.  
      
Antibody Dilution Supplier Cat. No Species MW 
HIF1A 1:500 Novus 
NB100-
105 
Mouse 93kDA 
Beta 
Catenin 
(mAb) 
1:1000 
BD 
Biosciences 
610154 Mouse 100 kDA 
cFLIP 
(7F10) 
1:1000 Enzo 
ALX-8084-
961-0100 
Mouse 55kDA 
GAPDH 1:1000 Santa-Cruz sc-32233 Mouse 35kDA 
 
Table 2.5- Primary antibodies used in Western Blotting 
2.9.3.5 Detection and quantification 
Membranes were then washed 3 times for 5 min in PBST and transferred to a 
30 ml tube containing 2 ml of the appropriate mouse horseradish peroxidise- 
conjugated secondary antibody (Dako) diluted 1:2000 in 5% BSA in PBST. 
Membranes were incubated in secondary antibody at room temperature for 1 
h on a roller. Finally, membranes were washed 3 times for 5 min in PBST. 
Antibody binding was detected using ECL prime detection reagent 
(Amersham) before being developed in a Biorad Chemidoc MP Imaging 
System.  Diigital images were then quantitatfed by densitometry using the 
program Image J (http://imagej.nih.gov/ij/).  
 
 
  58 
2.10 RNA Analysis 
Prior to working with RNA all equipment and work surfaces were cleaned 
using RNAseZAP (Ambion) to prevent contamination from RNAses.  
 
2.10.1  RNA extraction  
Cultured cells were pelleted via centrifuge at 1200 rpm for 5 min before being 
resuspended in 350 μL RLT buffer (Qiagen) and placed on ice for immediate 
extraction or frozen at -80oC for future extraction. RNA extraction was 
performed using the Qiagen RNEasy kit following the manufacturer’s 
instructions. The concentration and quality of RNA was analysed using a 
nanodrop 3000 spectrophotometer (Thermo Scientific).  
 
2.10.2  cDNA synthesis  
Previously isolated RNA was synthesized into cDNA using the QuantiTect 
Reverse Transcription kit (Qiagen). Frozen template RNA was thawed on ice 
along with gDNA Wipeout buffer, Quantiscript Reverse Transcriptase, 
Quantiscript RT buffer and RT Primer mix. 1 μg of RNA was diluted in 2 μL of 
gDNA Wipeout buffer and RNase-free water to a total volume of 14 μL and 
incubated for 2 min at 42oC before being placed immediately on ice. A master 
mix (Table 2.5) was then added to each reaction and incubated for 30 min at 
42oC followed by 3 min at 95oC to inactivate the reverse transcriptase. The 
cDNA product was then either used immediately or stored at -200C for future 
use.  
 
Component Volume per 1 μg reaction 
 
Quantiscript Reverse Transcriptase 1 μL 
Quantiscript RT Buffer, 5x 4μL 
RT Primer Mix 1 μL 
Table 2.6- ctDNA synthesis reagents and volumes 
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2.10.3 Quantitive-real time-polymerase chain reaction (qRT-PCR)  
2.10.3.1 Primer selection  
All primers were selected and bought from ThermoFischer Scientific using 
their inventoried TaqMan gene expression assay search tool and were 
selected to target human sequences (Table 2.6). Each primer was designed 
to carry a FAM-reporter dye with the exception of ACTB controls which were 
designed to carry a VIC-reporter dye so multiplex PCR reactions could be 
performed.  
 
Target Name Assay ID 
HIF1A Hs00153153_m1 
IL6 Hs00985639_m1 
IL8 Hs00174103_m1 
ABCB1(MDR1) Hs00184500_m1 
SNAI1 (Snail) Hs00195591_m1 
ACTB Hs99999903_m1 
 
Table 2.7- Taq man probes used for gene expression analysis 
2.10.3.2 qRT-PCR reaction  
All qRT-PCR experiments were designed to include both target gene probes 
as well as an ACTB control probe, which was selected as expression levels 
should remain constant across cell lines and therefore can be used to 
normalize target amplification to the amount of cDNA present in each sample. 
No template controls were also run alongside where cDNA was replaced with 
dH2O to control for the presence of contaminating DNA.  
 
For each experiment TaqMan Universal Master Mix II, with UNG 
(ThermoFischer Scientific) was used, which includes: AmpliTaq gold DNA 
polymerase, dNTPs (with dUTP), ROX passive reference dye, Uracil-N 
glycosylase (UNG) and optimized buffer components. TaqMan master mix 
was added to target and ACTB control probes as well as RNase free H2O to 
make individual target master mixes containing all reaction components, with 
the exception of cDNA, which was then added to either 96-well or 384-well 
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qPCR plates (Applied Biosystems) (Table 2.7). Either 18 μL or 8 μL of master 
mix was added to 96 or 384-well plates respectively before the appropriate 
amount of cDNA was added to each well.  
 
qRT-PCR Component Volume added 
per well for 96-
well 
Volume added 
per well for 384-
well 
Target primer/FAM-probe (20x) 1 μl 0.5 μL 
ACTB primer/VIC-probe (20x) 1 μl 0.5 μL 
TaqMan master mix (2x) 10 μl 5 μL 
RNase free-H2O  6 μl 3 μL 
cDNA  2 μl 1 μL 
Total Volume 20 μL 10 μL 
 
Table 2.8 - qRT-PCR master mix components 
 
Once each component had been added, plates were sealed with Micro AMP 
optical adhesive films (Applied Biosystems) before being shaken for 30 sec 
and centrifuged for 1 min at 1200 rpm at 4oC. Plates were then run on a 
QuantStudio 7 Real-Time PCR machine (Applied Biosystems) set to the 
following protocol: initial denaturation at 95oC for 10 min, followed by 40 
cycles of 95oC for 15 sec (denaturation), and 60oC for 1 min 
(annealing/elongation).  
2.10.3.3 qRT-PCR data analysis  
Data was analysed in the automated Thermo cloud software 
(ThermoScientific) using relative quantification whereby samples are 
quantified to a reference sample. First, target Ct values were subtracted from 
ACTB control Ct values for individual wells to create a ΔCt value, which was 
then averaged from triplicated wells for each sample. A relative value for the 
difference in transcript levels between samples was then calculated as a 
difference of ΔCt between samples and a reference sample resulting in the 
ΔΔCt value. This value was the calculated as 2-ΔΔCt to give the relative fold 
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change which was then transformed on a log10 scale. Statistical analysis was 
then performed by assessing the overlap between 95% confidence intervals 
as described in (Cumming, Fidler, and Vaux 2007) 
 
2.11 Caspase Inhibition 
For expimerents involving Caspase Inhibtiion, the pan-caspase inhibitor Z-
VAD-FMK was purchased from R & D Systems (Abingdon, UK) (Product 
Number FMK001).  Product was made up in DMSO and stored at -200C.  This 
was diluted 1:100 in cell culture plates and added onto cells one hour before 
the addition of the compound that we were attempting to block apoptosis in.  
This gave a final concentration of 20ng/ml. 
  
2.12 Animal experiments 
2.12.1 Licensing 
All procedures involving the use of animals were carried out according to 
institutional guidelines in accordance with UK Home Office Regulations 
(Animals (Scientific Procedures) Act 1986) under UK HO licence 3003433. 
2.12.2 Animals 
For immune-compromised animal transplantation experiments, 
NOD/SCID/Balbc mice were obtained from Charles River Laboratories 
(Wilmington, US) or Athymic Nude (Hsd:Athymic Nude-Foxn1nu) mice were 
obtained from Harlan Laboratories (Indianapolis, US). Animals were acquired 
at six to eight weeks of age and maintained in individually ventilated cages 
(Allentown Inc. NJ, US) with a 12hr day/night cycle. Mice received a Teklad 
global 19% protein extruded rodent diet (Harlan Laboratories) and water ad 
libitum. All food, drink, saw dust and water bottles were sterilised by 
autoclaving prior to use. All procedures and animal husbandry was performed 
within a laminar flow hood (Allentown).  
2.12.3 Experimental procedures involving animals 
2.12.3.1 Subcutaneous xenograft tumour models 
Prior to transplantation, cells were either treated under the conditions of 
interest (for serial dilution experiments) or grown to 70-80% confluency before 
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being detached with trypsin and agitated to form a single cell suspension.   
Cells were washed in 5mls RPMI media containing no additives (Invotrogen, 
Paisley, UK) and spun at 1200rpm for 5 minutes three times before being 
prepared at the concentrations required in a mix of 50% RPMI with no 
additives and 50% Matrigel (ThermoFisher) that had been thawed overnight at 
40C and kept on ice until transplantation.  For MDA-MB-231 and PDX 151 cell 
transplants, Athymic nude mice and NOD/SCID/Balbc mice were used 
respectively.   Cells were injected into the mammary fat pads bilaterally on the 
dorsum of mouse and allowed to grow. 
2.12.3.2 In vivo treatment of mice 
For some experiments mice were treated in vivo with paclitaxel and either 
OH14 or DMSO control.  Paclitaxel was obtained from our local oncology until 
(Velindre Cancer Centre, Cardiff, UK) at a maximum age of constitution of 48 
hours prior to injection.  For our protocol Paclitaxel was injected twice a week 
(Tuesdays and Fridays) for a total of seven injections at a concentration of 
20mg/kg intraperitoneally (IP).  Mice were also treated with OH14 at a 
concentration of 20mg/kg IP, prepared by diluting powdered compound in 
DMSO) and being treated five days per week finishing with the last dose of 
paclitaxel.  The DMSO was controlled for by using the same concentration of 
DMSO injected into mice at the same time as OH14. 
2.12.3.3 Tumour monitoring and measurements 
Mice were inspected at least twice weekly for tumours via palpation and 
measurements were taken with digital calipers (Fisher Scientific, 
Loughborough, UK).  The size of tumours was calculated as volume in mm3 
using the widely used formula: Volume= (Length x(Width2))/2 (Jensen et al. 
2008). 
 
2.13  Statistical analysis  
Error bars on all graphs represent standard error values with the exception of 
gene expression data which are represented by 95% confidence intervals.  
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An unpaired student’s T‐test was used to determine statistical differences 
between normally distributed data sets and between data sets with sample 
sizes of n=3 unless stated, which was performed using Graphpad prism.  
 
For calculation of IC50 values, non-linear regression was used with a 
standard Hill Slope (=-1.0) using GraphPad Prism. 
 
For calculation of significance in RT-PCR experiments, significance was 
determined by calculating overlap of error bars as described in (Cumming, 
Fidler, and Vaux 2007). 
 
 
  
  
  
3 Investigating the Viability and Stem Cell-like 
Activity of Breast Cancer Cells in Response to 
Chemotherapy 
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3.1 Introduction 
Our increasing understanding of the heterogeneity of breast cancer has led to 
advances in targeted therapy that have improved the outcome of those with 
certain subtypes of breast cancer, for example those with oestrogen receptor 
positive disease (Elżbieta Senkus, Cardoso, and Pagani 2014; Turner et al. 
2016).  Despite these advances the prognosis for patients with metastatic 
disease can be as low as a few months, particularly for those with TNBC for 
whom no targeted agents exist (Cardoso et al. 2012). 
 
Breast cancer stem cells (bCSCs) have been implicated in both inherent and 
acquired resistance to chemotherapy since their existence was first proposed 
over a decade ago. bCSCs have been implicated in breast cancer recurrence 
as well as resistance to chemotherapy and, naturally, there has been 
significant interest in exploring how chemotherapy impacts on bCSC 
populations (Liu, Lv, and Yang 2015). 
 
Cytotoxic chemotherapy has been one of the main components of breast 
cancer treatment since the 1970s but its use is associated with both 
significant side effects as well as an incomplete response.  This is manifest as 
either a failure of tumours to shrink with chemotherapy in the neo-adjuvant or 
metastatic setting or a recurrence of disease- often many years later. 
 
Previous studies have shown that chemotherapeutics in use in the breast 
cancer clinic, including FEC, paclitaxel and docetaxel, increase CSC-like 
activity (eg. tumoursphere-forming capability) of treated breast cancers from 
patients ex vivo (Samanta et al. 2014; Li et al. 2008).  There are also data 
showing an increase in the proportion of cells expressing markers associated 
with bCSC behaviour after chemotherapy in vivo, such as ALDH1 enzyme 
and the cell surface markers CD44 and CD24 (Alamgeer et al. 2014).  ALDH1 
expression has been shown to correlate with lymph node metastases and 
early recurrence in ER-positive/Her2 negative breast cancer receiving either 
adjuvant endocrine therapy or chemotherapy (Miyoshi et al. 2016). 
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The purpose of this chapter was to establish an in vitro cell line based model 
through which the effect of a wide-range of chemotherapeutic agents in use in 
the clinic on bCSCs could be evaluated in more detail at the molecular level. 
 
3.2 Results 
3.1.1 Establishing the susceptibilities of a range of cell lines to 
chemotherapy 
Before assays examining the effect of chemotherapy on bCSCs could be 
undertaken a range of cell lines representing the broad molecular subtypes of 
breast cancer were tested for their overall susceptibility to different 
chemotherapy agents.  The cell lines tested were MCF-7 (Luminal A, ER 
positive, Her-2 negative), HCC 1954 (Basal, ER positive, Her-2 negative) and 
SUM 149 (Basal, ER negative, Her-2 negative) (Neve et al. 2006).  These cell 
lines also have the advantage of being able to form mammospheres and have 
had their stem cell populations well characterised (Suling Liu et al. 2013).  
 
These cells were then subjected to a range of doses of 5- Fluorouracil (F), 
Epirubicin (E), Cyclophosphamide (C), the combination FEC and docetaxel 
(D) in order to establish the concentration needed to inhibit half of the 
maximum biological response of the individual drugs (IC50).  The regime of 
FEC or D is one that is widely used in the clinic within the UK and is a 
recognised first-line adjuvant and neo-adjuvant regime for breast cancer 
regardless of molecular subtype (Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) 2012). It is also a combination whose effects have not been 
tested on bCSCs in vitro, though some have examined it in combination with 
other compounds with respect to bulk cell viability and on ex vivo samples 
(Konecny et al. 2001; Ari et al. 2011). 
 
Though others have looked at susceptibility of cell lines to chemotherapy, the 
use of different cell densities, treatment times and assays mean that IC50 
values derived from the literature vary substantially.  A standardised approach 
to screening drug sensitivities is one of plating at around 15-20% confluency, 
allowing cells to seed overnight and then treating for 72 hours before 
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performing a viability assay (W. Yang et al. 2013).  This correlated to a plating 
density of 50000 cells/ml for the MCF7 and HCC1954 cell lines and a density 
of 25000 cells/ml for the faster proliferating SUM149 cell line.  This ensures 
that the cells remain pre-confluent, in a logarithmic growth phase, for the 
majority of the extended treatment period.  
 
Therefore, an 8-fold log dose range of chemotherapy doses was used to 
establish IC50 values for all four drugs against all three cell lines (Fig 3.1).  
The IC50 value for the combination of FEC chemotherapy was performed 
according to the Chou-Talay method (T. C. Chou and Talalay 1984), where 
each drug remains in fixed amount of any mixed solution.  In this experiment, 
drugs were tested in combination in a range starting at twice their individual 
IC50 values.  This was presented as a percentage of the individual IC50 
values.(Fig 3.2). 
 
The IC50 values obtained highlighted the fact that different cell lines have 
vastly different susceptibilities to different chemotherapy agents and justified 
the decision not to use a standard concentration across all cell lines.  For 
example, the IC50 value of the MCF7 cell line for epirubicin was twenty-two 
times that of the SUM149 cell line (220nm and 10.6nM respectively).  These 
IC50 values were used to perform further experiments on assessing the effect 
of chemotherapy on CSC formation in breast cancer cell lines for the 
remainder of this work. 
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Figure 3.1- Three-day dose-response curves of MCF7, HCC 1954 and 
SUM149 cell lines to individual chemotherapy drugs 
A MCF7 B HCC 1954 and C SUM 149 cells were plated in 96 well plates and 
allowed to adhere overnight.  Reducing doses of chemotherapy drugs were 
added as indicated and at 72 hours cell viability was assessed using cell titer 
blue.  All results are averages of a minimum of three independent 
experiments each performed with three internal technical replicates.  Error 
bars represent Standard Error of the Mean (SEM). 
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A                                                   B               
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Figure 3.2- Three-day dose-response curves of MCF7, HCC 1954 and 
SUM149 cell lines to FEC chemotherapy.  
A MCF7 B HCC 1954  and C SUM 149 cells were plated in 96 well plates and 
allowed to adhere overnight.  Reducing doses of FEC chemotherapy were 
added and viability was assessed 72 hrs later using the Cell Titer blue assay.  
All results are averages of a minimum of three independent experiments each 
performed with three internal technical replicates. Error bars represent 
Standard Error of the Mean (SEM). 
 
Cell line/Drug F E C FEC* D 
MCF7 22.5μM 220nM 0.918μM 12.16% 1.5nm 
HCC 54 10μM 108nM 28μM 10.59% 7.9nm 
SUM 149 10.8μM 10.6nM 2μM 38.99% 0.73nM 
Table 3.1- Three day IC50 values of cell lines to F,E,C, FEC and D 
Tabular representation of the IC50 values of both individual and combined 
chemotherapeutic agents for all three cell lines.  F= 5-fluorouracil, 
E=Epirubicin, C=4-Hydroxycyclophosphamide, FEC= all three drugs, D= 
Docetaxel. *= percentage of IC50 values of individual drugs that led to IC50 in 
combination 
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3.1.3 bCSC-like activity is responsive to cytotoxic chemotherapy in a 
range of different treatment conditions 
Having established IC50 treatment concentrations for our cell lines and 
chemotherapeutics, the MCF7 cell line was arbitrarily selected to begin 
assessing the effect of chemotherapy on bCSCs (Dontu et al. 2003).  As 
CSCs have been shown to be resistant to chemotherapy (Suling Liu and 
Wicha 2010), it was hypothesised that treatment with chemotherapy would 
potentially increase the proportion of bCSCs relative to non-bCSC cells 
remaining at the end of chemotherapy treatment.  For example, if we assume 
that the proportion of bCSCs within the MCF7 cell line is 2% but that these 
cells are completely resistant to chemotherapy, we could expect that, if 50% 
of the non-bCSC cells in the dish had been killed by chemotherapy, that the 
proportion of bCSCs in the remaining viable cell population would increase to 
4%; thus representing a two-fold increase in bCSCs in the treated group 
compared to control.  To test this hypothesis, cells were treated in adherent 
conditions for 72 hours before being trypsinised and plated into 
mammosphere forming conditions, a well-established in vitro test for CSC-like 
activity which quantifies the absolute number of sphere-forming cells within a 
tumour cell population (Charafe-Jauffret et al. 2009; Shaw et al. 2012; Dontu 
et al. 2003). 
 
While the MCF7 cells formed the predicted well-rounded uniform spheres in 
control conditions (Shaw et al. 2012) (Fig 3.3A), contrary to expectation pre-
treatment with both FEC and docetaxel at their IC50 values significantly 
decreased mammosphere formation (Fig 3.4).  In chemotherapy pre-treated 
cells, cells formed loose associations, did not grow well in spheres and often 
demonstrated the presence of vacuoles when grown in non-adherent 
conditions.  This is a phenomenon that has been observed in mammospheres 
that are entering senescensce and are no longer dividing (Dey et al. 2009) 
(Figs 3.3B and 3.3C).  The reduction in the number of spheres was present in 
the secondary passage of the mammosphere culture, confirming a reduction 
in self-renewing sphere-forming cells within the cell population (see Section 
2.3). 
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This result was inconsistent with the weight of published data for the individual 
FEC agents and docetaxel as previously both regimes had been shown to 
increase stem cell activity (as measured by mammospheres and ALDH1 
expression) both in vivo and in ex vivo mammosphere conditions (Alamgeer 
et al. 2014; X. Li et al. 2008).  
 
We found that a number of different conditions had been employed by other 
groups that had demonstrated chemotherapy increased mammosphere 
formation.  These included: allowing cells to recover in fresh media for three 
days after treatment with paclitaxel before plating on into mammosphere 
conditions (Bhola et al. 2013), treating in mammosphere conditions rather 
than pre-treating the cells (Hirsch et al. 2009; Sims-Mourtada et al. 2014; Li et 
al. 2008) and exclusion of non-viable cells before plating into mammosphere 
conditions (Samanta et al. 2014). 
 
Repeating the same experiments in the MCF7 cell line but with these 
additional parameters yielded the same results as our original experiment, 
with the different conditions of a tryphan blue exclusion dye before plating, a 
three day rest period after chemotherapy or treatment in mammosphere 
conditions (Fig 3.5 A-C) all showing a significant reduction in mammosphere 
formation in both Passage 1 and Passage 2.  
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Figure 3.3- MCF-7 mammospheres decrease after chemotherapy after 
one week of non-adherent culture 
MCF7 cells were plated into adherent conditions, allowed to adhere overnight 
and then treated with either control (A) or IC50 values of FEC (B) or 
Docetaxel (C) as shown in Table 3.1.  Whilst spheres formed in the control 
arm (A), mammosphere formation was less than in control groups after 
chemotherapy- often with loose association of cells (B, red arrow) and 
vacuole formation (B and C, blue arrows).  Magnification= x4 
 
 
A 
B 
C 
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Figure 3.4- Number of MCF7 mammospheres reduces after treatment 
with either FEC or docetaxel.   
After 3 days treatment in adherent conditions with the IC50 values of both 
FEC and docetaxel there was a significant decrease in sphere formation in 
the MCF7 cell line.  Cells were dissociated and then grown in non-adherent 
conditions for 7 days (Passage 1) before being dissociated and seeded again 
as single cells into Passage 2. Error bars represent SEM of the mean and 
results are an average of three experiments performed in triplicate.  (T-test, 
*=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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 A                                   B 
 
                                 C 
 
Figure 3.5- MCF7 mammospheres decrease after FEC chemotherapy in a 
number of different plating conditions 
In order to assess the effect of different plating conditions on mammopshere 
formation, MCF7 cells were treated with FEC at its IC50 value in adherent 
conditions for 3 days and then plated into non-adherent mammopshere 
conditions after A a tryphan blue exclusion stain or B three days rest in fresh 
media after treatment. For C, cells were treated at the IC50 value in 
mammosphere conditions. Error bars represent SEM of the mean and results 
are an average of three experiments performed in triplicate.  (T-test, *=p<0.1, 
**=p<0.01, ***=p<0.001   ****=p<0.0001). 
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3.1.4 Treatment with docetaxel for four days increased mammosphere 
formation in the MCF7 cell line 
A study in which bCSC-like activity (as measured by mammospheres and 
ALDH positivity) was enriched following treatment with paclitaxel in a panel of 
TNBC cell lines as well as the MCF7 cell line, included three additional 
alternative parameters: the length of time (four days versus three), the use of 
the drug paclitaxel and the non-adherent media used (Mammocult, Stem Cell 
Technologies instead of MEBM, Lonza) (Samanta et al. 2014). The authors 
eloquently demonstrated that levels of HIF1α increased at four days after 
treatment with chemotherapy and that this was responsible for the increased 
bCSC seen at this time point (Samanta et al. 2014).  The proposed 
mechanism was through interleukin 6 and 8 signalling leading to both 
increased expression of the multi drug resistance 1 (MDR1) protein as well as 
bCSC behaviour. 
 
We therefore sought to replicate this experiment but realised that an unknown 
variable was the initial plating density of cells within the experiment.  We 
reasoned that cell density could influence the clonal potential of resident stem 
cells within the tumour cell populations in vitro.  Thus experiments were 
performed at a range of cell densities (25000/ml, 50000/ml, 100000/ml and 
200000/ml) and treatment for four days at two concentrations of docetaxel 
(1nM and 5nM) in the MCF7 cell line (Fig 3.6).  We did not use the previously 
calculated IC50 value as we reasoned that this would be altered by both the 
different cell densities as well as the treatment time.  Cells were plated out at 
the different cell densities, allowed to adhere overnight and then treated with 
chemotherapy for 96hours. They were then dissociated and plated into non-
adherent conditions as described in Section 2.6 using Mammocult media 
(Stem Cell Technologies) 
 
After exposure of different concentrations of MCF7 cells to docetaxel for four 
days the proportion of self-renewing mammosphere forming cells increased 
for all densities of cells plated but significantly for cells at 50000 and 100000 
cells/ml (Figs 3.6A and B and 3.7).  The dose of 1nM corresponded roughly 
with our previous IC50 value for MCF7 cells for three days of treatment 
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(1.5nM).  At 5nM cells failed to form tight aggregates as previously observed 
(Fig 3.7C).   
 
As 50000 cells/ml was the cell density used in previous experiments, there 
were two differences between this experiment and the previous ones 
performed: the length of treatment and the non-adherent culture media used. 
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A                                    B 
 
Figure 3.6- MCF7 mammosphere formation increases with docetaxel at 
certain cell densities and drug concentrations 
When MCF7s were plated at different cell densities, allowed to adhere 
overnight and then treated with two concentrations of docetaxel (1nM and 
5nM) for 96 hours before being dissociated and plated into mammosphere 
conditions.  After 7 days (A, Passage 1) cells were counted and dissociated 
before being passaged on into Passage 2 (B) where they were counted a 
further seven days later. Error bars represent SEM of the mean and results 
are an average of two experiments performed in triplicate.  (T-test, *=p<0.1, 
**=p<0.01, ***=p<0.001   ****=p<0.0001). 
 
 
 
 
Figure 3.7- MCF7 mammospheres increase after chemotherapy 
After 96 hours of treatment in adherent conditions, mammosphere count 
increased from control (A) to 1nM of docetaxel treatment (B) but decreased 
with 5nM of docetaxel (C).  Cells looked sick at the higher concentration and 
did not form mammospheres in Passage 2. Plating density 100000cells/ml.  
Picture taken at the end of Passage 1. Scale bar 200M. 
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3.1.5 Re-establishing 96 hour IC50 values for all cell lines 
The docetaxel doses in the previous experiment were based on the IC50 
determinations from 72 hour experiments. Thus, on the basis that future 
experiments would need to be performed at 96 hours to further investigate the  
effects of chemotherapy on bCSC increases, dose response curves were 
repeated for 96 hour assays.  In addition, the drug paclitaxel, a taxane related 
to docetaxel, was also tested.  Although not licensed for adjuvant or neo-
adjuvant use in the UK, paclitaxel is in use in the metastatic setting and is 
commonly used worldwide in a weekly format in the adjuvant setting (Sparano 
et al. 2008).  As has been demonstrated by others, docetaxel is a more potent 
drug than paclitaxel with our IC50 values demonstrating that the concentration 
of paclitaxel needed to reach an IC50 values is 3-4 multiples of docetaxel 
(Izbicka et al. 2005). The IC50 doses of the individual drugs forming the 
regime FEC were not recalculated.  Instead the same method as above was 
used to make a mix of all three drugs representing the 72-hour IC50 dose that 
was then serially diluted so that all drugs remained in fixed proportions.  This 
dilution was then used for all future experiments.  As expected, the IC50 
doses differed from the 72 hour treatment (Fig 3.8 and Table 3.2).  Cell plating 
density was the same as the 72 hour experiments (see Section 2.2.1). 
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Figure 3.8- Four-day dose response curves of MCF7, HCC 1954 and 
SUM149 cell lines to paclitaxel, docetaxel and FEC chemotherapy 
A MCF7 B HCC 1954  and C SUM 149 cells were plated in 96 well plates and 
allowed to adhere overnight.  Reducing doses of paclitaxel, docetaxel and 
FEC chemotherapy were added and viability was assessed 96 hrs later using 
the cell titer blue assay.  All results are averages of a minimum of three 
independent experiments each performed with three internal technical 
replicates.  Error bars represent Standard Error of the Mean (SEM). 
 
Cell line/Drug FEC* Paclitaxel Docetaxel 
MCF7 19.83% 3.58nM 0.88nM 
HCC 54 10.29% 1.62nM 0.57nM 
SUM 149 22.19% 2.41nM 0.70nM 
Table 3.2- Four day IC50 Values 
Tabular representation of the IC50 values of both individual and combined 
chemotherapeutic agents for all three cell lines. F= 5-fluorouracil, 
E=Epirubicin, C=4-Hydroxycyclophosphamide, FEC= all three drugs *= 
percentage of IC50 values of individual drugs that led to IC50 in combination 
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3.1.6 Treatment at IC50 values for 96 hours increased the proportion of 
mammospheres in all cell lines 
Having established the new 96 hour IC50 values, the MCF7, HCC 1954 and 
SUM149 cell lines were plated, allowed to adhere overnight and exposed to 
either paclitaxel, docetaxel or the combination of FEC for 96 hours, before 
being plated into non-adherent, mammosphere forming conditions.  After 7 
days they were dissociated and passaged again for a further 7 days.  
 
The results showed that in all cell lines, across all chemotherapies, 
mammosphere formation increased in response to treatment (Fig 3.9 A-E). 
This was the reverse of what was seen after 72 hours of treatment in the 
MCF7 cell line (Figs 3.3 and 3.4). There were however some differences 
between the cell lines, for example in the MCF7 cell line both paclitaxel and 
docetaxel significantly increased the mammopshere formation in both 
Passage 1 and Passage 2 more than FEC.  In the SUM149 cell line, FEC only 
had a small effect on increasing mammosphere formation in Passage 1 that 
was significantly less than both paclitaxel and docetaxel.  In Passage 2, this 
situation was reversed with FEC increasing the mammosphere formation 
significantly more than that of both paclitaxel and docetaxel.  In the HCC 1954 
cell line, there was a significant increase in mammospheres seen in Passage 
1 with paclitaxel compared to the other chemotherapeutics that did not carry 
over into Passage 2, with no significant differences seen between the three 
agents.  
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Passage 1                                            Passage 2 
C   
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Figure 3.9- Increasing mammosphere formation induced by 
chemotherapy across a broad range of cell lines and chemotherapeutics 
In the MCF7 (A), HCC 1954 (B) and SUM 149 (C) cell lines there were 
significant increase in mammosphere formation in both Passage 1 and 
Passage 2 after treatment with 96hours of chemotherapy. Figs 19D and 19E 
show representative pictures of the HCC 1954 and SUM149 P1 
mammospheres respectively after treatment with DMSO (i), or the IC50 
values of Paclitaxel (ii), Docetaxel (iii) and FEC (iv). Error bars represent SEM 
of the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). Scale 
bar 200M. 
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3.1.7 A mathematical model demonstrates that chemotherapy increases 
the actual number of CSCs remaining in a cell population after 
treatment 
In an attempt to assess whether chemotherapy simply ineffectively targets 
CSCs (leading to a reduced overall number but increased overall percentage 
in a remaining population) or leads to an absolute increase in their total 
number mediated by a mechanism such as CSC signaling (leading to an 
increased overall number and percentage) a basic mathematical model was 
constructed (see Section 2.4).  There has been much interest in this area with 
tumours evaluated after both hormone and chemotherapy showing increased 
mesenchymal and tumour initiating features after chemotherapy (Creighton et 
al. 2009). 
 
The results show differing effects of chemotherapy depending on cell line 
(Tables 3.3A-C and Fig 3.10).  For example, in the SUM149 TNBC cell line, 
all chemotherapeutics significantly increased CSC number, but in the 
HCC1954 cell line, only paclitaxel did.  For the MCF7, ER positive cell line, 
both paclitaxel and docetaxel led to an increase but not FEC.  Although this is 
a result based on a hypothetical mathematical model, this implies that 
chemotherapy is likely not only ineffective in targeting CSC-like cells but, in 
some situations, also leads to an induction of new CSC formation. This is 
particularly true for the SUM149 TNBC cell line- a molecular subtype of 
cancer known to contain large numbers of CSCs (Habib and O’Shaughnessy 
2016). 
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A 
 Viability (%) Total cell 
number 
P2 sphere 
formation (%) 
CSCs in plate 
Control 100 10000 1.033 103 
Paclitaxel 61.5 6153.4 2.344 144 
Docetaxel 58.0 5805.2 2.7899 162 
FEC 65.8 6580 1.7556 116 
B 
 Viability (%) Total cell 
number 
P2 sphere 
formation (%) 
CSCs in plate 
Control 100 10000 1.044 104 
Paclitaxel 58.645 5864.5 2.622 154 
Docetaxel 57.5 5750 2.077 119 
FEC 43.79 4379 2.466 108 
 
C 
 Viability (%) 
Total cell 
number 
P2 sphere 
formation (%) CSCs in plate 
Control 100 10000 0.6222 62 
Paclitaxel 58.045 5804.5 1.8667 108 
Docetaxel 62.398 6239.8 1.4778 92.2 
FEC 59.675 5967.5 2.3333 139 
 
Tables 3.3A-C A Model to demonstrate the effect of chemotherapy on 
CSC number in breast cancer cell lines 
IC50 value viability was used to calculate viable cells left at the end of a 
96hour treatment period with chemotherapy.  This was then multiplied by the 
percentage mammosphere formation at the end of Passage 2 to give a total 
CSC number remaining in the plate at the end of chemotherapy treatment in 
the MCF7 (A), HCC 1954 (B) and SUM149 (C) cell lines.  Results are the 
mean of three independent experiments each performed in triplicate. 
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Figure 3.10- Chemotherapy increases the total number of CSCs 
remaining in a cell population after treatment. 
Graphical representation using cell viability to calculate the number of stem 
cells remaining after treatment multiplied by the sphere formation of the same 
treatment condition to give an actual number of CSCs left at the end of 
treatment.  Error bars represent SEM of the mean and results are an average 
of three experiments performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, 
***=p<0.001   ****=p<0.0001). 
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3.1.8 The proportion of ALDH MCF7 and SUM149 positive cells increase 
in response to chemotherapy 
ALDH has been identified as a marker associated with bCSC activity in all 
molecular subtypes of breast cancer and has been linked with prognosis 
(Alamgeer et al. 2014; Ginestier et al. 2007; Charafe-Jauffret, Ginestier, 
Iovino F, et al. 2010).  For example, it has been shown in paired biopsies of 
breast cancer patients before and after anthracycline and taxane containing 
chemotherapy that ALDH staining increased (Alamgeer et al. 2014; Tanei et 
al. 2009; Tiezzi et al. 2013).  The MCF7 cell line has been shown to have a 
baseline activity of around 1%, the HCC 1954 line 1-5% and the SUM 149 line 
around 5% (Suling Liu et al. 2013; Charafe-Jauffret, Ginestier, Iovino F, et al. 
2010).  
 
The Aldeflour assay (StemCell Technologies, Vancouver, Canada) was used 
to ascertain whether the increase in ALDH positivity correlated with 
mammosphere formation after treatment with chemotherapy.  After exposure 
to IC50 values of chemotherapy drugs for 96 hours, ALDH positivity 
significantly increased from 2.3% at baseline in the MCF7 cell line to 23.8% 
with paclitaxel, 25.8% with docetaxel and 24.8% with FEC.  In the SUM149 
cell line the results were more varied, increasing from 4.1% at baseline to 
32.2%, 16.1% and 31.8% with paclitaxel, docetaxel and FEC respectively (Fig 
3.11). The almost ten-fold increase in ALDH positivity is markedly more than 
the increase in mammosphere formation that was witnessed in these two cell 
lines.  Although ALDH has been correlated with CSCs and drug resistance 
(Januchowski, Wojtowicz, and Zabel 2013), this surrogate marker of CSC-like 
activity fails to precisely overlap with the  functional CSC mammosphere 
assay.  Nevertheless, the increase in ALDH correlates with the increase in 
functional CSC number seen in our mathematical model. As will be discussed 
in Chapter 4, the ALDH positivity of the HCC1954 line was not examined as 
the focus of this work changed to focusing on triple negative breast cancer. 
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B                                
 
C 
 
Figure 3.11- ALDH1 positivity increases in response to chemotherapy 
The treatment of MCF7 and SUM149 cells with paclitaxel, docetaxel or FEC 
chemotherapy significantly increases the proportion of ALDH1 positive cells 
compared to controls.  A, representative FACS plots of ALDH1 positivity in the 
MCF7 and SUM149 cell lines. B and C, Percentage of ALDH1 +ve cells in the 
MCF7 and SUM149 cell lines respectively after treatment with respective 
chemotherapy agent at IC50 concentration for 96hours. Error bars represent 
SEM of the mean and results are an average of three experiments performed 
in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ***=p<0.0001). 
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3.3 Discussion 
In this chapter, the sensitivities of a broad panel of cell lines representing the 
different molecular subtypes of breast cancer (MCF7- ER positive, HCC1954 
– HER2 positive and SUM149- triple negative) to different chemotherapeutic 
agents representing the current standard of care in breast cancer was 
established (E. Senkus et al. 2013).  This was done to establish an in vitro 
model through which the effect of these agents on the bCSC population within 
these three cell lines could be established.  Having established the IC50 
values for FEC and Docetaxel (Fig 3.2 and Table 3.1) our initial findings that 
chemotherapy effectively targets the mammosphere formation of this panel of 
cell lines (Fig 3.4) were unexpected, as they appeared to be inconsistent with 
the overwhelming weight of literary evidence that had suggested that bCSCs 
were resistant to chemotherapy.  Indeed, extensive literature searches yielded 
no evidence that cytotoxic chemotherapy effectively targets CSCs but a 
multitude of papers on approaches to target residual CSC populations that 
remained after chemotherapy ((Ranji et al. 2016; Angeloni et al. 2015; Dragu 
et al. 2015).  Our data did also not fit with clinical outcomes, if chemotherapy 
was so effective at targeting CSCs then there would be an expectation that 
these cells would not survive, reform tumours and lead to both recurrences 
and metastatic disease often years after the original treatment. 
 
This led us to re-evaluate a number of experimental parameters that could 
explain the disparity between our data and other published evidence (Fig 3.5).  
Eventually, treating the cells for 96 rather than 72 hours with chemotherapy 
and changing the mammosphere media (to Mammocult) led to increasing 
mammosphere formation across all chemotherapeutic agents in all cell lines 
(Figs 3.6-3.9).  Although we did not assess the effect of both different 
mammosphere media at 96 hours, we feel it is unlikely that the difference in 
media would explain the highly significant differences in mammosphere 
formation seen between the 72 and 96 hours treatment time points.  In the 
absence of publically available data as to the composition of the Mammocult 
media (as compared to the original MEBM media used) any potential 
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difference would have been assessed.  Unfortunately there was insufficient 
time to evaluate this.  
 
Figure 3.12- Effect of chemotherapy on CSCs 
After treatment with chemotherapy, the bulk of tumours cells (blue) are killed 
but the CSC remains (red).  Over time, this cell is able to divide and reform 
the tumour- leading to recurrence of the tumour at a later time point. 
 
As the mammosphere assay is a surrogate for measuring CSC-like behavior, 
this would suggest that chemotherapy is having a number of potential effects. 
The first possibility is that chemotherapy is ineffective at targeting CSCs and 
that they enjoy a preferential survival advantage over non-CSCs, meaning 
that they are present at an increased proportion of the remaining viable cell 
population which then translates into increased mammosphere formation 
when these cells are plated out at a fixed density.  Indeed, there is evidence 
that cells are inherently resistant to chemotherapy through utilizing 
mechanisms such as increased drug efflux pumps, DNA damage repair 
enzymes and resistance to apoptosis (Gottesman, Fojo, and Bates 2002; G. 
Liu et al. 2006; M. Zhang, Atkinson, and Rosen 2010) .  Our data would 
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potentially go against this as we saw an inhibition of mammosphere formation 
by chemotherapy at 72 hours when, presumably, CSCs should be able to 
form spheres as a functional surrogate of their activity at this time point. 
 
Another possibility is that cell signaling induced by chemotherapy leads to an 
induction of a CSC-like phenotype leading to non-CSCs being transformed 
into CSC-like cells.  This could be mediated through a process such as EMT 
and, indeed, there is evidence supporting the role of chemotherapy in 
inducing EMT and an increase in CSC-like behaviour (Pattabiraman and 
Weinberg 2014; Li et al. 2008; Mani et al. 2008; Chang et al. 2005).   
 
Combining both our cell viability and mammosphere data we then constructed 
a simple mathematical model to demonstrate this phenomenon.  The results 
differed depending on both cell line and chemotherapy with the most 
aggressive cell line, the TNBC SUM149 cell line, being the only line to have 
its actual number of CSCs significantly increased by all types of 
chemotherapy.  This is an interesting observation and correlates with the fact 
that TNBC is known to contain larger numbers of CSCs compared to other 
molecular subtypes of breast cancer (Habib and O’Shaughnessy 2016) 
(Tables 3.3A-C and Fig 3.10).  Whilst in the MCF7 cell line the taxane 
compounds significantly increased the number of CSCs, FEC did not and in 
the HCC1954 cell line only paclitaxel led to a significant increase.  
Nevertheless, it is still important to remember that no chemotherapeutic led to 
a reduction compared to control, confirming that chemotherapy poorly targets 
CSCs (Suling Liu and Wicha 2010) 
 
The increase in CSC-like activity at 96 hours was confirmed through the use 
of ALDH as a surrogate marker of CSC-like activity (Figure 3.11). Numerous 
studies have shown a relationship between ALDH and stem-cell like 
behaviour (Magni et al. 1996; Ginestier et al. 2007; Charafe-Jauffret et al. 
2009; Cao et al. 2013a; Samanta et al. 2014; H. Zhang et al. 2015) 
Additionally, the upregulation of ALDH after neoadjuvant chemotherapy is 
associated with worse overall survival (Alamgeer et al. 2014; H. E. Lee et al. 
2011; Tiezzi et al. 2013). ALDH has also been shown to correlate with 
   93 
chemoresistance and is associated with the more aggressive molecular 
subtypes of breast cancer such as triple negative and Her-2 positive disease 
(Kida et al. 2015).   Our data would suggest that in this setting, the increase in 
ALDH positivity is more than the increase in mammosphere formation 
witnessed after treatment with chemotherapy suggesting that ALDH positive 
cells do not exclusively represent CSCs but may represent a response to 
chemotherapy. 
 
These data have two potential implications.  Firstly, it means that perhaps 
standard protocols for testing oncology drugs may underestimate their effect 
on stem cell function as they commonly last 24-72 hours (W. Yang et al. 
2013).  As more is understood about patterns of recurrence and metastatic 
disease, it is clear that effectively targeting CSCs can only be beneficial to 
outcomes and the ability to target CSCs needs to be incorporated into 
standard novel drug testing.  Secondly, it also implies that there is a key event 
that occurs between 72 and 96 hours and that this event may represent a 
target against which a novel CSC compound could be targeted.   
 
When trying to elucidate this potential mechanism, attention turned to known 
CSC pathways such as TGF-β (Transforming Growth Factor β), Wnt 
(wingless-type MMTV (mouse mammary tumor virus), β-catenin, Notch and 
HIF1α (H. Zhang et al. 2015; Wu, Sarkissyan, and Vadgama 2016; Xie et al. 
2016).  As stated previously, one particular study examining the effect of 
chemotherapy on a panel of triple negative cell lines as well the MCF7 cell 
line demonstrated that four days rather than three of chemotherapy is needed 
to induce HIF1α expression leading to upregulation of IL-6 and Il-8 expression 
and CSC like features (Samanta et al. 2014). Though a recent paper by the 
same group has now shown three days treatment may increase 
mammospheres in triple negative cell lines (Lu et al. 2015).  IL6 has been 
shown to be important in the ability of CSCs to self-renew and can force non-
CSCs into a CSC-like state (Iliopoulos et al. 2011).  IL8 leads to a pro-
inflammatory response, increases CSC invasion, has been shown to be 
upregulated in ALDH positive cells and leads to increased mammosphere 
formation when added to cell culture (Charafe-Jauffret et al. 2009).  The 
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relationship between HIF1α and chemotherapy will be explored in later 
chapters to assess whether this is at least partially responsible for the change 
in mammosphere number seen after 96 hours of treatment. 
 
Having established a model through which an increase in CSC-like behaviour 
can be induced by chemotherapy in vitro the aims of subsequent chapters are 
to assess whether this increase can be either stopped, or preferably, reversed 
so that chemotherapy leads to both a reduction on both CSCs and their non-
CSC counterparts. 
 
  
   
4 Investigating Breast Cancer Cell Viability and Stem 
Cell Activity following chemotherapy combined 
with cFLIP-inhibition and/or TRAIL 
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4.1 Introduction 
Having demonstrated that conventional cytotoxic chemotherapy targets bulk 
cells but increases CSC-like activity (Chapter 3), our attention turned towards 
targeting this residual stem-like population with a combinatorial therapeutic.  
TRAIL, a ligand for activating the extrinsic apoptosis pathway, and cFLIP, a 
key regulator of this pathway, are potential  targets with which to overcome 
resistance to apoptosis seen in bulk cells but particularly in CSCs (Hanahan 
and Weinberg 2011; Fulda 2013).  This chapter aims to explore whether 
targeting this pathway leads to a further reduction in bulk-cell viability when 
combined with chemotherapy, and moreover whether this combinatorial 
approach stems the increase in CSC-like activity observed when 
chemotherapy is used alone. 
4.1.1 TRAIL 
Despite promising pre-clinical activity, especially against mesenchymal cell 
lines (that broadly represent the TNBC molecular subtype of breast cancer), 
and evidence of synergistic activity with both anthracycline and taxane 
chemotherapeutic classes (of which epirubicin, paclitaxel and docetaxel are 
members), a recent trial of paclitaxel with or without tigatuzumab, a DR5 
monoclonal antibody, showed no difference in recurrence-free or overall 
survival in triple-negative breast cancer (Oliver et al. 2012; Buchsbaum et al. 
2003; Forero-Torres et al. 2015).  This was a disappointment but fits in with 
the overall picture that, despite promising pre-clinical data, multiple TRAIL 
receptor agonists have failed in clinic trials (Holland 2014).  Further work is 
needed to identify those patients with breast cancer who may benefit from 
TRAIL- with strategies adopted that may sensitise cells to TRAIL mediated 
apoptosis both with and without chemotherapy. 
 
4.1.2 cFLIP 
The intensive efforts to sensitise resistant cells to TRAIL have identified cFLIP 
as a key factor in resistance to TRAIL-induced apoptosis (Safa 2012). 
Previous work in our laboratory using siRNA-mediated knockdown of cFLIP 
combined with TRAIL has shown promising activity against CSC-like activity 
across a broad-range of molecular subtypes of breast cancer (Piggott et al. 
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2011).  This has led to the development of an experimental compound named 
OH14 that binds to the DED1 domain on cFLIP, preventing incorporation of 
cFLIP into the Caspase 8 / 10 chain complexes recruited to the DISC and 
thus de-repressing apoptosis induced by death ligands (see Chapter 1.9).  
Whilst others in our laboratory have demonstrated an effect on CSC-like 
behaviour of this experimental compound in combination with TRAIL 
(Hayward et al, unpublished work) we wanted to assess whether this effect 
could be replicated after treatment with chemotherapy. 
4.1.3 Combination of TRAIL and cFLIP inhibition with chemotherapy 
There have been many attempts to combine TRAIL with a wide-range of 
chemotherapeutics across almost all tumour types (Holland 2014; Yang, 
Wilson, and Ashkenazi 2010).  We hypothesis that by preventing the inhibition 
of apoptosis induced by TRAIL by using a cFLIP inhibitor, that any cytotoxic 
effect of chemotherapy would be enhanced.  A review of the literature 
highlighted that, interestingly, there is evidence to show that paclitaxel in 
particular is dependent upon the extrinsic pathway to induce its apoptotic 
effect (Day et al. 2006).  This raised the possibility that inhibition of cFLIP 
alone, in combination with paclitaxel in particular, may be sufficient to 
sensitise to chemotherapy-induced death. 
 
Paclitaxel mediates its apoptotic effects through Caspases-8 and -10, 
increases expression of the DR5 death receptor and increased apoptosis- 
even in the absence of a ligand binding to this receptor. Knockdown of cFLIP 
significantly enhances the apoptosis induced by paclitaxel (Day, Huang, and 
Safa 2008a; Day et al. 2006) and it has been shown that paclitaxel induced 
apoptosis in a leukaemic cell line in a FADD-dependent manner, mediated 
primarily thorough Caspase 10 (Park et al. 2004).  In this paper, neutralising 
antibodies to the external apoptotic pathway receptors Fas, TNF-Receptor 1, 
DR4 or DR5 did not reduce the apoptosis induced by paclitaxel suggesting 
that its apoptotic effect was mediated downstream of the extrinsic apoptosis 
pathway receptors. In cells that were transfected with FADD lacking a DED 
domain, apoptosis was reduced in cells treated with paclitaxel, showing that 
its apoptotic effect is dependent upon FADD.  MCF7 cells overexpressing 
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cFLIP were resistant to apoptosis induced by paclitaxel but not docetaxel, 
possibly showing that the former is more dependent upon the extrinsic 
apoptosis pathway to induce apoptosis (Wang et al. 2005).  Paclitaxel has 
been shown to elevate both Caspase-8 and TNF-α components of the 
extrinsic apoptosis pathway, whereas docetaxel has not.  siRNA-mediated 
knockdown of cFLIP has also shown to sensitise a panel of ovarian 
carcinomas to apoptosis mediated by either paclitaxel or carboplatin (Vidot et 
al. 2010).  Therefore, although the potential interactions between paclitaxel, 
docetaxel and FEC with both OH14 and TRAIL will be explored, there will be 
a particular focus on cFLIP inhibition with paclitaxel in this chapter as a route 
to assess whether cFLIP inhibition alone, as opposed to its combination with 
TRAIL therapy, after chemotherapy leads to a targeting of remaining CSCs 
after chemotherapy. 
 
4.2 Results 
4.2.1 Assessing the effect of OH14 and TRAIL on bulk cell viability 
4.2.1.1 The MCF7, HCC 1954 and SUM149 cell lines are resistant to cell 
death induced by OH14 
We tested the viability of the MCF7, HCC1954 and SUM149 cell lines after 
being treated with OH14 for 24hours after cells had been allowed to grow for 
96 hours. This time point was chosen as we wanted to assess the effect of 
OH14 on CSC surrogate assays (such as mammospheres and ALDH1 
positivity) and, as was established in Chapter 3, treatment for 96 hours with 
chemotherapy was needed to increase CSC-like behaviour.  There was no 
significant difference in toxicity between 0.01 and 10M, though the MCF7 
cell line was the most sensitive at this level with around a 20% drop in 
viability, and the SUM149 cell lines the most resistant (Fig 4.1).  There was a 
significant drop in viability at 100M for all cell lines to around 40% for the 
MCF7 and HCC 1954 cell lines and 20% for the SUM149 cell line.   As such a 
dose of 10M was selected for further experiments as it was felt that this 
would offer the potential to observe sensitization in combined treatments. 
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A                                       B 
 
                                   C 
 
Figure 4.1- Viability of cell lines in response to OH14 
The MCF7 (A), HCC 1954 (B) and SUM149 cell lines were plated and allowed 
to grow for 96 hours before a 24 hour treatment with OH14 at a 5-log dose 
range. Viability was assessed via Cell Titer Blue. Error bars represent SEM of 
the mean and results are an average of three experiments performed in 
triplicate.  
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4.2.1.2 The MCF7, HCC 1954 and SUM149 cell lines have different 
sensitivities to TRAIL 
Previous studies have shown a wide range of response to TRAIL: varying 
from sensitive mesenchymal cell lines, such as SUM149, to resistant 
oestrogen receptor positive lines, such as MCF7.  Her-2 receptor positive 
lines, such as HCC 1954, lie somewhere in the middle of the spectrum 
(Rahman, Pumphrey, and Lipkowitz 2009).  Previous experiments in our 
laboratory have identified that TRAIL at 20ng/ml was the minimum 
concentration that led to the maximum amount of Caspase-8 activation 
(Piggott et al. 2011) and as such, in the absence of a reduction in viability of 
cell lines to TRAIL, this was used as a treatment dose. 
 
Cells were plated out at 50000 cells/ml (25000 cells/ml for the SUM149 and 
MDA-MB-231 cell line) and treated at a time point that would correlate with 
the end of a four-day chemotherapy experiment (allowed to adhere overnight, 
left for 72 hours and then treated for 24 hours before analysis).  This ensured 
that they were allowed to reach near-confluency before being treated for 24 
hours with TRAIL.  The MCF7 and HCC54 cell lines were resistant to TRAIL-
induced apoptosis with a maximal reduction in viability of around 20% above 
10ng/ml.  In contrast to this, and as expected, the SUM149 cell line was 
exquisitely sensitive to TRAIL with an IC50 value of 0.13ng/ml (Fig 4.2). 
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Figure 4.2- Susceptibility of cell lines to TRAIL 
The MCF7 (A), HCC 1954 (B), and SUM 149 (C) cell lines were plated and 
left for four days (to near confluency) and treated for 24 hours. Viability was 
assessed via Cell Titer Blue. Error bars represent SEM of the mean and 
results are averages of a minimum of three independent experiments each 
performed with three internal technical replicates. 
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4.2.1.3 The combination of OH14 and TRAIL has different effects on the 
viability of the MCF7 and SUM149 cell lines 
To determine the effect of cFLIP inhibition on TRAIL sensitivity we took the 
two cell lines that represented both TRAIL resistance (MCF7 cell line) and 
TRAIL sensitivity (SUM149 cell line).  The respective cell lines were then 
plated into adherent conditions, allowed to grow for 96 hours and then treated 
with either control (DMSO vehicle), 10 M OH14, TRAIL or a combination of 
10 M OH14 one hour before TRAIL for 24 hours.  Viability was then 
assessed using a Cell Titer Blue assay. 
 
Our results in the MCF7 cell line concur with those seen by other member of 
our group when using both OH14 (Hayward, unpublished work) and siRNA-
mediated knockdown of cFLIP (Piggott et al. 2011).  We saw a small but 
significant reduction in viability of around 10% compared to control when cells 
were treated with either single agent OH14 or TRAIL.  The combination led to 
a further 10% reduction (to around 75% overall viability) that was significant 
compared to control and significantly more than either single agent OH14 or 
TRAIL (Fig 4.3A).   However, it is likely that this effect is additive as the 
reduction in viability of the combined treatment is no more than the single 
effect of each compound alone added together. 
 
The SUM149 cell line showed a different pattern of response, these cells were 
highly sensitive to TRAIL consistent with previous studies (eg. (Rahman et al. 
2009) and there was no significant reduction seen with either single agent 
OH14 or the addition of OH14 to TRAIL as compared to TRAIL alone (Fig 
4.3B) 
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B 
 
Figure 4.3 Susceptibility of the MCF7 and SUM149 cell lines to OH14 and 
TRAIL 
The MCF7 (A) and SUM149 (B) cell lines were plated in adherent conditions 
for 96 hours before being treated with a vehicle control, 10 M OH14, IC50 
TRAIL or a combination of both 10M OH14 and IC50 TRAIL (with OH14 
added one hour before TRAIL) and left for 24 hours.  Cell viability was 
assessed via Cell Titer Blue assay.   Error bars represent SEM of the mean 
and results are an average of three experiments performed in triplicate.  (T-
test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001).  
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4.2.2 Assessing the effect of TRAIL and OH14 on CSC-like behaviour 
4.2.2.1 The combination of OH14 and TRAIL abrogates mammosphere 
formation in the MCF7, SUM149 and MDA-MB-231 cell lines 
Previous work in our laboratory has shown that siRNA-mediated knockdown 
of cFLIP and treatment with TRAIL leads to the abrogation of mammosphere 
formation across a broad panel of breast cancer cell lines (Piggott et al. 2011; 
French et al. 2015) and further work with OH14 has repeated this finding 
(Hayward et al, unpublished work).  The aim was to confirm that this was still 
the case after treatment with chemotherapy.  
 
In these experiments, cells were plated into adherent conditions, allowed to 
grow for 96 hours and then treated with 10μM OH14 at least one hour before 
treatment with TRAIL at either 20ng/ml in the MCF7 cell line or 0.13ng/ml in 
the SUM 149 cell line.   
 
There was a significant reduction in mammosphere formation in both Passage 
1 and Passage 2 (Fig 4.4A) with the addition of TRAIL and TRAIL/OH14 In 
the MCF7 cell line. This was more than the effect of these treatments on the 
bulk cell population and therefore we can conclude that the combination of 
OH14 and TRAIL seems to preferentially target the CSC-like cells within the 
MCF7 cell line.  
 
The same effect was seen on the SUM149 and MDA-MB-231 cell lines (Figs 
4.4B-E), with significant reductions seen in mammosphere formation in both 
Passage 1 and 2 with the addition of TRAIL and OH14 and also a significant 
reduction between the TRAIL and OH/14 treatment arms in both passages.  
Here though, the results mirrored more closely the effect seen on the bulk cell 
population.  The TNBC MDA-MB-231 cell line was added at this point as, as 
will become apparent, the focus of this work shifted to TNBC. 
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Figure 4.4 – Effect of TRAIL and OH14 on mammosphere formation in 
the MCF7 and SUM149 cell lines 
The MCF7 (A) SUM149 (B) and MDA-MB-231 (C) cell lines were plated in 
adherent conditions for 96 hours before being treated with a vehicle control, 
OH14, TRAIL or a combination of both OH14 and TRAIL (with OH14 added 
one hour before TRAIL) and left for 24 hours.  Cells were then dissociated 
and plated into non-adherent conditions at a fixed concentration for seven 
days before being counted (Passage 1), dissociated and plated again in a 
fixed concentration and counted seven days later (Passage 2). D and E, 
These pictures show mammosphere formation at the end of Passage 2 for A) 
control B) OH14 C) TRAIL and D)TRAIL/OH14 in the MDA-MD-231 (D) and 
SUM149 (E) cell lines respectively.  Error bars represent SEM of the mean 
and results are an average of three experiments performed in triplicate.  (T-
test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). Scale bars 200M. 
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4.2.2.2 A mathematical model shows that TRAIL and TRAIL/OH14 
reduces absolute CSC number 
Next we employed the same mathematical model that we used in Section 
3.17 (Explained in detail in Methods section 2.4) to demonstrate the effect of 
OH14, TRAIL and the combination of the two on absolute CSC number 
surviving at the end of adherent treatment. In the MCF7 cell line, TRAIL led a 
significant reduction in CSC number as a single agent and this was 
proportionally more than the effect of single agent TRAIL on overall cell 
viability, suggesting it is an effective agent at targeting CSCs (Figs 4.5 A and 
C).  This concurs with previous work (French et al. 2015; Piggott et al. 2011).  
This effect was further increased by the addition of OH14 with its magnitude, 
a roughly 50% further decrease in mammospheres, being proportionally more 
than the extra reduction in bulk cell viability seen with the addition of OH14 to 
TRAIL.  This suggests some synergy in targeting CSCs when OH14 is added 
to TRAIL. 
 
In the SUM149 cell line, OH14 alone led to a small reduction in absolute CSC 
number whereas TRAIL and TRAIL with OH14 led to large drop to around a 
third of the control treated group and a half of the TRAIL alone treated group 
respectively (Figs 4.5 B and C).  As with the MCF7 cell line, the effect on CSC 
number was proportionally more than the reduction in bulk cell viability 
suggesting that TRAIL targets CSCs within the SUM149 cell line and that 
there is likely some synergism with the addition of OH14 on this CSC 
population. 
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A 
 Viability (%) Total cell 
number 
P2 sphere 
formation (%) 
CSCs in plate 
Control 100 10000 1.05 105 
OH14 89.6 8960 1.25 112 
TRAIL 86.4 8640 0.58 50 
TRAIL/OH14 76 7600 0.37 28 
B 
 Viability (%) Total cell 
number 
P2 sphere 
formation (%) 
CSCs in plate 
Control 97.5 10000 0.63 63 
OH14 92.5 9250 0.59 55 
TRAIL 65.2 6520 0.34 22 
TRAIL/OH14 48.7 4870 0.2 10 
 
C 
 
 
Figure 4.5 Effect of OH14 and TRAIL on absolute CSC number 
The overall cell viability of the MCF7 (A) and SUM149 (B) cell lines was 
multiplied by the percentage mammosphere formation at the end of Passage 
2 for the respective treatment condition to give an absolute CSC number 
remaining at the end of adherent treatment (C). Error bars represent SEM of 
the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001).  
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4.2.3 Establishing the efficacy of OH14 and TRAIL after Chemotherapy 
4.2.3.1 The combination of OH14 and/or TRAIL reduces mammosphere 
formation in the MCF7 and SUM149 cell lines after chemotherapy 
We next wanted to assess whether the addition of OH14 and/or TRAIL had 
the same effect on mammosphere formation following chemotherapy.  Cells 
were treated with chemotherapy (paclitaxel, docetaxel and FEC) at the IC50 
doses described in Chapter 3 for 96 hours.  At 72 hours either OH14, TRAIL 
or both (with OH14 being added 1 hour before TRAIL) were added and left for 
24hrs before plating into mammosphere conditions. 
 
Interestingly, for the MCF7 cell line, OH14 alone after chemotherapy led to a 
significant reduction in mammosphere formation in both Passages 1 and 2 in 
almost all types of chemotherapy tested- with the only non-significant result 
being in Passage 1 of the paclitaxel treated arm and most significant in the 
FEC treated samples (Fig 4.6 A-C).  TRAIL after chemotherapy led to an even 
greater reduction in sphere formation and for almost all passages and 
chemotherapeutic agents and this effect was enhanced further by the addition 
of OH14 to TRAIL after chemotherapy (with the exception of Passage 1 after 
FEC treatment) 
 
In the SUM149, triple negative inflammatory cell line across all 
chemotherapeutic agents and passages, there was a significant reduction in 
mammosphere formation after treatment with chemotherapy with single agent 
OH14, often at the same level as, or more than, the addition of TRAIL or 
TRAIL and OH14 (Figs 4.6 D-F and 4.7).  This led us to explore whether there 
was a potential relationship between cFLIP, chemotherapy and a triple 
negative phenotype.  Although the triple combination of chemotherapy, OH14 
and TRAIL was not going to be excluded at this point, we wanted to assess 
whether there was merit in adopting a double combination approach rather 
than involving TRAIL as a third drug, as this would have implications for the 
validity and efficacy of drug administration in the clinical setting. 
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Figure 4.6 OH14 and TRAIL abrogate mammosphere formation after 
chemotherapy in both the MCF7 and SUM149 cell lines 
The MCF7 (Fig 4.7A-C) and SUM149 (Fig 4.7 D-F) were plated into adherent 
conditons, treated with chemotherapy at the previously calculated IC50 values 
and 72 hours later OH14, TRAIL or both was added and left for a further 24 
hours.  Cells were then dissociated and plated into non-adherent conditions at 
a fixed cell concentration.  After 7 days they were counted (Passage 1), 
dissociated and plated as single cells again at a fixed cell concentration.  After 
a further 7 days they were counted again (Passage 2). Error bars represent 
SEM of the mean and results are an average of three experiments performed 
in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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Figure 4.7 SUM149 Mammospheres increase after chemotherapy and are 
abrogated by the addition of OH14. 
Representative pictures at the end of Passage 2 of SUM149 mammospheres 
that had been treated with: A) control (vehicle) B) OH14 C) Paclitaxel D) 
Paclitaxel and OH14 E) Docetaxel F) Docetaxel and OH14 G) FEC H) FEC 
and OH14. Scale bars 200M. 
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4.2.4 Investigating a link between cFLIP and Paclitaxel 
As stated in Section 4.1.3, a potential relationship between cFLIP and 
paclitaxel has previously been reported by several groups (Day et al. 2006; 
Day, Huang, and Safa 2008b; Park et al. 2004; Wang et al. 2005).  Thus it 
has been reported that paclitaxel appears, at least in part, to mediate its 
apoptotic effects in a ligand-independent manner through the extrinsic 
apoptotic pathway.  Although a strong relationship had been seen between 
FEC, docetaxel and paclitaxel and OH14 in the SUM149 cell line, a sound 
scientific rationale therefore existed in investigating paclitaxel alone. As an 
antagonist of this pathway, cFLIP is a natural target to try and increase the 
cytotoxic effect of paclitaxel against both bulk cells and CSCs. In addition, it 
was decided to assess whether this relationship existed in TNBC cell lines- as 
the SUM149 cell line had responded better than the MCF7, oestrogen 
receptor positive, cell line in the previous section.  As the prognosis for TNBC 
is the worst of all the molecular subtypes of breast cancer and an area where 
novel treatments are urgently needed, two further TNBC cell lines were 
added, MDA-MB-436 and MDA-MB-231, in order to give a panel of three 
TNBC cell lines in which to examine the effect of this combination 
4.2.4.1 TNBC cell lines, but not ER or HER-2 positive cell lines, are 
sensitized to paclitaxel by OH14. 
The effect of paclitaxel and OH14 was assessed on the MCF7, HCC1954, 
SUM149, MDA-MD-436 and MDA-MD-231 cell lines. Cells were plated at 
100000 cells/ml in 96 well plates, allowed to adhere overnight and then 
treated with a range of paclitaxel doses (1nM, 5nM and 10nM) for 24hrs with 
either vehicle or 10M of OH14 one hour before paclitaxel. 
 
Though the addition of OH14 to the ER-positive MCF7 and Her2-positive 
HCC1954 cell lines did not increase the cytotoxicity seen with paclitaxel, the 
three TNBC cell lines showed a significant reduction in viability of 19.6%, 
19.75% and 25.45% for the MDA-MB-231, SUM149 and MDA-MB-436 lines 
respectively when OH14 was added one hour before paclitaxel at a 10nM 
dose (Fig 4.8A).  This gave credence to the hypothesis that TNBC lines may 
be sensitive to the combination of paclitaxel and c-FLIP suppression. 
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In order to continue and assess the relationship between OH14 and paclitaxel 
in TNBC cell lines the 96hr paclitaxel IC50 value of both the MDA-MB-231 
and MDA-MB-436 cell was established at 5.01nM respectively 2.1nM (Fig 4.8 
B and C).
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B                                  
 
C 
 
 
Figure 4.8- OH14 enhances the cytotoxic effect of paclitaxel in a panel of 
TNBC cell lines 
A, the MCF7, HCC1954, MDA-MB-231, MDA-MB-436 and SUM149 cell lines 
were plated at 100000 cells/ml to allow near confluency before a 24 hour 
treatment with either vehicle control, 10M OH14, varying doses of Paclitaxel 
alone or varying doses of paclitaxel with OH14. B and C, the 96hr IC50 values 
for both the MDA-MB-436 (2.1nM) and MDA-MB-231 (5.01nM) were then 
established to be used in further experiments. Error bars represent SEM of 
the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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4.2.4.2 OH14 and TRAIL lead to a decrease in the viability of MDA-MB-
231 and SUM149 cell lines both with and without chemotherapy 
We wanted to assess the effect of OH14, both with paclitaxel and in 
combination with TRAIL, on cell viability in TNBC cell lines. 72hrs after 
chemotherapy was added to MDA-MB-231 or SUM149 cell lines, either 
vehicle, TRAIL, OH14, or OH14 and TRAIL was added for 24hrs before the 
cells were analysed by Cell Titer Blue.  
 
The addition of OH14 did not lead to a reduction in viability but the addition of 
TRAIL led to a significant reduction in both the MDA-MB-231 (Fig 4.9 A) and 
SUM149 (Fig 4.9 B) cell lines.  Additionally, in the MDA-MB-231 cell line, the 
combination of OH14 and TRAIL led to a significant drop above TRAIL 
treatment alone, something that was not seen in the SUM149 cell line.  After 
treatment with paclitaxel the addition of OH14 alone led to a significant 
reduction in viability in the MDA-MB-231 cell line (Fig 4.9C) but not in the 
SUM149s (Fig 4.9D).  Indeed, in the MDA-MB-231 cell line it was more 
effective as a single agent than TRAIL, although the combination of both was 
the most effective treatment with a significant drop in viability compared to all 
other arms. In the SUM149 line, the addition of single agent OH14 or TRAIL 
after paclitaxel did not lead to a significant drop in viability, although the 
combination treatment did. 
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A                                     B 
 
 
C                                     D 
 
 
Figure 4.9- Effect of OH14 and TRAIL alone and with chemotherapy on 
cell viability in the MDA-MB-231 and SUM149 cell lines 
The effect of OH14, TRAIL or the combination was assessed on the MDA-
MB-231 (A) and SUM149 (B) cell lines. These drugs were then tested again 
72hrs after the addition of IC50 paclitaxel before being left for 24hrs and 
analysed by CellTiter Blue (C, MDA-MB-231 and D, SUM149). Error bars 
represent SEM of the mean and results are an average of three experiments 
performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   
****=p<0.0001).  
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4.2.5 Paclitaxel followed by OH14 reduces mammosphere formation in 
a panel of TNBC cell lines 
Next we examined the effect of treating three TNBC cell lines (MDA-MB-231, 
MDA-MB-436 and SUM149) with paclitaxel for 96 hours with OH14 added at 
72 hours after chemotherapy treatment. Treatment with paclitaxel increased 
mammosphere formation in both Passage 1 and Passage 2 across all 
passages in all cell lines (Fig 4.10), suggesting that as seen previously in the 
MCF7 and SUM149 cell lines, paclitaxel significantly increased the CSC 
content of these cell lines at the end of treatment. 
 
The addition of OH14 as a single agent did not lead to a significant difference 
compared to the control (vehicle) arm but did reverse the significant increase 
seen with paclitaxel (Figs 4.10 and 4.11).  This suggests that the combination 
of paclitaxel and OH14 may be a viable treatment option to target CSCs that 
are present either before chemotherapy or that are induced by chemotherapy 
after treatment with paclitaxel. 
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Figure 4.10- Effect of Paclitaxel and OH14 on mammosphere formation in a panel of TNBC cell lines 
The MDA-MB-231, SUM149 and MDA-MB-436 cell lines were plated into adherent conditions for 96hrs and treated with IC50 
paclitaxel +/- 10 M OH14 at 72 hrs.  Cells were then dissociated and plated into non-adherent conditions at a fixed cell 
concentration.  After 7 days they were counted (Passage 1), dissociated and plated as single cells again at a fixed cell 
concentration and a further 7 days they were counted again (Passage 2). Error bars represent SEM of the mean and results are an 
average of three experiments performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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A) 
 
B) 
 
 
Figure 4.11-  Representative pictures of mammosphere formation in the 
MDA-MB-436 (A) and SUM 149 (B) at the end of Passage 2 .  
Scale bars 200M.
Ctrl OH14 
Pac Pac/OH14 
Ctrl OH14 
Pac Pac/OH14 
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4.2.6 Use of a mathematical model to assess whether OH14 
preferentially targeted bCSCs after chemotherapy 
To evaluate the effect of OH14 and paclitaxel on bCSCs in two TNBC cell 
lines, the mathematical model employed in Chapter 3 was used again to show 
the effect of treatment, with and without chemotherapy, on bCSCs. 
 
Single agent OH14 did have an effect in reducing the total number of CSCs in 
both the MDA-MB-231 and SUM149 cell lines as a single agent.  Although 
paclitaxel increased the remaining CSC population above control in the 
SUM149 cell line it importantly did not significantly change the number in the 
MDA-MB-231 cell line (Fig 4.12). This addition of OH14 after paclitaxel not 
only reversed the increase in bCSC number but led to a reduction in bCSCs 
below the level in the control group.  If paclitaxel demonstrated equal efficacy 
in targeting CSCs and non-CSCs within the original population a proportional 
reduction in CSC number with viability would be expected. However, once 
again in these experiments the total number of CSCs actually increases 
above control, even though there is a significant reduction in viability.  This 
effect is completely reversed by the addition of OH14- the addition of which 
leads to an almost proportional reduction of CSCs in line with cell viability.  
For example, in the MDA-MB-231 cell line the total number of CSCs falls from 
42 to 11, a 74% reduction- this correlates with a reduction in overall cell 
viability of 60.7%.  In Chapter 3, the point was made that chemotherapy not 
only poorly targets CSCs but also can increase them, likely through inducing 
signaling pathways.  Therefore, OH14, by reducing the total number of CSCs 
to below control levels, must be enabling not only the paclitaxel to kill CSCs, 
but also blocking the signaling pathways that lead to CSC induction.  This will 
be explored further in Chapter 5. 
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A 
 Viability (%) Total cell 
number 
P2 sphere 
formation 
(%) 
CSCs in 
plate 
Control 100 10000 0.34 34 
OH14 94.1 9410 0.22 21 
Paclitaxel 61.7 6170 0.77 48 
Paclitaxel/OH14 39.3 3930 0.27 11 
B 
 Viability (%) Total cell 
number 
P2 sphere 
formation 
(%) 
CSCs in 
plate 
Control 97.5 9750 0.66 64 
OH14 92.5 9250 0.40 37 
Paclitaxel 65.7 6570 1.9 125 
Paclitaxel/OH14 53.7 5370 0.53 28 
 
C 
 
Figure 4.12- Total CSC number after treatment with paclitaxel and OH14 
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The overall cell viability of the MDA-MB-231 (A) and SUM149 (B) cell lines 
was multiplied by the percentage mammosphere formation at the end of 
Passage 2 for the respective treatment condition to give an absolute CSC 
number remaining at the end of adherent treatment (C). Error bars represent 
SEM of the mean and results are an average of three experiments performed 
in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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4.2.7 The effect of OH14 and TRAIL on the ALDH+ population of TNBC 
lines 
In order to confirm that the effects of OH14 on PAC-induced tumoursphere 
numbers was due to an increase in CSCs, an independent surrogate marker 
of CSC-like activity was used.  ALDH-positive cells are enriched for CSC-like 
properties, and initially we wished to confirm our previous published 
observations that c-FLIP suppression and TRAIL treatment reduced the 
proportion of ALDH-positive cells in the cancer cell population (Piggott et al. 
2011).  MDA-MB-231 or SUM149 cell lines were plated into adherent 
conditions, left for 96 hours and then treated with either TRAIL, OH14 or a 
combination of both for 24 hours.    
 
In both the MDA-MB-231 and SUM149 cell lines, there was a significant 
reduction in the ALDH+ population with single agent OH14 and TRAIL arm as 
well as the combined OH14+TRAIL arm (Fig. 4.13).  In the MDA-MB-231 cell 
line, the biggest effect was seen in the OH14 alone treatment arm. 
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Figure 4.13 Effect of OH14 and TRAIL on mammopshere formation and 
ALDH+ in representative TNBC cell lines 
The MDA-MB-231 (B) and SUM149 (C) cell lines were plated into adherent 
conditions and 96 hours later treated with Ctrl, OH14, TRAIL or TRAIL+OH14 
for 24 hours. Cells were dissociated and underwent flow cytometry using the 
Aldeflour assay following the manufacturers protocol.  Representative plots 
are shown in A. Error bars represent SEM of the mean and results are an 
average of three experiments performed in triplicate (SUM149 Flow cytometry 
was 2 repeats).  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
C
on
tro
l
O
H
14
TR
A
IL
TR
A
IL
/O
H
14
0.0
0.5
1.0
1.5
2.0
2.5
Treatment condition
P
e
rc
e
n
ta
g
e
 A
L
D
H
 p
o
s
iti
v
e
*
****
*
C
tr
l
14
TR
A
IL
TR
A
IL
/O
H
14
0
2
4
6
8
Treatment condition
P
e
rc
e
n
ta
g
e
 A
L
D
H
 p
o
s
it
iv
e
**
*
*
   129 
4.2.8 OH14+/- TRAIL with paclitaxel targets the ALDH+ population in 
TNBC cell lines  
Next an assessment of the response of the ALDH+ population in the MDA-
MB-231 and SUM 149 cells to OH14 with paclitaxel was assessed and in 
addition the effect of adding TRAIL with paclitaxel was assessed in the MDA-
MB-231 cell line. The MD-MB-231 or SUM149 cell lines were plated into 
adherent conditions, the relevant IC50 value (MDA-MB-231 4.989nM, 
SUM149 2.41nM) of paclitaxel was added after cells were allowed to adhere 
overnight and left for 96 hours with OH14 +/- TRAIL being added 72hours 
later for the final 24 hours of the experiment. 
 
Consistent with the mammosphere data, in the MDA-MB-231 cell line, there 
was a significant rise in the ALDH+ population with paclitaxel compared to the 
untreated (vehicle) control group and this increase was significantly reduced 
by the addition of OH14, TRAIL or the combination of the two (Fig 4.14A).  
The effect of treatment with OH14 and TRAIL after paclitaxel was significantly 
more than single agent TRAIL after paclitaxel but not OH14 after paclitaxel 
 
When evaluating the effect of OH14 alone after paclitaxel, for both the MDA-
MB-231 and SUM149 cell lines, there was a significant reduction of the highly 
significant increase in ALDH+ seen with paclitaxel, with the addition of OH14 
(Figs 4.14 B and C).  As shown previously, in the MDA-MB-231 cell line, there 
was a significant reduction in the ALDH+ population with single agent OH14 
without chemotherapy.  Interestingly, there was a much larger increase in the 
ALDH+ population in the SUM149 cell line compared to the MDA-MB-231 cell 
line.
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C                                  D 
 
Figure 4.14 Effect of OH14, TRAIL and Paclitaxel on TNBC ALDH+ cells  
The MDA-MB-231 (B and C) and SUM149 (D) cell lines were plated into 
adherent conditions for 96 hours and 72 hrs later treated with Ctrl, OH14, 
TRAIL or TRAIL+OH14 for 24 hours. Cells were dissociated and underwent 
flow cytometry using the Aldefluor assay following the manufacturers protocol.  
Representative plots are shown in A. Error bars represent SEM of the mean 
and results are an average of three experiments performed in triplicate 
(SUM149 Flow cytometry was 2 repeats).  (T-test, *=p<0.1, **=p<0.01, 
***=p<0.001   ****=p<0.0001). 
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4.2.9 Confirming an ‘on-target’ effect of OH14 
4.2.9.1 SiRNA-mediated knockdown of cFLIP sensitises TNBC cell lines 
to paclitaxel 
It has previously been shown that overexpression of cFLIP led to a reduction 
in the cytotoxicity of paclitaxel in both leukaemic and the MCF7 breast cancer 
cell lines (Day et al. 2006).  In addition, paclitaxel mediates its apoptotic 
effects through the extrinsic apoptosis pathway in a ligand-independent 
manner (Day, Huang, and Safa 2008a) meaning that a sound rationale exists 
to combine an agent targeting cFLIP with paclitaxel. Previously in this chapter 
we demonstrated that OH14, a novel compound targeted against a binding 
pocket of cFLIP on FADD, sensitised TNBC cell lines to paclitaxel (Section 
4.2.4.1). Next an assessment as to whether using siRNA-mediated 
knockdown of cFLIP levels led to a similar reduction in viability to OH14 
(compared to a scrambled RNA control) in two TNBC cell lines. The MDA-MB-
231 and SUM149 cell lines were transfected as described in Chapter 2, left for 
48 hrs and then treated overnight with 10nM of paclitaxel to replicate the 
conditions used in the previous OH14 experiment. 
 
In both the MDA-MB-231 and SUM149 cell lines, use of siRNA against cFLIP 
led to a significant increase in the toxicity of paclitaxel over the level seen with 
scrambled RNA (Fig. 4.15).  This mirrored the effect of OH14 seen previously 
(Fig. 4.9). 
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                 A 
 
B  
 
Figure 4.15- Effect of siRNA knockdown on TNBC cell lines in 
combination with paclitaxel 
The MDA-MB-231 and SUM149 cell line was plated into adherent conditions 
and 24 hours later treated with either scRNA or siRNA against cFLIP.  48 
hours later paclitaxel was added at 10nM and left on for 24 hours. Cell viability 
was then evaluated using CellTiter Blue. Error bars represent SEM of the 
mean and results are an average of three experiments performed in triplicate 
(SUM149 Flow cytometry was 2 repeats).  (T-test, *=p<0.1, **=p<0.01, 
***=p<0.001   ****=p<0.0001). 
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4.2.9.2 Paclitaxel-induced mammosphere formation is reduced by the 
SiRNA-mediated knockdown of cFLIP  
We then sought to assess whether reducing cFLIP levels led to a reduction in 
PAC-induced mammosphere formation. MDA-MB-231 and SUM149 cells 
were treated with scRNA or SiRNA against cFLIP for 24hours and then 
treated with paclitaxel and left for 96 hours.  Then the cells were dissociated 
and plated into non-adherent mammopshere conditions at a fixed 
concentration and counted seven days later (Passage 1) or following a 
subsequent passage (Passage 2). 
 
SiRNA treated cells exhibited smaller spheres and reduced the paclitaxel-
mediated increase in sphere numbers seen when scRNA cells were treated 
with Paclitaxel (Fig 4.16) 
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A 
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Passage 1                          Passage 2 
B 
 
C 
 
Figure 4.16 Effect of SiRNA-mediated cFLIP knockdown on 
mammosphere formation after paclitaxel 
The MDA-MB-231 (A and B) and SUM149 cell lines (C) were plated into 
adherent conditions and 24 hours later treated with either scRNA or siRNA 
against cFLIP.  24 hours later paclitaxel was added and left on for 96 hours. 
Cells were then dissociated and plated into non-adherent conditions at a fixed 
cell concentration.  After 7 days they were counted (Passage 1, B), 
dissociated and plated as single cells again at a fixed cell concentration and a 
further 7 days they were counted again (Passage 2, C). A shows 
representative pictures in the MDA-MB-231 cell line at the end of Passage 2.  
Error bars represent SEM of the mean and results are an average of three 
experiments performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   
****=p<0.0001).  
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4.2.10 In vivo experiments using OH14, TRAIL and paclitaxel suggest 
OH14 targets CSC-like cells in vivo 
The gold standard assay for CSC-like activity within a tumour cell population 
is the ability of cells to initiate tumour growth in vivo.  Thus in order to 
determine how the in vitro responses of CSC-like activity influenced tumour 
establishment in vivo, two different xenograft models of TNBC were 
employed. 
4.2.10.1 Determination of tumour establishment by TNBC cell lines 
Before using the TNBC cell lines MDA-MB-231 or SUM 149 in mouse 
experiments we wanted to establish the efficiency of tumour growth when 
cells were implanted into the mammary fat pads of mice with matrigel.   
 
We injected a range of cells bilaterally into NOD/SCID mice (MDA-MB-231 
100000, 10000, 1000 cells and SUM149 5000, 500, 100 cells) to assess how 
successfully tumours formed.  Tumours were measured twice a week. Using 4 
mice per cell line, all the dilutions of MDA-MB-231 cells grew tumours around 
a month after injection whereas in the SUM149 cell line, both tumours at 5000 
cells formed tumours and one tumour formed in a mouse with 500 cells (Table 
4.1). 
 
MDA-MD-231 
Cells injected 
Tumour take SUM149 
Cells Injected 
Tumour take 
100000 2/2 5000 2/2 
10000 3/3 500 1/3 
1000 3/3 100 0/3 
 
Table 4.1 – Rates of tumour take in NOD-SCID mice when injected with 
varying concentrations of TNBC cells 
MDA-MB-231 and SUM149 cells were harvested from adherent culture and 
diluted in matrigel (50%) before injection into mammary fat pads of NOD/SCID 
mice.  Mice were then checked twice a week until tumour formation was 
noted.  The cell numbers were lower in SUM149 due to previous reports of 
superior tumour efficacy of the SUM149 cells compared to MDA-MB-231 cells 
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4.2.10.1.1 Pre-treatment with OH14 and TRAIL reduced tumour initiation 
in mice 
Having established that an injection of either 10000 or 1000 cells of the MDA-
MB-231 cell line established tumours, we then set out to assess the effect of 
TRAIL and OH14 on tumour initiation. 10000, 1000 or 100 cells were injected 
bilaterally into recipient mice and the latency of tumour establishment 
determined.  This provides a relative assessment of the proportion of viable 
tumour-initiating cells in a given tumour cell population. 
 
Cells were seeded in vitro and allowed to grow for 72hrs prior to the addition 
of TRAIL/OH14/vehicle for 24 hours.  Attached (ie predominantly viable) cells 
were then harvested with trypsin, washed three times in additive-free RPMI 
and then suspended in a solution of 50% matrigel and 50% additive-free 
RPMI.  100μL of solution was injected into each mammary fat pad and 
tumours were observed for growth twice weekly.  Three mice with two 
tumours each were used to give a total potential of six tumours per condition.  
A determination of stem cell frequency and statistical comparison was 
undertaken using the ELDA calculator available online 
(http://bioinf.wehi.edu.au/software/elda/).  This is a widely cited formula for 
determining CSC number in limiting dilution experiments (Hu and Smyth 
2009) 
 
At 10000 cells per mammary fat pad, single OH14 led to a small reduction in 
tumour formation from 6/6 to 4/6 (Fig 4.17).  Whilst single agent TRAIL had no 
effect on tumour formation at this cell density, which is perhaps surprising 
seeing as in our in vitro experiments it led to a significant reduction in 
mammosphere formation as a single agent, the combination of both agents 
had a large effect with only 1/6 tumours forming. At 1000 cells per mammary 
fat pad, fewer tumours formed in the control arm (2/6) and this was halved by 
treatment with single agent OH14 or TRAIL and completely abolished by 
combined treatment.  At 100 cells, no tumours formed in any treatment arm.  
Our stem cell calculator demonstrated a large reduction in CSC frequency for 
OH14, slightly less for TRAIL and the largest reduction for combined 
treatment with OH14 and TRAIL. 
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A 
 
B 
No. of cells Control 14 TRAIL TRAIL/14 
10000 6/6 4/6 6/6 1/6 
1000 2/6 1/6 1/6 0/6 
100 0/6 0/6 0/6 0/6 
CSC freq 
(95% CI) 
1/2340 
(1/862-
1/6351) 
1/8447 
(1/3335-
1/21391) 
 
1/3220 
(1/1281-
1/8144) 
1/61464 
(1/8705-
1/434007) 
Significant 
differences in CSCs 
(p value, Chi 
Squared test) 
   Ctrl- 0.000173 
14- 0.0341 
TRAIL- 
0.000868 
 
Figure 4.17- Tumour take of MDA-MB-231 cells when treated with OH14, 
TRAIL or a combination and calculation of stem cell frequency 
MDA-231-wells were plated into adherent conditions, left for 96 hours and 
then treated with either control (DMSO vehicle),  OH14, TRAIL or 
OH14/TRAIL for 24 hours.  They were then injected bilaterally into mammary 
fat pads of NOD/SCID mice in a 50:50 mix of serum-free media and matrigel 
and observed twice weekly for tumour growth.  3 mice were used per 
condition with bilateral tumours in each.  A, graphical representation of tumour 
formation. B, The number of stem cells was estimated using ELDA software 
(http://bioinf.wehi.edu.au/software/elda/) and comparison made via Chi 
squared test as described in (Hu and Smyth 2009) 
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4.2.10.1.2 Treatment with paclitaxel increases tumour formation that is 
likely abrogated by a combination of OH14 and TRAIL 
Cells were seeded in vitro and allowed to grow for 24hrs prior to the addition 
of paclitaxel.  72 hours later TRAIL/OH14/vehicle was added for 24 hours.  
Attached (ie predominantly viable) cells were then harvested with trypsin, 
washed three times in additive-free RPMI and then suspended in a solution of 
50% matrigel and 50% additive-free RPMI.  100μL of solution was injected 
into each mammary fat pad and tumours were observed for growth twice 
weekly.  Three mice with two tumours each were used to give a total potential 
of six tumours per condition. We again used the ELDA calculator available 
online (http://bioinf.wehi.edu.au/software/elda/) to calculate CSC frequency 
and statistical significance. 
 
Paclitaxel alone led to a 6/6 tumour formation rate at 10000 and 1000 cells 
(compared to 2/6 in the 1000 cell arm in the control group).  There was also 
tumour formation in half of the mice that were injected with 100 cells 
compared to none in both the control arm (Fig 4.18) and with any other 
treatment in this group.  This is clearly indicative of an increased CSC-like 
population remaining at the end of in vitro paclitaxel treatment.  The 
combination of paclitaxel with OH14 resulted in a lack of tumour formation in 
the 100 cell arm suggesting that OH14 did potentially reverse the paclitaxel-
mediated increase in CSCs.  Single agent TRAIL after paclitaxel had a better 
effect with tumour formation being halved at highest cell concentration (10000 
cells, 3/6 tumours) with an even stronger effect at the 1000 cells per injection 
concentration (1/6 tumours) and 100 cells (0/6).  The relationship between 
tumour formation for the combined treatment of OH14 and TRAIL after 
paclitaxel is more complicated, whilst at 10000 cells there as a 50% reduction 
in tumour forming ability (6/6 to 3/6) and at 100 cells there was no tumour 
formation (from 3/6) at 1000 cells per injection there was a surprising 
increase.  It is likely this reflects a degree of technical variability in this 
biological assay, and it will be necessary to repeat this experiment in the 
future to determine whether this unexpected result is reproduced. 
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Our CSC frequency calculator again confirmed these findings, with a 
significantly higher proportion of CSCs in paclitaxel compared to untreated 
control that was reduced by combination of paclitaxel with OH14 and 
paclitaxel OH14 and TRAIL.  However, the combination of paclitaxel and 
OH14 had the lowest frequency- again confirming that the technical variability 
of this assay 
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B 
No. of cells Pac Pac/14 Pac/TRAIL Pac/TRAIL/14 
10000 6/6 3/4 2/4 1/4 
1000 6/6 1/6 1/6 0/6 
100 3/6 0/6 0/6 0/6 
CSC freq 
(95% CI) 
1/142 
(1/47.4-
1/428) 
1/6896 
(1/2408-
1/19742) 
1/11556 
(1/3525-
1/37877 
1/41399 
(1/5899-
1/290524) 
Significant 
differences 
in CSCs 
(p value, 
Chi 
Squared 
test) 
 Ctrl- 8.45x10-8 Ctrl- 2.01x10-9 Ctrl- 8.02x10-12 
 
 
Figure 4.18 Effect of OH14 and TRAIL after paclitaxel on tumour 
formation in vivo and calculation of stem cell frequency 
MDA-231-wells were plated into adherent conditions, left for 24 hours and 
then treated with paclitaxel followed by either control (DMSO vehicle),  OH14, 
TRAIL or OH14/TRAIL7 2 hours later for 24 hours.  They were then injected 
bilaterally into mammary fat pads of NOD/SCID mice in a 50:50 mix of serum-
free media and matrigel and observed twice weekly for tumour growth.  3 
mice were used per condition with bilateral tumours in each.  . A, graphical 
representation of tumour formation. B, The number of stem cells was 
estimated using ELDA software (http://bioinf.wehi.edu.au/software/elda/) and 
comparison made by chi-squared test as described in (Hu and Smyth 2009) 
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4.2.10.1.3 Treatment with OH14 with paclitaxel stops the recurrence of 
tumours in an in vivo TNBC model 
 
Having shown that the combination of OH14 and Paclitaxel was potentially 
effective in targeting bCSCs in pretreatment of TNBC cell line xenografts, we 
wanted to assess the potential for in vivo administration of OH14/paclitaxel on 
established tumours.  The expected outcome of targeting CSCs in this context 
relies on the ability of the chemotherapy to regress, or partially regress tumour 
growth by diminishing bulk-cell viability, followed by an increased latency of 
relapse occurring through the suppression of tumour-initiating (CSC) activity 
within the remaining tumour cell population.  TRAIL was not tested in this 
experiment due to the financial cost of the experiment.  500000 MDA-MB-231 
cells were implanted into each mammary fat pad of an athymic mouse and 
allowed to grow until tumours measured over 5mm in their longest dimension. 
The mice were then divided into four arms: control (DMSO), OH14, Paclitaxel 
(with DMSO) and Paclitaxel and OH14.  They were then treated twice a week 
with paclitaxel at 20mg/kg or control for a total of seven doses (represented 
by arrows on in Fig 4.19A). During this 20-day period some mice were also 
treated with OH14 at 20mg/kg or DMSO control five days a week.  Tumour 
volume was measured at least twice weekly.  
 
The mice in the control and OH14 alone arms had a rapid tumour growth that 
led to the mice in those groups being culled (due to maximum permitted 
tumour size being reached) at around 18 days on average in the control group 
and around 22 days in the OH14 arm (Fig 4.19A). 
 
There was a marked response to paclitaxel treatment with both paclitaxel 
alone or paclitaxel/OH14.  Tumour regression was sustained for a minimum 
47 days whereupon one of the paclitaxel treated tumours began to rapidly 
grow, followed at Day 69, by the remaining paclitaxel treated mouse. In 
contrast, the two OH14/paclitaxel treated mice remained tumour free for up to 
Day 141 (Fig 4.19B), whereupon the animals were culled as a humane 
endpoint to the experiment. 
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A 
 
B 
 
Figure 4.19 Treatment of MDA-MB-231 xenografts with paclitaxel and 
OH14. 
500000 MDA-MB-231cells were injected bilaterally into mammary fat pads of 
athymic mice in a 50:50 solution of serum-free media and matrigel.  Once 
tumours reached a minimum of 5mm in one dimension, they were either 
treated with control, OH14, paclitaxel or paclitaxel and OH14 for a total of 
seven doses (Represented by arrows on graph).  Tumour size was then 
measured until culling criteria was met.  In the case of the Paclitaxel and 
OH14 treated mice, no tumour growth was detected at 141 days and the 
experiment was ended. 
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4.3 Discussion 
Having established a model in Chapter 3 to demonstrate that chemotherapy 
increased CSC-like activity in a panel of cell lines, we sought to assess 
whether TRAIL, with and without the novel cFLIP inhibitor OH14, could 
successfully target this induced CSC-like population.  Furthermore, previous 
work without chemotherapy had demonstrated that the combination of cFLIP 
inhibition alongside TRAIL led to a reduction in CSC-like activity (Piggott et al. 
2011; French et al. 2015) and we wanted to assess whether this was still the 
case after chemotherapy.   
 
Using the MCF7 and SUM149 cell lines, representing two key subtypes of 
breast cancer – and two contrasting cell types with respect to their known 
sensitivity to TRAIL, we initially assessed the cytotoxicity of OH14, TRAIL and 
their combination on bulk-cell viability and mammosphere formation (Figs 4.3-
4.5). We employed the same mathematical model as in Chapter 3 to 
demonstrate that both OH14 and TRAIL reduced absolute CSC numbers (Fig. 
4.6). The effect on CSC-like behaviour was more marked than in bulk cells 
suggesting that OH14/TRAIL preferentially target CSC-like cells over bulk 
tumour cells.   
 
We then demonstrated that the increase in mammosphere formation seen 
with FEC, paclitaxel and docetaxel chemotherapy was abrogated with the 
addition of OH14 and TRAIL (Fig. 4.7).  Interestingly, in the SUM149 cell line, 
there was a highly significant reduction in mammosphere formation using 
OH14 alone after chemotherapy in all passages with FEC, paclitaxel and 
docetaxel and that this reduction was greater than seen with TRAIL (Figs 4.7 
D-F and 4.8).  Although not completely wanting to rule out the combination of 
chemotherapy, OH14 and TRAIL, this led to the possibility that OH14 alone 
after chemotherapy could be a viable therapeutic option.  As stated at the 
beginning of the chapter, it was clear from previous studies that paclitaxel 
seemed to exert its effects predominantly through the extrinsic apoptosis 
pathway and as such there was a sound scientific rationale for combining 
paclitaxel with OH14 (Day, Huang, and Safa 2008b; Day et al. 2006; Park et 
al. 2004).  As we had seen the greatest effect in the SUM149 cell line, and 
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TNBC is an area of breast cancer in urgent need of novel treatment 
strategies, the focus of this work switched mainly towards assessing whether 
OH14 alone after paclitaxel in TNBC would be a viable treatment strategy. 
 
An initial experiment on a panel of TNBC cell lines, MDA-MB-231, MDA-MB-
436 and SUM149, showed that an overnight treatment of paclitaxel at 10nM 
decreased viability when OH14 was added 1 hour before and this effect was 
not seen in the MCF-7 and HCC 1954 (both non-TNBC) cell lines (Fig 4.9). 
This confirmed that TNBC seemed like a reasonable choice in which to 
assess this combination.  Given more time, an exploration of whether this 
effect on the bulk cell population was synergistic could be explored by using 
log-fold dose increases of both paclitaxel and OH14. 
 
However, our main focus was on the effect of OH14 in combination with 
paclitaxel on the CSC-like formation within TNBC. As previously discussed in 
Chapter 3, our mathematical model of mammosphere formation had 
concluded that paclitaxel caused an increase in the absolute number of 
mammosphere forming cells (CSC-like cells) in the treated cell pool, which 
suggested that CSCs were not only more resistant to paclitaxel than bulk-
cells, as suggested previously (Samanta et al. 2014; Alamgeer et al. 2014), 
but that they were actively promoted by paclitaxel.   
 
In this chapter we found that OH14 reduced this paclitaxel-induced CSC 
population, and diminished CSC numbers to below untreated levels (Figs 
4.11, 4,12, 4.13 and 4.16A and C-D).  For example, in our model (Fig 4.13) of 
MDA-MB-231 cells, the total number of CSCs fell from 34 to 11, a 67.3% 
reduction- this correlated with a reduction in overall cell viability of 60.7%. 
Therefore, we postulate that OH14, by reducing the total number of CSCs to 
below control levels, is potentially enabling paclitaxel to target CSC-like cells, 
but also blocking the signaling pathways that lead to CSC-like cell formation. 
This raises the possibility that treatment with paclitaxel, whilst increasing 
absolute CSC number and mammosphere formation, leaves an ‘Achilles Heel’ 
that can be targeted by the addition of OH14 alone.  
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We used siRNA-mediated knockdown of cFLIP to confirm these observations 
- demonstrating that OH14 was likely having an ‘on-target’ effect. 
 
As described in Chapter 3, the relationship between ALDH+ and 
mammosphere formation was not exact. When examining the effect of 
paclitaxel on ALDH+ we saw a similar 10-fold increase between the MDA-MB-
231 and SUM149 cell lines (0.52 in control to 4.84 with paclitaxel in the former 
and 3.5 to 27.3 in the later) though the SUM149 cells consistently had more 
ALDH+ at baseline (Fig 4.14). This was far more than the 2-3 fold increase in 
mammosphere formation at Passage 2 for both of these cell lines (Fig 4.11).  
The SUM149 cell line represents an inflammatory breast cancer, a type of 
breast cancer where ALDH has been shown to represent a CSC-like 
population and correlate with both metastases and survival (Charafe-Jauffret 
et al. 2010).  It is possible that the higher ALDH+ in the SUM149 cell line is 
due to its inflammatory origin. 
 
Not wanting to exclude TRAIL from our experiments completely at this point, 
the effect of the combination of OH14 and TRAIL alone on mammosphere 
formation and with paclitaxel on cell viability of the SUM149 and MDA-MB-231 
cell lines was investigated,  We demonstrated that the combination of OH14 
and TRAIL leads to a significant reduction in viability compared to control, 
OH14 and TRAIL alone (though the later only in the MDA-MB-231 cell line) 
and that the combination of OH14 and TRAIL after chemotherapy lead to the 
most significant reduction in viability (Fig 4.10).  In the MCF7 and SUM149 
cell line, OH14 did not have an effect on mammosphere formation but TRAIL 
and TRAIL/OH14 did (Figs 4.3-4.4).  In the MDA-MB-231 cell line, single 
agent OH14 significantly reduced mammosphere formation, though the effect 
was greater with TRAIL and TRAIL/OH14.  In the MDA-MB-231 and SUM149 
cell lines, the effect of TRAIL +/- OH14 on the ALDH+ was investigated and 
had a significant effect on ALDH positivity (Fig 4.15).  In the SUM149 cells 
there was a significant effect of OH14, TRAIL and TRAIL/OH14 on the ALDH+ 
positive population that was not replicated in mammosphere conditions where 
OH14 had no effect (Fig 4.4).  In the MDA-MB-231 cell line, the greatest 
reduction in ALDH+ cells came with the use of single agent OH14, with 
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smaller reductions seen in the TRAIL and TRAIL/OH14 arms.  Although a 
significant reduction in mammosphere formation was seen with single agent 
OH14, the effect of TRAIL and TRAIL/OH14 on mammosphere formation was 
greater than OH14 alone.   
 
Lastly, we used two in vivo experiments to assess whether these results could 
be replicated in the MDA-MB-231 cell line.  Firstly, we performed a serial 
dilution experiment that tests the ability of cells to form tumours in mice.  We 
performed these experiments again with TRAIL as we did not want to 
disregard it at this point.  Without chemotherapy, OH14 alone led to a slight 
reduction in tumour formation at the highest concentration of cells injected 
(10000 per mammary fat pad) but that combination treatment of OH14 and 
TRAIL was the most effective reducing tumour formation. When repeating the 
experiments with paclitaxel we saw a marked increase in tumour formation.  
This correlates with the increase in both mammosphere formation and ALDH+ 
cells that we saw in vitro.  These results were confirmed by a model 
calculating CSC in each of the arms (Figs 4.19 and 4.20) 
 
We next wanted to assess the effect of combination treatment in vivo on both 
a MDA–MB–231model as well as a patient derived TNBC cell line called PDX 
151 as patient derived samples are taking on increasing importance in 
assessing tumour behaviour (Bruna et al. 2016).    Unfortunately, the strain of 
mouse used for the PDX experiment (NOD/SCID/Balbc, Charles River 
Laboratories, Wilmington, US)  did not tolerate the combined treatment with 
all three mice being treated with a combination of OH14 and paclitaxel dying 
within 48 hours of administration. This is an experiment that we would like to 
repeat.  In the athymic mice used to evaluate the MDA-MB-231 cell line the 
mice tolerated treatment well, maintaining weight and appearing healthy.  
Here we saw a marked regression in tumour size after 7 doses of paclitaxel 
(given twice a week) with OH14 being given 5 times a week whilst the 
paclitaxel was being given.  Of the initial three mice, one of the paclitaxel mice 
did not respond to paclitaxel and was culled early in the experiment due to 
tumour size.  One of the paclitaxel/OH14 mice was also culled due to the 
presence of an intra-abdominal tumour meaning that there were only two mice 
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per arm for comparison.  The profound increased latency in tumour relapse 
observed in the OH14/paclitaxel combined treatment arm helps support our in 
vitro data that OH14 seems effective at targeting a CSC-like population that 
could be responsible for tumour initiation associated with tumour relapse (Fig 
4.19).  A larger cohort of animals would help to confirm these promising 
findings. 
 
Therefore, having established that OH14 seems to target the CSC-like 
population in TNBC cell lines our attention turns to possible mechanisms 
through which this may be occurring.  There is a possibility that this is due to 
apoptosis in that paclitaxel has been shown to induce its apoptotic effect in a 
non-ligand dependent manner through the extrinsic apoptotic pathway (Day, 
Huang, and Safa 2008a).  As an antagonist of this pathway, cFLIP is a natural 
target to increase the cytotoxicity of paclitaxel with previous evidence that 
over-expressing cFLIP protects cells from paclitaxel-mediated apoptosis (Day 
et al. 2006).  We would hypothesise that this effect may be more significant in 
CSC-like cells as more of an effect was observed on mammosphere formation 
than than with bulk cell viability.   Another possibility is that OH14 is targeting 
a component of CSC signalling that is induced by paclitaxel and two signalling 
pathways are worthy of consideration.  The first is the WNT/ β-catenin 
pathway that has been shown in other work to be down-regulated with 
suppression of cFLIP (French et al. 2015) and the second is HIF1α.  HIF1α 
has been shown to be prognostic in TNBC and blocking HIF1α using digoxin 
after paclitaxel has been shown to reduce CSC-like activity in TNBC cell lines 
(Samanta et al. 2014).  Aggregates of cFLIP have been shown to interfere 
with the ubiquitynation and degradation of both molecules, leading to 
increased cellular levels (Ishioka et al. 2007; Safa 2012). These mechanisms 
will be explored in Chapter 5. 
 
 
 
 
 
 
   
5 Investigating the mechanisms of cFLIP-mediated 
decreased viability and CSC-like activtity  
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5.1 Introduction 
Results in previous chapters have demonstrated that firstly, chemotherapy 
leads to an increase in CSC-like behaviour (Chapter 3) and that secondly, this 
effect can be reversed with a combination of OH14 and TRAIL (Chapter 4). 
Interestingly, the use of single agent OH14 in combination with paclitaxel led 
to a significant reduction both in viability and in CSC-like behaviour in TNBC 
cell lines and in a mouse model using the combined treatment in vivo.   
 
This chapter seeks to explore the mechanism behind this observed effect.  As 
stated in the conclusion to Chapter 4, our mathematical model demonstrated 
that paclitaxel led to an increase in the number of CSCs compared to control 
(Fig. 4.13).  Previous work has shown that chemotherapy can lead to the 
induction of a CSC-like phenotype (H. Liu, Lv, and Yang 2015) and as such 
this led to the generation of two hypotheses for the role of OH14 in 
suppressing the expansion of the CSC pool:  Firstly, that OH14 may be 
having an additional pro-apoptotic effect on cells treated with chemotherapy- 
lowering the apoptotic threshold in the CSC population. Other compounds, 
such as salinomycin, have been shown to target CSCs in this manner (P. B. 
Gupta et al. 2009).  Secondly, that cFLIP suppression may inhibit the 
upregulation of CSC signalling induced by chemotherapy such as β-catenin 
and HIF1α, resulting in the prevention of the generation of CSCs. 
 
It has previously been shown that over-expression of cFLIP protects cancer 
cell lines from paclitaxel-induced apoptosis and as such reducing levels of 
cFLIP could lead to an increased sensitivity to paclitaxel (Day et al. 2006; S.-
J. Park et al. 2004).  Paclitaxel has been shown to lead to apoptosis through 
the extrinsic apoptosis pathway.  As shown in Fig. 5.1A in this pathway FADD 
usually binds to Caspases 8 and 10, forming the Death Inducing Signalling 
Complex (DISC) and lead to the induction of the apoptotic pathway.  cFLIP 
can inhibit this pathway by binding to Caspases 8 and 10 and FADD thereby 
preventing formation of the DISC (Safa 2012) (Fig 5.1B and Section 1.10.5). 
With the addition of OH14, that binds to the DED1 domain of cFLIP (Hayward 
et al, unpublished work), we could prevent the inhibition of DISC formation by 
cFLIP, allowing apoptosis to occur (Fig. 5.1C).  
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In TNBC, as outlined in Chapter 1, HIF1α has been shown to both be induced 
by chemotherapy and be prognostic (Samanta et al. 2014; Lu et al. 2015).  It 
has been demonstrated that overexpression of cFLIP increases levels of 
HIF1α and β-catenin. These proteins would usually be degraded by the 
Ubiquitin Proteosome System (UPS) leading to their reduced intracellular 
levels (Fig 5.2A). cFLIP can lead to elevation of HIF1α and β-catenin through 
forming cellular aggregates that interfere with the functioning of the UPS (Fig 
5.2B) (Naito et al. 2004; Ishioka et al. 2007).  Interfering with the UPS through 
using the proteasome inhibitor MG132 reversed the increase protein levels of 
HIF1α and β-catenin when cFLIP was overexpressed.  In addition, mutating 
the DEDs of cFLIP led to a similar effect, as binding through DEDs are 
thought to be responsible for the aggregation of cFLIP and UPS inhibition 
(Ishioka et al. 2007).  OH14, our novel cFLIP inhibitor, has been designed to 
target the DED1 domain of cFLIP and therefore we hypothesise that we 
should see a reduction in HIF1α and β-catenin levels due to OH14 blocking 
cFLIP aggregate formation (Fig. 5.2C).   Previous work undertaken in our 
laboratory, though not in combination with chemotherapy, has demonstrated 
that siRNA-mediated knockdown of cFLIP in combination with TRAIL 
selectively targets CSC-like behaviour across a broad panel of breast cancer 
cell lines and increases levels of cell death in the bulk population (Piggott et 
al. 2011).  Further work has demonstrated that SiRNA-mediated cFLIP 
suppression leads to a reduction in β-catenin (French et al. 2015) 
 
This main aim of this chapter is to assess whether the mechanism of a cFLIP-
mediated reduction in CSC function in the context of chemotherapy is 
mediated through an increased apoptotic effect or through reduced CSC-
signalling. 
   
152 
  
 
 Figure 5.1 Potential effect of OH14 on apoptosis 
Diagram representing the potential anti-apoptotic effects of OH14. A, FADD (black) binds to Caspases 8/10 (red) and triggers 
apoptosis via the extrinsic apoptotic pathway.  B, cFLIP (blue) prevents apoptosis. C, OH14 blocks cFLIP (blue with yellow circle) 
allowing Caspases 8/10 to initiate apoptosis. 
FADD and Caspases- 
Apoptosis 
cFLIP blocks FADD and 
Caspases 8/10 – No 
apoptosis 
OH14 blocks cFLIP binding to 
Caspases, FADD binds – 
Apoptosis 
=cFLIP 
=FADD 
=Caspases 8/10 
=OH14 bound to cFLIP 
KEY 
A 
B 
C  
   
153 
  
 
Figure 5.5.2 Potential effect of OH14 on cFLIP aggregation and UPS function 
A diagram demonstrating the effect of OH14 on HIF1α and β-catenin degradation.  A, HIF1α and β-catenin (grey circle) are 
degraded (leading to blue three-quarter circle) by the UPS (Green triangles).  B, if cFLIP aggregates (blue trapezoids) the UPS is 
inhibited and HIF1α and β-catenin are not detgraded. C, when OH14 binds cFLIP (blue chevrons with yellow circle), OH14 allows 
HIF1α and β-catenin to be degraded by the UPS.
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5.2 Results 
5.2.1 Investigating the role of apoptosis 
5.2.1.1 cFLIP inhibition and TRAIL lead to increased apoptosis and cell 
death in the bulk MDA-MB-231 cell population with and without 
paclitaxel 
An assessment as to whether OH14 was having its intended effect through 
increasing apoptosis on the general cell population was carried out by 
Annexin V assay.  MDA-MB-231 cells were plated into adherent conditions 
and left overnight before the addition of paclitaxel at its IC50 value.  Then 72 
hours later, control (vehicle), 10M OH14, TRAIL or a combination of the two 
were added and left for 24hours before the cells were dissociated and stained 
with antibodies as per manufacturers protocols. 
 
Without chemotherapy OH14 did not lead to an increase in either apoptosis or 
cell death whereas TRAIL led to a drop in viable cells to 47% as a single 
agent.  The addition of OH14 to TRAIL led to a significant further drop of 16% 
compared to TRAIL alone (Figure 5.3 A and C) 
 
The addition of paclitaxel saw a reduction in the mean percentage of viable 
cells to 65% from 88% in the DMSO treated control (Fib 5.3B and C).  The 
addition of single agent OH14 or TRAIL significantly reduced this remaining 
viable population to 54%.  The combination of OH14 and TRAIL resulted in 
29% of the population remaining viable at the end of treatment, this was a 
significant reduction compared to paclitaxel, paclitaxel and OH14 or paclitaxel 
and TRAIL. 
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Figure 5.3 – TRAIL and OH14 lead to increased cell death and apoptosis 
with and without chemotherapy 
MDA-MB-231 cells were treated with OH14 and TRAIL with/without paclitaxel 
before being trypsinised and undergoing flow cytometry with the Annexin V 
and DAPI stain.  This gives an alive, early apoptotic, late apoptotic and dead 
population.   Figs 5.3 A-B show representative pictures whereas Fig 5.3C 
shows a graphical representation of the results without error bars to ease 
interpretation.  Dotted line is the alive population after paclitaxel treatment to 
allow comparison.  Results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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5.2.1.2 The effect of blocking apoptosis on the viability of TNBC cell 
lines in response to OH14 
As OH14 was designed as a pro-apoptotic molecule that, by binding to the 
DED1 domain of cFLIP (Hayward et al, unpublished work), leads to increased 
apoptosis mediated through the extrinsic apoptosis pathway, we wanted to 
investigate whether blocking apoptosis using a pan-caspase inhibitor lead to a 
reversal of the effect seen with OH14 on both bulk and CSC-like cells. 
 
Using two representative TNBC cell lines, SUM149 and MDA-MB-231, we 
assessed the effect of adding Z-VAD-FMK on both the overall cell viability of 
treated cells.  Cells were plated into adherent conditions, left overnight and 
then treated with their respective IC50 values of paclitaxel.  72 hours after 
chemotherapy, OH14 or vehicle was added, with Z-VAD-FMK added one hour 
before, and left for a further 24 hours.  Cell viability was then assessed by Cell 
Titer Blue assay. 
 
Addition of Z-VAD-FMK led to a significant increase in the viability of the 
remaining cells in all conditions in both the MDA-MB-231 as well as the 
SUM149 cell lines apart from the SUM149 control group (Fig. 5.4).  
Interestingly, this effect was also observed for the control and the paclitaxel 
conditions – even though in the case of the latter it was added 72 hours after 
the addition of the chemotherapy or vehicle.  With single agent OH14, 
paclitaxel and paclitaxel/OH14 the increase in viability after addition of Z-VAD-
FMK was 15-20% across all conditions in both cell lines. 
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A  
 
B 
 
Figure  5.4- Caspase inhibition leads to an increase in viability in both 
the MDA-MB-231 and SUM 149 cells when treated with either paclitaxel, 
OH14 or a combination of the two 
A) MDA-MB-231 and B) SUM149 cell lines were treated with their IC50 value 
of paclitaxel before OH14 was added 72hrs later +/-Z-VAD-FMK Caspase 
inhibition (CI) 1hr before.  Viability was assessed via Cell Titer Blue.  Error 
bars represent SEM of the mean and results are an average of three 
experiments performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   
****=p<0.0001). 
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5.2.1.3 Caspase inhibition decreases the effect of OH14 on 
mammosphere formation in the MDA-MB-231 cell line 
As we particularly wanted to examine the potential role of apoptosis in 
mediating the effect of OH14 on CSC-like behaviour, we repeated the 
mammosphere forming experiments with paclitaxel and OH14 with and 
without caspase inhibition (CI). We again combined our viability and 
mammosphere data to construct our mathematical model combining viability 
and mammosphere data as used in previous chapters (See Sections 3.17 and 
4.26).  MDA-MB-231 cells were treated as per Section 5.1.1.2 and then plated 
into mammosphere conditions with mammospheres being counted at 7 days 
(Passage 1), dissociated into single cells and plated again into non-adherent 
conditions at a fixed cell density for a further seven days and counted again 
(Passage 2).   
 
As previously described in Chapter 4, paclitaxel led to a significant increase in 
mammosphere formation that was reduced by the addition of OH14. (Figs 5.5 
A and B and 5.6). If the effect of OH14 on CSC-like cells was dependent upon 
apoptosis, we would expect there to be a significant difference between the 
magnitude of difference in mammosphere formation between CI and control 
arms in the OH14 treated cells compared to the control treated cells. For 
example, if in the control treated cells, there was a difference 0.2% in the 
mammosphere formation between control and CI arms, we would expect the 
difference in the OH14 group to be much larger, for example 0.4%. 
 
CI with ZVAD-FMK significantly increased mammosphere formation in control 
conditions, an effect that could be due to increased resistance to anoikis due 
to inhibition of apoptosis.  This effect was seen again and in the presence of 
OH14 and paclitaxel/OH14 though the magnitude of difference between the 
control and CI arms in each treatment condition was similar. (Figs 5.5A and 
B). This suggests that OH14 is not having a significant effect on 
mammosphere formation that is mediated through apoptosis.  The addition of 
Z-VAD-FMK to paclitaxel alone however led to a non-significant reduction in 
sphere formation.  
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This is confirmed by our mathematical model.  In our control arm there was an 
increase in absolute CSC numbers from 89 in the control arm to 129 with CI.  
With OH14 the magnitude of increase was similar- increasing from 100 to 145 
without paclitaxel and from 63 to 110 with paclitaxel without and with CI 
respectively (Fig. 5.6). There was no significant difference between the actual 
numbers of CSCs between the control and CI treated cells, possibly because 
the CI was added 72 hours after the paclitaxel and apoptosis had already 
occurred.   
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A     
 
B    
 
Figure 5.5 – Effect of caspase inhibition on mammosphere formation in 
TNBC is complex 
MDA-MB-231 cells were treated with their IC50 value of paclitaxel before 
OH14 was added 72hrs later +/-Z-VAD-FMK Caspase inhibition (CI) 1hr 
before.  After 24hrs they were plated into mammosphere conditions and 
counted at Passage 1 (A) and Passage 2 (B).  Error bars represent SEM of 
the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
Control 99.8 9980 0.89 89 
OH14 102.8 10280 0.97 100 
Paclitaxel 70.7 7070 2.54 180 
Paclitaxel/OH14 61.9 6190 1.02 63 
 
Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
Control with CI 105.8 10580 1.22 129 
OH14 with CI 113.5 11350 1.28 145 
Paclitaxel with CI 80.8 8080 1.93 156 
Paclitaxel/OH14 
with CI 
81.2 8120 1.36 
110 
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Figure 5.6 – Table and Graphical Representation of mathematical CSC 
model in MDA-MB-231 cells with or without Caspase Inhibition 
The overall cell viability of the MDA-MB-231 cell line was multiplied by the 
percentage mammosphere formation at the end of Passage 2 for the 
respective treatment condition to give an absolute CSC number remaining at 
the end of adherent treatment Error bars represent SEM of the mean and 
results are an average of three experiments performed in triplicate.  (T-test, 
*=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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5.2.1.4 Caspase inhibition also decreases the effect of OH14 on 
mammosphere formation in the SUM149 cell line 
SUM149 cells were treated as above (5.2.1.2) and again the effect on 
mammosphere formation was observed. 
 
As in the previous section, if the effect of OH14 on CSC-like behaviour was 
mediated by apoptosis we would expect there to a proportional difference in 
the effect of CI on OH14 treated cells as compared to control. 
 
In this cell line, addition of Z-VAD-FMK had a significant effect on 
mammosphere formation or actual CSC number (Figs 5.7 and 5.8).  There 
was however a small increase in mammosphere formation seen in both OH14 
and OH14 combined with paclitaxel treated cells of around 40 (148 to 189 in 
OH14 treated cells and 86 and 127 in combined treated cells without and with 
CI repectively (Fig 5.8).  Again, there was no effect on the paclitaxel treated 
cells.  Although this is different to the MDA-MB-231 cell line, the overall trend 
of data is the same.   
 
Taken together, the results in our two cell lines suggest that the effect of 
OH14 after paclitaxel is minimally dependent upon apoptosis and that another 
mechanism must be involved. As discussed in the introduction to this chapter 
(Section 5.1), the other major hyppthesised mechanism of action of OH14 on 
CSC-like function is CSC signalling.  
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A 
 
B   
 
Figure 5.7  Mammosphere formation in the  SUM 149 cell line is altered 
by Caspase inhibition 
SUM149 cells were treated with their IC50 value of paclitaxel before OH14 
was added 72hrs later +/-Z-VAD-FMK Caspase inhibition (CI) 1hr before.  
After 24hrs they were plated into mammosphere conditions and counted at 
Passage 1 (A) and Passage 2 (B).  Error bars represent SEM of the mean 
and results are an average of three experiments performed in triplicate.  (T-
test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
Control 99.7 9970 1.59 159 
OH14 84.2 8420 1.76 148 
Paclitaxel 72.8 7280 2.96 215 
Paclitaxel/OH14 66.7 6670 1.29 86 
 
Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
Control with CI 104.9 10490 1.36 143 
OH14 with CI 98 9800 1.93 189 
Paclitaxel with CI 93 9300 2.36 219 
Paclitaxel/OH14 
with CI 
81.1 8110 1.57 127 
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Figure 5.8 – Table and Graphical Representation of mathematical CSC 
model in SUM149 cells with or without Caspase Inhibition 
The overall cell viability of the SUM149 cell line was multiplied by the 
percentage mammosphere formation at the end of Passage 2 for the 
respective treatment condition to give an absolute CSC number remaining at 
the end of adherent treatment.  Error bars represent SEM of the mean and 
results are an average of three experiments performed in triplicate.  (T-test, 
*=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001) 
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5.2.2 Investigating the role of OH14 in paclitaxel-induced CSC signaling  
Having established in the previous sections that pan-caspase inhibition did 
not significantly restore the effect of OH14 on paclitaxel-induced CSC-like 
behaviour, we wanted to assess the role of OH14 on CSC signalling.  This 
section will address our alternative hypothesis that OH14 prevented the 
acquisition of CSC-like characteristics, either through trans-differentiation or 
proliferation of CSCs following paclitaxel treatment.  Two representative cell 
lines, SUM 149 and MDA-MB-231 were chosen to study the mechanisms 
underlying a cFLIP-mediated anti-CSC signalling effect.  
 
5.2.2.1 Paclitaxel leads to an increase in HIF1α but not β-catenin protein 
expression at 96 hours 
The elevation of CSC markers such as HIF1α and β-catenin in response to 
chemotherapy has been previously reported. In a panel of breast cancer cell 
lines treated with the chemotherapeutics paclitaxel and gemcitabine, it took 96 
hours for the elevation of HIF1α to occur (Samanta et al. 2014).  HIF1α has 
been shown to be elevated in response to chemotherapy, particularly in TNBC 
and to be prognostic (Lu et al. 2015; Buffa et al. 2010; Rohwer and Cramer 
2011).  It has also been shown to promote EMT (W. Zhang et al. 2015).  β-
catenin is also known to be associated with EMT and CSC-like behaviour and 
its inhibition has been shown to increase the cytotoxicity of a number of 
different chemotherapeutics across a broad-range of cancer types (Saifo et al. 
2010).  However, it has been demonstrated in breast cancer that neoadjuvant 
chemotherapy did not lead to altered β-catenin levels (as measured by 
immunohistochemistry) and that β-catenin could not be used to predict 
treatment resistance (Rosa et al. 2015).  These proteins are both of interest 
as, as has been previously discussed, both potentially have an association 
with cFLIP and β-catenin has already been demonstrated in our laboratory to 
be affected by cFLIP- though this was not in association with chemotherapy 
(Safa 2012; French et al. 2015; Ishioka et al. 2007).   
 
As our results to date (Chapter 3 and Chapter 4) have shown that paclitaxel  
increases CSC-like mammosphere over an extended perioded of time (4 
   170 
days).  We wanted to assess the levels of these proteins in response to 
chemotherapy over a similar extended period of time to assess whether they 
correlated with mammosphere formation. 
 
Two representative TNBC cell lines (MDA-MB-231 and SUM 149) were 
treated with the 96-hour IC50 value of paclitaxel that had been established.  
Cells were harvested at 24, 48, 72 and 96 hours after the addition of 
chemotherapy.  Western blotting was used to examine the effect of 
chemotherapy on HIF1α, β-catenin and cFLIP protein levels in total cell 
lysates. qPCR was then used to confirm the levels of both HIF1α and β-
catenin at the transcriptional level. 
 
In both cell lines all three proteins exhibited increases in expression over the 
96 hour time course, yet only HIF1α was significantly elevated in both cell 
lines by the 96-hours time point (Fig 5.9).  
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Figure 5.9- Time course of protein expression in response to paclitaxel 
in TNBC cell lines 
The MDA-MB-231 (A and C) and SUM149 (B and D) cell lines were treated 
with paclitaxel and cells were harvested at 24,48,72 and 96 hours for protein 
analysis. A and B are representative pictures and C and D are a graphical 
representation of results.  Error bars represent SEM of the mean and results 
are an average of three experiments.  (T-test, *=p<0.1, **=p<0.01, 
***=p<0.001   ****=p<0.0001).   
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5.2.3 HIF1α mediated gene expression is increased in a time-dependent 
manner 
Having demonstrated that HIF1α, but not β-catenin, is significantly elevated 
by chemotherapy at 96 hours we examined HIF1α- gene expression and 
downstream HIF-α -dependent gene expression over the same time course.  
Again, we treated both MDA-MB-231 and SUM149 cell lines with their 
respective IC50 values of paclitaxel and harvested cells for RNA at 24,48, 72 
and 96 hours.  Targets of HIF1α that we wanted to examine were IL6, IL8, 
MDR1 and Snail, all of which have been shown to be under control of HIF1α 
(Shujing Liu et al. 2011; L. Zhang et al. 2013; Samanta et al. 2014). 
 
In the MDA-MB-231 cell line there was significant upregulation of IL6, IL8, 
MDR1 and Snail prior to the 96 hours time point but the increase was largest 
at 96 hours for all targets and, for HIF1α itself, only significant at this time 
point (Fig 5.10A).  In the SUM149 cell line (Fig 5.10B), there is a similar 
picture, with all targets upregulated before 96 hours but most markedly so at 
this point, with the exception of Snail that was most elevated at 24 hours. 
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Figure 5.10 HIF1α-mediated gene expression increases over time in 
TNBC cell lines in response to paclitaxel 
The MDA-MB-231 (A) and SUM149 (B) cell lines were treated with paclitaxel 
and cells were harvested at 24,48,72 and 96 hours for RNA analysis. Error 
bars represent CI of the mean and results are an average of three 
experiments each performed in triplicate. Statistical analysis was then 
performed by assessing the overlap between 95% confidence intervals 
(Cumming, Fidler, and Vaux 2007)  (*=p<0.1, **=p<0.01).   
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5.2.4 The paclitaxel-mediated increase in HIF1α protein levels and 
gene-expression is reversed by OH14 
Next we wanted to assess whether the increase in HIF1α that was seen with 
paclitaxel could be reversed by the addition of OH14, our novel cFLIP 
inhibitor.  As previously described, cFLIP has been shown to interfere with the 
breakdown of HIF1α and therefore we hypothesised that OH14 would lead to 
increased breakdown of HIF1α mediated by the ubiquitin proteosome system  
(UPS) (Ishioka et al. 2007; Safa 2012).  Thus we predicted that protein levels, 
but not mRNA levels of HIF1α would be affected by OH14, while downstream 
HIF1a-dependent gene targets would also be reduced.  We also wanted to 
evaluate any potential effect on β-catenin and cFLIP. 
 
The MDA-MB-231 or SUM149 cell lines were plated into adherent conditions, 
the relevant IC50 value of paclitaxel was added after cells were allowed to 
adhere overnight and left for 96 hours with OH14 +/- TRAIL being added 
72hours later for the final 24 hours of the experiment.  Cells were harvested 
and stored for either analysis of protein levels via Western Blotting or RNA 
analysis by RT-PCR. 
 
Confirming our previous time course data, in both the MDA-MB-231 (Fig 5.11 
A and B) and SUM149 (Fig 5.11 A and C) there was a significant rise in 
HIF1α protein expression when treated with paclitaxel.  This increase was 
reversed by the addition of OH14, though in the MDA-MB-231 cell line the 
level of HIF1α was still significantly more than the control group.  In the 
SUM149 cells, the levels of HIF1α were higher in the combined 
paclitaxel/OH14 group than control but this was not significant.  In both cell 
lines, there were no significant differences between treatment arms seen with 
either β-catenin or cFLIP. 
 
The effect of paclitaxel on HIF1α gene expression differed between the two 
cell lines.  As expected MDA-MB-231 cells exhibited no transcriptional 
increase in HIF1α, suggesting that increased protein levels were due to 
stabilisation and/or post-translational modification.  HIF1α gene expression in 
the SUM149 cell line however exhibited a significant increase, suggesting an 
   176 
alternative, or additional, mechanism of regulation.  However, the effect of 
OH14 on HIF1α  gene expression was consistent, with both cell lines 
exhibiting a significant decrease in HIF1α  mRNA levels with combined 
treatment.   
 
The effect of OH14 on paclitaxel-mediated HIF1a-induced gene expression 
was also consistent between the cell lines, with OH14 inhibiting downstream 
paclitaxel-mediated gene transcription.  In the SUM149 cell line, OH14 alone 
had the unexpected effect of reducing baseline transcription in 3 of the 4 
downstream HIF1α gene targets. 
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Figure 5.11 Effect of paclitaxel and OH14 on HIF1α, β-catenin and cFLIP 
protein expression and HIF1α-mediated gene expression 
The MDA-MB-231 (Figs A, B and D) and SUM149 cell lines (A, C and E) were 
treated with paclitaxel before the addition of OH14 72 hours later.  After 24 
hours they were harvested for either protein or RNA analysis.  For Western 
blots, Error bars represent SEM of the mean and results are an average of 
three experiments.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
For RT-PCR error bars represent CI of the mean and results are an average 
of three experiments performed in triplicate.  Statistical analysis was 
performed by assessing the overlap between 95% confidence intervals 
(Cumming, Fidler, and Vaux 2007)  (*=p<0.1, **=p<0.01).   
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5.2.5 Confirming the role of HIF1α in TNBC CSC-like activity 
5.2.5.1 HIF1α plays an important role in viability and mammosphere 
formation both with and without chemotherapy 
Having established in the previous section that HIF1α, but not β-catenin, was 
affected by OH14 we sought to investigate the role of HIF1α further.  HIF1α is 
known to play an important role in tumourigenesis, slow down tumour initiation 
in vivo and abrogate mammosphere formation in mammary tumour epithelial 
cells derived from mice in a MMTV-Cre model (Schwab et al. 2012; H. Zhang 
et al. 2015). For these experiments, MDA-MB-231 cells were plated overnight 
and then either scRNA or SiRNA HIF1α was added the next day before 
chemotherapy was added the day afterwards and allowed to remain in culture 
for another 96 hours.   Cells were then examined for either viability using Cell 
Titer Blue or transferred into mammosphere conditions as described in 
Section 2.6.  In addition cells were harvested between 24-96 hours to check 
the efficacy and duration of knockdown of HIF1α. 
 
The siRNA-mediated knockdown of HIF1α was both persistent (lasting up to 
96 hours) and highly significant at all time points (Fig 5.12A). There was no 
effect of siHIF1α  alone, but a small yet significant difference in cell viability 
when paclitaxel treated cells were treated with SiRNA compared to scRNA 
(mean 69% with scRNA and 60% with SiRNA HIF1α).  When examining the 
effect of mammosphere formation, the effect of knocking down HIF1α is highly 
significant.  In both Passage 1 and Passage 2, there was a highly significant 
increase with paclitaxel in the scRNA group as has been seen in our previous 
experiments.  Knockdown of HIF1α led to not only a significant reduction in 
mammosphere formation compared to scRNA in both Passage 1 and 
Passage 2 (Fig 5.13 A-C) but also abrogated the increase in mammosphere 
formation seen in both passages with paclitaxel.  When combining our data 
into our mathematical model, it can be seen that knockdown of HIF1α leads to 
a significant reduction in absolute CSC number from 133 in the scRNA group 
to 61.  It also leads to a 50% reduction in absolute CSC number with 
chemotherapy (61 to 31) compared to the 25% increase seen with paclitaxel 
with scRNA (Fig 5.14). 
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Figure 5.12 Effect of siRNA against HIF1α on cell viability in combination 
with paclitaxel 
MDA-MB-231 cells were plated overnight and then either scRNA or SiRNA 
HIF1α was added the next day.  A, to confirm knockdown of HIF1α cells were 
harvested for RNA between 24 and 96hrs. B, after knockdown chemotherapy 
was added the day afterwards and allowed to remain in culture for another 96 
hours.   Cells were then examined for either viability using Cell Titer Blue.  For 
RT-PCR error bars represent CI of the mean and results are an average of 
three experiments performed in triplicate.  Statistical analysis was performed 
by assessing the overlap between 95% confidence intervals (Cumming, 
Fidler, and Vaux 2007)  (*=p<0.1, **=p<0.01). For viability, error bars 
represent standard error of the mean and results are an average of three 
experiments performed in triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   
****=p<0.0001). 
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Figure 5.13-   Knockdown of HIF1α stops the increase in mammosphere 
formation seen in the MDA-MB-231 cell line with paclitaxel 
MDA-MB-231 cells were plated overnight and then either scRNA or SiRNA 
HIF1α was added the next day before chemotherapy was added the day 
afterwards and allowed to remain in culture for another 96 hours.   Cells were 
then dissociated and plated at a fixed density in mammosphere conditions. 
After 7 days they were counted (Passage 1, A), dissociated and plated again 
at a fixed concentration.  7 days later they were counted again (Passage 2, 
B).  C, Pictures at the end of Passage 2.   Error bars represent standard error 
of the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
scRNA 100 10000 1.325 133 
scRNA  with 
Paclitaxel 
69.4 6940 2.4 167 
siRNA HIF1 99.1 9910 0.62 61 
siRNA HIF1 
with paclitaxel 
60.3 6030 0.52 31 
 
 
  
Figure 5.14 – Table and Graphical Representation of mathematical CSC 
model in MDA-MB-231 cells with or without Caspase Inhibition 
The overall cell viability of the MDA-MB-231 cell line was multiplied by the 
percentage mammosphere formation at the end of Passage 2 for the 
respective treatment condition to give an absolute CSC number remaining at 
the end of adherent treatment.  Error bars represent standard error of the 
mean and results are an average of three experiments performed in triplicate.  
(T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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5.2.5.2 Establishing the role of apoptosis in HIF1α-mediated CSC 
suppression 
Hypoxia has been shown to play an anti-apoptotic role with mechanisms 
mediated both with and without HIF1α (Flamant et al. 2010).  Flamant and co-
workers eloquently showed in the MDA-MB-231 cell line that HIF1α is 
involved in hypoxia-induced protection against paclitaxel-induced apoptosis.  
In addition, hypoxia led to lower expression of extrinsic apoptosis pathway 
genes such as Caspases 8 and 10 as well as TRAIL receptor family that was 
reversed by knockdown of HIF1α by siRNA.  This has important implications 
and suggests that OH14, as an antagonist of cFLIP activity, could be having a 
duality of effect on CSC-like activity.  Firstly, it may increase apoptosis by 
directly blocking the antagonostic activity of cFLIP on the extrinsic apoptosis 
pathway.  By reducing HIF1α levels, through allowing its degradation through 
the UPS, it also potentially increases the gene expression of components of 
this pathway.  This would also result in the reduction of paclitaxel induced 
HIF1α-mediated gene expression of genes associated with CSC-like 
behaviour such as IL6, IL8 and MDR1 (Section 5.1.4). 
 
In this section we therefore sought to assess the effect of Caspase Inhibition 
(CI) on both viability and mammosphere formation in HIF1a-siRNA treated 
MDA-MB-231 cells.  Cells were plated, allowed to seed overnight, treated with 
siRNA HIF1α and then treated with paclitaxel 24 hours later for 96 hours.  CI 
was added one hour before paclitaxel.  Cells were then analysed for viability 
by Cell Titer Blue or trypsinised, dissociated and plated into mammosphere 
condition as described in detail in Section 2.6. To conclude that apoptosis was 
an important mechanism in altering CSC-like behaviour in the context of HIFα 
suppression and paclitaxel, we would expect CI to cause a significant change 
in the magnitude of the effect of paclitaxel in the context of HIFα suppression 
compared to the control group with no paclitaxel. 
CI led to a significant increase in cell viability when combined with paclitaxel 
with viability increasing from 66 to 76% (Fig 5.15).  The effects of CI on 
mammosphere formation in both Passage 1 and Passage 2, with and without 
paclitaxel, (Fig 5.16A and 5.16B respectively) were similar.  As seen in 
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Sections 5.1.1.3 and 5.1.1.4, CI led to a significant increase in mammosphere 
formation in all conditions.  However, as there was no differences between the 
control and paclitaxel treated groups we conclude that apoptosis is unlikely to 
play a major role. 
 
The mathematical model that combines cell viability with mammosphere 
formation yields similar results.   Without CI, when HIF1α is suppressed 
paclitaxel leads to a significant fall in CSC numbers and this effect persists 
with CI. (Fig 5.16).  This does not suggest that apoptosis is playing a signicant 
role in the HIF1α-mediated effect on CSC number induced by paclitaxel 
 
 
 
 
  
  
   186 
 
 
Figure 5.15- Effect of Caspase Inhibition on cell viability in combination 
with paclitaxel and siRNA-mediated knockdown of HIF1α  
MDA-MB-231 cells were plated overnight and then either scRNA or SiRNA 
HIF1α was added the next day before chemotherapy was added the day 
afterwards and allowed to remain in culture for another 96 hours.   Z-VAD-
FMK was added one hours before chemotherapy. Cells were then examined 
for either viability using Cell Titer Blue.  Error bars represent standard error of 
the mean and results are an average of three experiments performed in 
triplicate.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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C 
Treatment 
Condition 
Viability 
(%) 
Cell number 
(100%-10000) 
P2 sphere 
formation 
(%) 
Total 
number of 
CSCs 
siRNA HIF1 95.4 9540 0.58 55 
siRNA HIF1 with 
paclitaxel 
66 6600 0.46 30 
siRNA HIF1 with 
CI 
94.2 9420 1.08 101 
siRNA HIF1 with 
paclitaxel and CI 
76.9 7690 1 76.9 
 
  
Figure 5.16 Effect of CI on CSC-like activity with paclitaxel and siRNA-
mediated knockdown of HIF1α 
MDA-MB-231 cells were plated overnight, SiRNA HIF1α was added 24hr 
later, before chemotherapy was added 24hr later again (+/- CI 1hr before) for 
96 hours.   Cells were dissociated and plated into mammosphere conditions. 
After 7 days they were counted (Passage 1, A), dissociated and plated again 
at a fixed concentration.  7 days later they were counted again (Passage 2, 
B). C, the overall cell viability of the MDA-MB-231 cell line was multiplied by 
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the percentage mammosphere formation at the end of Passage 2 for the 
respective treatment condition to give an absolute CSC number remaining at 
the end of adherent treatment.  Error bars represent standard error of the 
mean and results are an average of three experiments performed in triplicate.  
(T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001).  
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5.2.5.3 Inhibiting the proteasome pathway, reverses the reduction in 
HIF1α seen in response to cFLIP inhibtion 
Having established that OH14 leads to a reduction in HIF1α and that 
supressing HIF1α leads to a suppression of mammosphere activity, with and 
without paclitaxel, we wanted to establish a mechanism of action.  Previous 
studies have shown that over expression of cFLIP led to upregulation of both 
HIF1α and β-catenin that was reversed through using MG132, a proteasome 
inhibitor that disrupts the ubiquitin proteasome system (UPS) (Ishioka et al. 
2007; Naito et al. 2004).  This effect was replicated by mutating the DEDs of 
cFLIP, one of which (DED1) is known to be bound by our novel compound 
OH14 (Hayward et al, unpublished work). 
 
We therefore assessed the effect of MG132 on reversing the reduction of both 
HIF1α and β-catenin by siRNA-mediated knockdown of cFLIP and HIF1α in 
the MDA-MB-231 cell line.  In these experiments we stimulated HIF1α through 
hypoxic conditions, rather than using chemotherapy.  This is because MG132 
is toxic to cells and therefore combining it with chemotherapy would lead to 
too much cell death.  Cells were treated with either a scrambled siRNA control 
or siRNA targeted against cFLIP or HIF1α for 48hrs and then treated with 
10μM of MG132 for 5 hours whilst in a 1% O2/ 5% CO2 incubator at 37oC.  
Western blotting (Fig 5.15A) showed that in scrambled control the level of 
HIF1α and β-catenin went up with MG132 (shown graphically with white bars 
in Fig 5.15B for HIF1α and Fig 5.15C for β-Catenin).  cFLIP, although known 
to be degraded by the UPS (Safa 2012) did not change (Fig 5.15D, white 
bars).   
 
Knocking down cFLIP led to a 60% reduction in HIF1α (Fig 5.15B) that was 
significantly reversed with MG132.  Although suppression of cFLIP had not 
previously been shown to cause a reduction in β-Catenin in the MDA-MB-231 
cell line, there was a trend but no significant increase in β-Catenin with 
MG132 following knockdown of cFLIP (Fig 5.15C).  cFLIP levels were 
suppressed by an average of 85% at 48hrs with siRNA and therefore were not 
affected by MG132 (Fig 5.15D).   
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Finally, suppression of HIF1α led to an 80% reduction in HIF1α levels that 
was not changed by MG132 (Fig 5.15B), though there was a small but non-
significant increase in β-Catenin and decrease in cFLIP seen with MG132 
after knockdown (Figs 5.15C and 5.15D respectively). 
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D 
 
Figure 5.17- Inhibition of the UPS reverses the reduction in HIF1α levels 
in response to siRNA mediated knockdown of cFLIP 
The MDA-MB-231 cell line was treated with either scRNA, siRNA against 
cFLIP or siRNA against HIF1α for 48hrs before being placed in hypoxic 
condition for 5 hrs with or without the proteasome inhibitor MG132.  Cells 
were then harvested for protein analysis.  A, representative Western Blot. B, 
graphical representation of effect of siRNA on HIF1α. C, graphical 
representation of effect of siRNA on β-Catenin. D, graphical representation of 
effect of siRNA on cFLIP. Error bars represent SEM of the mean and results 
are an average of three experiments.  (T-test, *=p<0.1, **=p<0.01, 
***=p<0.001   ****=p<0.0001). 
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5.2.5.4 OH14 reverses the increase in colony forming ability seen with 
hypoxia in MDA-MB-231 cells 
Next we wanted to assess whether OH14 could block any increase in colony 
formation ability (CFA) of MDA-MB-231 cells when they were plated at low 
confluency and left for a period of time in either hypoxic (1% 02/5%CO2) or 
normoxic (20% 02/5%CO2) conditions. The CFA is an in vitro assay which 
tests one of the functional characteristics of stem cells: the ability to propagate 
colonies from single cells through enhanced proliferative potential (Locke et 
al. 2005).  Hypoxia has previously been shown to increase the stem cell 
markers and colony forming ability of the MDA-MB-231 cell line (Xie et al. 
2016).  In this experiment, MDA-MB-231 cells were plated at a confluency of 
185 cells/ml into a 12 well dish, allowed to adhere overnight, then treated with 
either DMSO control or 10μM OH14, placed in differing oxygen 
concentrations and then left for 6 days.  This experimental design was chosen 
as the passaging step of the mammosphere experiment would have involved 
passaging cells in non-hypoxic conditions- potentially altering the outcome. 
 
Hypoxia led to a highly significant increase in the colony forming ability of the 
cells (20% average 115.5 colonies, 1% 194.5 colonies, a 68% increase) (Fig 
5.16 below).  In normoxia, OH14 significantly reduced colony formation (115.5 
to 101.5 colonies on average, a 12% decrease) but under hypoxic condition, 
the addition of OH14 greatly reduced the ability of the cells to form colonies 
(194.5 to 118.8, a 39% decrease).   
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Figure 5.18- Effect of OH14 on CFA of the MDA-MB-231 cell line 
A-D, representative pictures of different treatment condition (A, 20% control, 
B, 20% OH14, C, 1% Control, D, 1% OH14) after being left for 6 days in 
respective treatment conditions.  E, Graphical representation of results. Error 
bars represent SEM of the mean and results are an average of three 
experiments.  (T-test, *=p<0.1, **=p<0.01, ***=p<0.001   ****=p<0.0001). 
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5.3 Discussion 
Previous work in our laboratory had shown that the combination of cFLIP 
suppression and TRAIL was effective against CSCs in a broad panel of breast 
cancer cell lines without chemotherapy (Piggott et al. 2011).  The original aim 
of this thesis was to assess whether the combination of cFLIP suppression, 
using the subsequently developed cFLIP inhibitor OH14, and TRAIL 
abrogated CSC-like activity as effectively in breast cancer cell lines that had 
been treated with chemotherapy.  It was demonstrated in Chapter 3 that 
chemotherapy led to an increased CSC-like phenotype across a panel of 
breast cancer cell lines and then in Chapter 4 that the combination of 
paclitaxel and OH14 alone led to a significant effect on CSC-like activity in 
TNBC cell lines alone without TRAIL.  Although, not wanting to discount 
TRAIL entirely, the aim of this chapter was to assess the mechanism through 
which OH14, or cFLIP suppression using siRNA, may be leading to a 
reduction in a CSC-phenotype in the context of chemotherapy.   
 
There were two main mechanisms that we wished to explore- apoptosis and 
CSC-like signalling.  As described in Section 5.1, cFLIP has an important 
antagonistic role in the extrinsic apoptosis pathway and its overexpression 
has been shown to protect against the apoptosis induced by paclitaxel in 
particular (Safa 2012; Day, Huang, and Safa 2008a; Day et al. 2006).  CSC-
signalling has been shown to be induced by chemotherapy and two targets 
were of interest- HIF1α and β-catenin.  Whilst both have been implicated in 
CSC-like behaviour, the former has been shown to be both induced by 
chemotherapy and to be prognostic in TNBC (Samanta et al. 2014; Lu et al. 
2015).  Although such a strong link does not exist for β-catenin, it has been 
shown to be involved in EMT, a key mechanism through which cancerous 
cells acquire CSC-like attributes (Mani et al. 2008; Rosa et al. 2015). The 
degradation of both these proteins has been shown to be under the control of 
the ubiquitin proteasome system (UPS), of which cFLIP is an inhibitor (Ishioka 
et al. 2007).  Indeed, previous work in our laboratory has shown that siRNA-
mediated suppression of cFLIP leads to a reduction in β-catenin and here we 
wanted to assess whether this remained the case both in using OH14 rather 
than siRNA and in the context of chemotherapy (French et al. 2015).   
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Wanting to firstly assess the role of apoptosis, the Annexin V and DAPI assay 
was used to examine apoptosis and cell death via flow cytometry in the MDA-
MB-231 cell line.  We demonstrated that without chemotherapy OH14 did little 
to effect overall cell viability as a single agent (Fig 5.3),  TRAIL alone led a 
highly significant drop to 47% of control that was further increased by 16% to 
31% overall alive population with the combination of both TRAIL and OH14 
together. With the addition of paclitaxel, both OH14 and TRAIL led to a 
reduction in viability compared to paclitaxel alone, though interestingly for 
TRAIL the overall viable population was higher with the combination of 
paclitaxel and TRAIL than TRAIL alone (54% v 47%) though this was not 
statistically significant.  This is somewhat surprising as a previous synergistic 
relationship has been shown between paclitaxel and TRAIL and paclitaxel has 
been shown to up regulate the death receptors to which TRAIL binds 
(Buchsbaum et al. 2003; de Miguel et al. 2016) and therefore we would 
expect the viability to decrease above single agent TRAIL as we previously 
saw with our Cell Titre Blue assay in Section 4.2.4.  The combination of OH14 
and TRAIL led to an increase in cell death with only 30% of the population 
remaining viable. 
 
We then wanted to assess whether blocking apoptosis using a pan-caspase 
inhibitor (CI) Z-VAD-FMK led to OH14 having different effects on both overall 
viability and CSC-like activity (Figs 5.4-5.8). When examining the effect of CI 
on overall cell viability, in both the MDA-MB-231 and SUM149 cell lines, CI 
led to an increased viability in control, OH14 paclitaxel and paclitaxel/OH14 
arms. This effect was broadly similar across all treatment arms suggesting 
that OH14 was not having a marked effect on the overall bulk cell population 
through apoptotic pathways.  We subsequently went on to examine the effect 
of CI on mammosphere formation, hypothesising that in previous Chapters 
OH14 had affected CSC-like activity more than its effects on a bulk cell 
population. In these experiments, CI led to an increase in mammosphere 
formation and actual CSC number across all treatment groups- likely because 
anoikis uses apoptosis pathways to induce cell death and this is a key 
biological process in resisting death in non-adherent cell culture conditions. 
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(Gilmore 2005).  We again explored as to whether there as a difference in 
magnitude different conditions had CI added.  In none of our treatment 
conditions did CI lead to a change in magnitude of either mammospheres or 
numbers of CSCs in our mathematical models.  This suggests that the 
primary anti-CSC activity of OH14 is not dependent upon apoptosis.  Further 
experiments examining the effect of OH14 on apoptosis in CSCs could be 
undertaken on a purified CSC population (fox example that had been FACS 
sorted by ALDH+) and could include either recalculation of an IC50 value on 
these cells compared to an overall cell population or an Annexin V/DAPI 
assay.  
 
Having shown that OH14 was not having a major effect through apoptosis, we 
examined the role of the CSC-signalling proteins HIF1α and β-catenin.  As 
shown in Fig 5.9, there was no significant increase in β-catenin with paclitaxel 
at any time point after chemotherapy but HIF1α levels increased significantly 
at 96hrs.  This could explain why, in Chapter 3, no increase in mammosphere 
formation was seen at 72hrs but was at 96 hrs.  Indeed, others have shown 
that it takes 96hrs for HIF1α levels to be elevated in response to 
chemotherapy in breast cancer cell lines (Samanta et al. 2014)- although the 
same laboratory subsequently published a paper showing an increase in 
mammosphere formation after 72hrs of treatment (Zhang et al. 2015).  Further 
experiments will be undertaken to assess whether β-catenin gene expression 
was increased despite no increase in protein levels.  This could be through a 
mechanism such as nuclear localisation and therefore nuclear and 
cytoplasmic levels of β-catenin could be examined.  In addition, further 
experiments using reporter assays for both HIF1α and β-catenin (for example 
luciferase reporters) could be undertaken to examine both the time course of 
any increase in response to chemotherapy and also the effect of OH14 on this 
process. 
 
Having demonstrated an increased in HIF1α protein levels, we wanted to 
assess whether HIF1α-mediated gene expression also increased at this time 
point using qRT-PCR (Fig 5.10).  The results showed that at the 48, 72 and 
96 hours, there was an increase in IL6, IL8, MDR1 and Snail expression but 
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that this effect was most profound at 96 hours.  Whilst IL6, IL8 and MDR1 are 
known to be under the influence of HIF1α, expression of IL6 and IL8 has been 
shown to be increased by paclitaxel in ovarian cancer cell lines after 24 hours 
(Wang et al. 2006; Lee et al. 1997) and therefore it is likely that increased 
expression was non-HIF1α dependent.  A potential mechanism could include 
activation of the c-Jun N-terminal kinase (JNK) and Nuclear Factor-κB (NFκB) 
pathways that have been shown to be upregulated by paclitaxel and lead to 
increases in anti-apoptotic proteins such as MDR1 and IL6 and IL8. (Wang et 
al. 2006).  
 
The next experiments set out to evaluate the effect of OH14 on HIF1α protein 
levels and gene expression. When examining protein levels, paclitaxel led to a 
significant increase in HIF1α that was abrogated by the addition of OH14 (Fig. 
5.11). The effect of paclitaxel on HIF1α gene expression differed between the 
two cell lines.  As expected MDA-MB-231 cells exhibited no transcriptional 
increase in HIF1α, suggesting that increased protein levels were due to 
stabilisation and/or post-translational modification.  HIF1α gene expression in 
the SUM149 cell line however exhibited a significant increase, suggesting an 
alternative, or additional, mechanism of regulation.  However, the effect of 
OH14 on HIF1α gene expression was consistent, with both cell lines 
exhibiting a significant decrease in HIF1α mRNA levels with combined 
treatment.   
 
The effect of OH14 on paclitaxel-mediated HIF1 α -induced gene expression 
was also consistent between the cell lines, with OH14 inhibiting downstream 
paclitaxel-mediated gene transcription.  In the SUM149 cell line, OH14 alone 
had the unexpected effect of reducing baseline transcription in 3 of the 4 
downstream HIF1α gene targets whereas in the MDA-MB-231 cell line, OH14 
increase all 4 targets.  These experiments firstly need repeating to ensure that 
this is a true effect but this is a potentially interesting observation, suggesting 
that there may be differences in biology between the two cell lines.  One 
potential mechanism is through the JNK mediated proteasomal degradation of 
cFLIP, leading to enhanced apoptosis (L. Chang et al. 2006).  An isoform of 
cFLIP, cFLIP-L, has been shown to inhibit the JNK pathway (Nakajima et al. 
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2006). OH14, by binding to cFLIP, may be inhibiting this inhibition, therefore 
leading to elevation of JNK and an elevation of IL6 levels.  When examining 
potential mechanisms of IL8 elevation with OH14, there is a potential complex 
mechanism involving both pro- and anti-inflammatory signalling involving both 
cFLIP and NF-κB signaling. cFLIP has also been shown to inhibit the death 
receptor induced activation and induction of the NFB target gene IL8. 
Therefore inhibiting cFLIP with OH14 may stop this process causing elevation 
of IL8 (Kavuri et al. 2011).  Further experiments looking at both protein levels 
of the JNK and NFB pathways could be undertaken should this effect persist 
in repeat experiments. 
 
Together, these data demonstrated that paclitaxel induced HIF1α and that 
OH14 seemed to have an effect on both protein levels and HIF1α-mediated 
gene expression when combined with paclitaxel.  We therefore sought to 
confirm the role of HIF1α in CSC-like behaviour.  As can be seen in Fig 5.12, 
siRNA-mediated knockdown of HIF1α led to both an increased in the 
cytotoxicity of paclitaxel on the bulk cell population of MDA-MB-231 cells as 
well as significantly reducing mammosphere formation compared to 
scrambled control.  It also reversed the increase in mammosphere formation 
seen with paclitaxel.  Using our mathematical model confirmed that blocking 
HIF1α led to an almost proportional reduction in CSCs as compared to the 
reduction in overall cell viability.  Cell viability decreased from 99.1% with 
siRNA HIF1α to 60.3% with siRNA HIF1α and paclitaxel (a 60.8% reduction), 
with a drop in absolute CSC numbers from 61 to 31 (a 50.8% drop). This 
suggests that HIF1α may also have a role in potentiating the apoptotic effect 
of paclitaxel.  We sought to evaluate this further by using a CI to examine this 
effect on both cell viability and mammosphere formation.  As seen with OH14 
and paclitaxel there were no differences in the proportion of increase with the 
addition of CI in siRNA treated cells both with and without paclitaxel 
suggesting that HIF1α was not having its predominant effect through 
apoptosis (Fig 5.16 A and B).  In our CSC model (Fig 5.16C), paclitaxel after 
siRNA-mediated knockdown of HIF1α led to reduction in CSC number that 
was maintained with the addition of CI.  These results suggest a minor role for 
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apoptosis in the HIF1α-mediated reduction in CSC-like behaviour but further 
work could look at examining the levels of Caspase activation in response to 
HIF1α knockdown. 
 
Having established the role of HIF1α, we wanted to confirm the mechanism of 
reduction in HIF1α by cFLIP suppression.  Using MG132, a proteasome 
inhibitor, we sought to show that cFLIP prevented the ubiquitin proteasome 
system (UPS) from degrading HIF1α as has been shown by others previously 
(Ishioka et al. 2007).  Our results showed that in hypoxic conditions (to 
elevate HIF1α), siRNA-mediated knockdown of cFLIP led to a significant 
reduction in HIF1α levels that was reversed by MG132 (Fig 5.15).  This 
confirms that the mechanism of action of OH14 is via the UPS.   
 
Lastly, we demonstrated that hypoxia increased colony formation in the MDA-
MB-231 cell line and that this effect was reversed by the addition of OH14 (Fig 
5.16).  This experiment was chosen rather than a mammsophere experiment 
as we wanted to avoid the handling of cells (for example during the passage 
step of the mammosphere experiment). 
 
This chapter has therefore demonstrated that OH14 is having its effect on 
CSC-like behaviour in two ways: Firstly, and primarily, through increasing the 
degradation of HIF1α that is induced by chemotherapy and secondly, through 
increasing apoptosis in CSCs.  HIF1α leads to the expression of a number of 
genes that are associated with CSC-like behaviour and drug resistance, such 
as IL6, IL8 and MDR1.   
  
  
6 Discussion and Future Work 
 
  
  202 
6.1 Discussion 
There has been a significant improvement in breast cancer survival over the 
last few decades with much of this improvement attributable to a combination 
of earlier detection of breast cancer, improvement in systemic therapy and 
improved surgical techniques (J.-H. Park, Anderson, and Gail 2015).  Despite 
this, breast cancer remains that largest cause of cancer death in females in 
the Western world and novel treatment strategies are needed to improve 
survival (Turner et al. 2016).  
 
The importance of inter tumour heterogeneity in breast cancer has long been 
recognised, for example through the oestrogen, progesterone and Her2 
receptors.  We know and appreciate that these markers have a large impact 
on disease progression, response to treatment and overall prognosis (Prat 
and Perou 2011).  Nevertheless, it is only in the last 10 to 15 years that the 
concept of intra tumour heterogeneity has been both appreciated and studied.  
The emergence of the cancer stem cell hypothesis over the last 15 years has 
led to possible explanations to previously poorly understood clinical concepts 
such as tumour dormancy, metastases and recurrence (Al-Hajj et al. 2003; 
Azizi and Wicha 2013).  
 
Naturally, there has been a focus on how chemotherapeutic agents in use 
affect this population.  A large body of previous work has demonstrated that 
chemotherapy poorly targets the CSCs within many tumours, including breast 
cancer (Suling Liu and Wicha 2010).  When treating patients in clinic, both the 
physician and the patient are reassured that chemotherapy seems to shrink 
tumours and ‘cure’ patients- only for the disease to return, often at a distant 
site.  This phenomenon can increasingly be understood through the CSC 
model and the characteristics that these cells possess such as resistance to 
apoptosis and drug efflux (hence resistance to chemotherapy) as well as 
tumour dormancy and the ability to migrate through EMT (Pattabiraman and 
Weinberg 2014).  In most tumour types, the establishment of metastatic 
disease heralds incurable disease and increasingly it is recognised that this 
could be due to CSCs residing at metastatic niches throughout the body 
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where they can resist treatment, lie dormant and eventually thrive (Plaks, 
Kong, and Werb 2015).  In a few tumour types, such as germ cell cancer, 
metastatic disease is not incurable as the tumours are exquisitely sensitive to 
chemotherapy with cure rates of over 90%.  Germ cell tumours have been 
shown to have very low levels of MDR proteins, as well as having an 
increased susceptibility to apoptosis, perhaps offering a window in which to 
study the differential responses of the CSCs of these types to chemotherapy 
(Savage 2016). 
 
Work demonstrating that CSCs are increased in chemotherapy has led to 
intensive efforts to target this population using both novel and other 
compounds, whose use has been repurposed after recognition that they seem 
to possess some anti-CSC activity.  Such examples include digoxin, a cardiac 
glycoside used for atrial fibrilliation, and salinomycin, an antibiotic that is 
widely-used in chicken feed, that was identified through high-throughput 
screening to target breast cancer CSCs 100 times more effectively than 
paclitaxel (P. B. Gupta et al. 2009; Lu et al. 2015). 
 
Previous work in our laboratory has identified that the apoptotic-inducing 
ligand TRAIL seems to target CSCs in a broad range of molecular subtypes 
and that this effect is potentiated by inhibiting the anti-apoptotic protein cFLIP 
(Piggott et al. 2011).  Whilst demonstrating that the method of synergy was 
through increased apoptosis previous work been demonstrated that 
aggregates of cFLIP can interfere with the degradation of HIF1α and β-
catenin, two known CSC signalling pathways (Naito et al. 2004; Ishioka et al. 
2007; Safa 2012).  A relationship between cFLIP and β-catenin was 
subsequently confirmed by other members of our laboratory (French et al. 
2015).  HIF1α has been shown to be prognostic in breast cancer, upregulated 
by chemotherapy, lead to a CSC phenotype in breast cancer and induce EMT 
(Lu et al. 2015; H. Zhang et al. 2015; Samanta et al. 2014; W. Zhang et al. 
2015).   
 
This led to the development of a novel cFLIP inhibitor, OH14, that was 
designed to work concurrently with TRAIL to target CSC-like behaviour in 
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breast cancer and hopefully lead to an improvement in the, so far, 
disappointing activity of TRAIL in the breast clinic- despite promising pre-
clinical activity (Oliver et al. 2012; Holland 2014; Forero-Torres et al. 2015). 
 
The aims of this project were therefore to:  1) to establish an in vitro to model 
to demonstrate that different chemotherapeutic agents in use in the clinic led 
to an increase in CSC-like behaviour; 2) show whether the combination of 
OH14 and TRAIL could effectively target this population; and 3) characterise 
the mechanism through which OH14 and TRAIL was having this effect. 
 
In Chapter 3, we began by establishing IC50 values of chemotherapeutics in 
use in the breast clinic such as FEC and docetaxel in a panel of three cell 
lines representing a broad range of molecular subtypes of breast cancer 
(MCF-7- ER positive, HCC1954- Her2 positive and SUM149- Triple negative).  
We then assessed the effect of chemotherapy on mammosphere formation, a 
recognised and established surrogate of CSC-like behaviour (Dontu et al. 
2003).  However, our initial results did not show an increase in mammosphere 
formation something that we felt went against the weight of previously 
published evidence.  After trying multiple variables, an increase in the 
treatment time from 72 to 96 hours led to an increase in mammosphere 
formation and we speculated that this may have been due to an increase in 
HIF1α that had previously been shown in an in vitro model to take 96 hours to 
be upregulated by chemotherapy (Samanta et al. 2014). A mathematical 
model that we had constructed by combining viability and mammosphere data 
demonstrated that chemotherapy not only poorly targeted CSCs but, across 
most cell lines and chemotherapeutics, led to an increase in overall CSC 
number suggesting that CSC signalling was being induced by chemotherapy. 
This was most marked in our TNBC SUM149 cell line. 
 
Having established this 96 hour time point to use as our model of CSC-like 
behaviour, in Chapter 4 we tested the effect of OH14 and TRAIL after 
chemotherapy in the MCF7 and SUM149 cell line. Whilst demonstrating the 
combination was effective across all cell lines, in the SUM149, triple negative 
line, the use of single agent OH14 led to a greater effect that the use of the 
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combination of OH14 and TRAIL.  A literature search identified that a 
particular chemotherapy drug, paclitaxel, worked predominantly through the 
apoptosis pathway under negative regulation of cFLIP and therefore was 
chosen to investigate the effect of single agent OH14 after chemotherapy in 
TNBC (Day, Huang, and Safa 2008b; Day et al. 2006).  TNBC cell lines were 
used to demonstrate that single agent OH14 seemed to target mammosphere 
formation and the ALDH+ cell population, both surrogate markers of CSCs, 
after paclitaxel. The same mathematical model confirmed that the addition of 
OH14 was leading to an overall reduction in CSCs, suggesting that it was 
both increasing the cytotoxic of paclitaxel against CSCs as well as potentially 
influencing CSC signalling.   In vivo serial dilution experiments confirmed that 
paclitaxel increased tumour formation compared to untreated controls and 
that OH14 and TRAIL without paclitaxel decreased tumour formation.  
However, our results combining OH14 and TRAIL with paclitaxel were 
confusing in that no effect was seen and these experiments are being 
repeated.  In vivo treatment of established TNBC cell line tumours showed 
that single agent OH14 had no effect on tumour growth but that both 
paclitaxel and the combination of paclitaxel and OH14 led to a dramatic 
reduction in tumour size.  Interestingly, many weeks later the paclitaxel only 
treated mice begun to rapidly regrow tumours whilst those treated with OH14 
and paclitaxel continued disease free.  This could potentially be explained by 
our CSC hypothesis- undetectable TNBC cells continued to exist within the 
mice that begun to regrow after time.  In those mice treated with OH14, this 
process was interrupted.  This experiment is again being repeated with larger 
numbers of mice to confirm this effect. 
 
Lastly, we wanted to show a potential mechanism of the relationship between 
OH14 and paclitaxel.  In the MDA-MB-231 TNBC cell line, we demonstrated 
that both TRAIL and OH14 with TRAIL increased cell death and apoptosis in a 
bulk cell population without paclitaxel. With paclitaxel, single agent OH14 and 
TRAIL led to a significant reduction in viability suggesting a synergy between 
paclitaxel and these two compounds.  Nevertheless, the most significant 
decrease in viability was seen by using both agents together with paclitaxel- 
suggesting that the combination of OH14 and TRAIL in combination with 
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paclitaxel is a therapeutic option worth exploring.  Blocking apoptosis with a 
pan-caspase inhibitor in two TNBC cell lines demonstrated little effect on both 
cell viability and mammosphere formation.  This suggests that apoptosis is 
only having a minor role in the activity of OH14 on CSC-like activity after 
chemotherapy.  This effect could be examined further by testing the effect of 
caspase inhibition on a pure CSC population and also investigating whether 
any effect is related to Caspases 8 and 10, the initiator caspases in the 
extrinsic apoptosis pathway. 
 
We subsequently demonstrated in two TNBC cell lines, that the increase in 
HIF1α protein levels did occur at 96 hours post-paclitaxel, a finding that was 
in concordance with others (Samanta et al. 2014) and went someway towards 
showing why our mammospheres only increased after 96 hours in Chapter 3. 
However, our rRT-PCR data showed a more complex picture with elevation of 
HIF1α-mediated gene expression before 96 hours, though at lower levels.  
Others have shown that IL6 and IL8, two genes under control of HIF1α, were 
elevated by chemotherapy at earlier time points and therefore there is likely to 
be a non- HIF1α dependent mechanism occurring, such as through the JNK 
pathway (Wang et al. 2006) and this could be investigated further. 
 
Next we showed that the paclitaxel-induced increase in HIF1α protein 
expression was abrogated by OH14. Paclitaxel increased the HIF1α mediated 
gene-expression of IL6, IL6, MDR1 and Snail that was reversed by the 
addition of OH14.  However, in the MDA-MB-231 cell line, single agent OH14 
led to an increase in IL6, IL8, Snail and MDR1 gene expression that was 
reversed when OH14 was combined with paclitaxel. This was not seen in the 
SUM149 inflammatory breast cancer cell line.  If time had allowed, I would 
have liked to explore the relationship between OH14, the MAPK and NFB 
pathways and IL6 and IL8 signalling.  Of particular interest would be the 
different effects seen between the MDA-MB-231 cell line and the SUM149, 
inflammatory breast cancer cell line, as NFB has been shown to be 
upregulated in inflammatory breast cancer (Lerebours et al. 2008).   
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The importance of HIF1α in mammosphere formation was shown by siRNA-
mediated knockdown that closely mirrored the effect of both OH14 and siRNA 
against cFLIP.  Blocking apoptosis with z-VAD-FMK, did not alter the 
relationship between control and paclitaxel treated cells suggesting that the 
effect was not mediated through apoptosis. 
 
Blocking the degradation of HIF1α using the proteasome inhibitor MG132 
reversed the reduction in HIF1α protein levels seen with siRNA-mediated 
knockdown of cFLIP. This supports previously published evidence suggesting 
that aggregates of cFLIP inhibit the proteasome system and lead to increased 
levels of proteins such as HIF1α (Ishioka et al. 2007).  Finally, we used 
hypoxic conditions to show that hypoxia increased colony formation and that 
this increase was reversed by the addition of OH14.   
 
In conclusion, and as shown in Figure 6.1 below, our data show that paclitaxel  
targets differentiated cells leading to cell death but leads to an induction of a 
CSC-like phenotype.  This is either through resistance of existing CSCs to its 
effects or, and more likely, through induction of CSC-signalling and 
conversion of differentiated cells into CSCs (through the process of plasticity, 
See Section 1.5.7).  HIF1α is an important mediator of increased CSC 
signalling and may also lead to plasticity between differentiated cancer cells 
and cancer stem cells.  cFLIP is both an inhibitor of apoptotic pathway and 
inhibits the degradation of HIF1α. OH14, our novel cFLIP inhibitor, reverses 
the increase in CSC-like behaviour seen with paclitaxel and has a small effect 
on increasing apoptosis. OH14 may have an important role in the treatment of 
cancer, both in combination with chemotherapy and TRAIL, potentially 
increasing the effect of the latter as an antagonist of the extrinsic apoptosis 
pathway and the former by inhibiting induced CSC-signalling. There may be 
more cancer types that benefit from a combination of paclitaxel and OH14 
treatment with notable examples being castrate-resistant prostate cancer 
(McCourt et al. 2012) and also pancreatic cancer (Haag et al. 2011), where 
cFLIP has been shown to be over-expressed, and also inflammatory breast 
cancer, where complex interactions may lie with immune signalling pathways.
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Figure 6.1 The effect of cFLIP and OH14 on paclitaxel-induced effects on cancer cells 
Paclitaxel leads to both apoptosis (primarily in Differentiated cells) and an induction of CSC-signalling mediated by HIF1α.  This 
may induce non-CSCs into a CSC state.  cFLIP leads to resistance to paclitaxel through both inhibiting apoptosis and inhibiting the 
breakdown of HIF1α through the Ubiquitin Proteosome System (UPS).  OH14 blocks this inhibition, leading to a reduction in CSC-
signalling and an increase in apoptosis. 
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